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  Abstract	  
 
At the forefront of revolutionizing medicine, gene therapy provides an effective way to 
treat a range of diseases by regulating defective genes at the root of the disease. Short 
interfering RNA (siRNA) holds great promise as therapeutic agents in this domain. The 
siRNAs are a class of 20 to 25 nucleotide-long double-stranded RNA molecules that play 
an important role in the RNA interference (RNAi) pathway. RNA interference is a post 
transcriptional process triggered by siRNA, which inhibits the expression of a specific 
gene by the degradation of its complementary messenger RNA (mRNA). Despite its 
potential value, intracellular delivery remains a major obstacle to clinical applications of 
therapeutic siRNAs. Its large size and negative charge prevent siRNA molecules from 
crossing cellular membranes while the sensitivity of naked siRNA to endogenous 
enzymes makes it vulnerable in serum. To address these problems, several novel 
strategies are created to achieve an effective and safe mode of delivery. Among them, 
peptide based drug/gene carriers are emerging as one promising delivery system for safer 
in vitro and in vivo applications.   
       This thesis focuses on the design, characterization and utilization of novel 
endosomolytic peptides for siRNA delivery. The studies include the following: (i) the 
design of new peptide sequences, and modification of existing sequences; (ii) the 
physicochemical characterization of peptides, and the interaction between peptides and 
siRNA molecules; (iii) the evaluation of the silencing efficiency, and toxicity of 
	   iv	  
peptides/siRNA complexes in cultured cells and in vivo; (iv) the study of their 
intracellular pathway, and endosomal release mechanism; (v) the in vitro 
biocompatibility study of the peptides/siRNA nanocomplexes, and (vi) the co-delivery of 
anti-cancer drugs and siRNA into cancer cells. 
       The peptide C6, a 18-mer peptide, was first evaluated as an siRNA carrier. C6 
contains three types of amino acids: positively charged arginine, hydrophobic leucine and 
tryptophan. C6 would bind to negatively charged siRNA molecules through electrostatic 
interaction, whereby a peptide/siRNA molar ratio above 10/1 is needed to neutralize all 
the negative charges of siRNA molecules, indicated by the agarose gel shift assay. 
Fluorescence microscopy shows a punctuated distribution of peptide/siRNA complexes. 
Despite the great intracellular uptake, the silencing efficiency of siRNA delivered by C6 
is very low, probably due to the entrapment in the endocytic vesicles.  
        Therefore, modifications by including pore-formation or pH-sensitive moiety to the 
sequence have been applied to enhance the endosomal escape capability of C6/siRNA 
complexes. Based on these strategies, a peptide library was generated by modifying 
prototype peptide C6. All the modifications improved the transfection efficiency of C6 to 
some degree. After completing the pre-screening for the activity, several promising 
candidates were used for further evaluations. Aromatic tryptophan residues were used to 
substitute some leucine residues in the sequence, since tryptophan rich motif is found 
abundantly in the pore-forming toxins of bacteria. The resulting peptide C6M1 shows 
increased endosomal membrane disruption ability in acidic environment. In addition, 
certain residues in C6 were replaced by histidine in the hope that they will facilitate the 
endosomal escape of peptide/siRNA complexes through the “proton sponge effect.” 
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Selected peptides C6M1, C6M3, and C6M6 could form stable complexes with siRNA. 
Formed nanoscale complexes are able to deliver siRNA into different cells and induce 
specific gene knockdown. Effective in vivo RNAi was achieved in a mouse model 
bearing a subcutaneous tumor. Intratumoral injection of the complexes resulted in a 
marked reduction of tumor growth through downregulation of antiapoptotic Bcl-2 protein 
in mice. Furthermore, these complexes were proven safe at transfection concentration by 
the cytotoxicity, the complement activation, and the cytokines activation assays. These 
results demonstrate that the C6 family peptides are a potent system for efficient gene 
delivery in vitro and in vivo. 
      As positive charges and endosomal escape ability both play an important role in 
promoting the transfection efficiency of siRNA, next the structure-activity relationship of 
efficient peptide-based siRNA carriers were explored. Here, oligoarginine peptides, 
prominent members in cell-penetrating peptide family, are rationally modified with 
oligohistidine and stearyl moieties (STR-). It is found that when the ratio of 
histidine/arginine in a stearylated peptide sequence is >1.5, pronounced GAPDH gene 
silencing is induced in a range of cell lines. Among these peptides, STR-HnR8 (n>12) 
showed high knockdown efficiency, which was rarely reported before. The main 
endosomal escape mechenism of stearylated and oligohistidylated oligoarginine/siRNA 
complexes is determined to be the “proton-sponge” effect. This peptide could also 
stabilize hydrophobic EPT/HCPT hybrid NPs in water. Co-delivery of EPT/HCPT hybrid 
NPs and Bcl-2 siRNA into cancer cells achieved a triple synergistic effect by greatly 
inhibiting cancer cells proliferation. Together, this work suggests a new strategy for the 
improvement and optimization of CPP-based siRNA delivery systems. 
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Chapter 1 
Introduction 	   	  
1.1 Overview 
The discovery of RNA interference (RNAi) is considered to be the most important and 
exciting breakthrough of the past decade by many biologists [1]. RNA interference is a 
highly efficient regulatory process in most eukaryotic cells by which double-stranded 
RNA (dsRNA) is able to cleave complementary mRNA and causes posttranscriptional 
gene silencing [2–4]. The high significance and transformative values of this discovery 
gained its inventors the award of Nobel Prize in Physiology or Medicine in 2006. 
     In general, long dsRNAs derived from either convergent transcription or hairpin- 
structured RNAs are the precursor of the short interfering RNA (siRNA) that can trigger 
RNAi [5]. When introduced into cells, dsRNA will be processively cleaved by the RNase 
III like enzyme, dicer, into short duplexed RNAs, i.e. siRNAs [6]. These newly formed 
21-23nt long nucleotides will then be loaded onto an RNA-induced silencing complex 
(RISC). Argonaute 2 (Ago-2) is the catalytic core of RISC. Upon binding to siRNA, it 
will release one strand from the siRNA, resulting in an activated form of RISC containing 
a single-strand RNA (guide strand) that directs the specific recognition of complementary 
mRNA [7–10]. Ago-2 then cleaves the target mRNA, thereby preventing specific genes 
from expression of proteins [11]. Tuschl and his colleagues found that instead of using 
long dsRNA, the introduction of chemically synthesized siRNA into mammalian cells 
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can also efficiently silence specific genes [4]. Figure 1.1 shows the entire RNA 
interference pathway [12]. 
              
 
              Figure 1.1 Schematic representation of siRNA mediated gene silencing 
       RNA interference has been widely used in basic biological research and clinical 
applications. Short interfering RNA therapy is becoming an important means for 
functional genomics study and the development of gene-specific drugs [13,14]. In 
biology, one of the most effective ways to determine the biological function of a protein 
or a pathway is to examine the phenotype of organisms that lack of or contain mutations 
in its encoding gene [15]. Thus, molecules that can specifically silence the expression of 
certain genes are powerful tools. The high efficiency and diversity in source of siRNA 
has made it one of the latest additions to gene-silencing reagents. RNA interference has 
also stimulated considerable interest in the pharmaceutical field as a potential therapeutic 
agent. Turning off problematic genes with RNA interference shows tremendous promise 
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for a huge number of human diseases. The first clinical trial with short interfering RNA 
(siRNA) in patients suffering from age-related macular degeneration (AMD) started in 
2004 [16]. The relatively low safety concerns of siRNA in humans have led to its clinical 
evaluation in other genetic and viral diseases [17]. Moreover, the rapid development of 
RNA interference technology opens the path to powerful gene therapy for cancer 
treatment where traditional surgery, radiation and chemotherapy cause deleterious side 
effects due to their non-specificity to the tumor cells [18]. Some in vivo experiments have 
already demonstrated that siRNA could significantly inhibit tumor cell growth in a 
xenograft mouse model [19–23].  
       However, despite abundant promise, a number of problems and hurdles remain in the 
way for siRNA-based therapeutics. The most important concern is the effective delivery 
of siRNA to its site of action in the cytoplasm. Some unfavorable physicochemical 
properties, including their large molecule weight, negatively charged surface, 
hydrophilicity, sensitivity to nuclease degradation and instability with plasma half-lives 
of less than ten minutes [24] impede the uptake of siRNA into the cells, especially after 
systemic administration [25]. Therefore, the application of siRNA as a potential 
therapeutic agent requires efficient and safe delivery that will retain their biological 
functions. An ideal delivery system should bear following properties: (1) siRNA carriers 
should protect siRNA from serum degradation (2) increase the retention time of siRNA in 
the circulatory system by reducing clearance rate in the human body (3) ensure effective 
biodistribution (4) facilitate siRNA delivery to specific cell types (5) promote cellular 
uptake and release siRNA to the cytoplasm after internalization (6) be made from 
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biocompatible, well characterized and easily prepared material, showing minimized 
toxicity to the human body. 
       Many non-viral carriers have been developed to deliver siRNAs, including liposome 
[26], polymeric complexes [27],  dendrimers [28] and gold nanoparticles [29]. They all 
have achieved varying degrees of success. Among the siRNA carriers, liposomes or 
lipidic carriers represent a mature technology. Cationic lipids have been used to 
encapsulate negatively charged siRNA molecules and deliver them into cells. Although 
satisfactory in certain in vitro systems, there are still difficulties with the lipidic 
strategies. The relatively large amount of the lipids required for siRNA transfection can 
often cause severe toxicity [30]. It has been reported that cationic lipids can modify 
cellular signaling pathways and stimulate specific immune or anti-inflammatory 
responses [31]. These toxic/immunogenic features limit the use of lipidic carriers in vivo. 
A clinical trial of liposomal siRNA delivery for hypercholesterolemia was terminated 
recently because of the potential for immune stimulation to interfere with further dose 
escalation [32]. Although new approaches have addressed some of the toxicity and 
targeting issues, long term in vivo safety and efficacy of this strategy remain in question. 
 Synthetic and natural polymers, consisting of repeated units of covalently bonded 
monomers, are another class of carrier systems for siRNA therapeutics. The structural 
and chemical properties of the polymers are well established, and cationic polymers bind 
to siRNAs through electrostatic interactions. A number of polymers, including poly 
(ethyleneimine) (PEI), poly (L-lysine) (PLL), chitosan, gelatin, poly-D, L-lactide-co-
glycolide (PLGA), poly (dimethylaminoethylmethacry-late) (PDMAEMA), and poly 
(trimethylamino-ethylmethacrylate) (PTMAEMA) have been investigated as siRNA 
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carriers. Like lipidic carriers, polymeric delivery systems also suffer from cellular 
toxicity and immunogenicity [33]. So their in vivo applications have been hindered thus 
far. 
       In light of the safety concerns and efficacy issues with current drug delivery systems, 
peptide-based carriers are emerging as an alternative for safer in vitro and in vivo 
delivery. They can traverse cellular membrane and deliver a variety of cargos including 
small molecule pharmaceuticals, proteins and oligonucleotides into cells with efficiency 
and specificity. Particularly, these cell penetrating peptides can deliver active substances 
to area of the body that are not easily accessible, the blood-brain barrier for instance. Our 
lab has been studying a class of peptides, the self-assembling/co-assembling peptides, 
which can be used as drug or gene delivery vehicles [34]. These peptides have been 
successfully used to encapsulate a model anticancer drug and deliver it across the cell 
membrane in a controlled manner. Encouraged by these results, we generated libraries of 
peptides that have potential to deliver siRNAs into cells. After high-throughput 
screening, several peptides with high transfection efficiency were selected for further 
study. Physicochemical characterizations were first applied to study the formed 
peptide/siRNA complexes, which include the interaction between peptides and siRNAs; 
the size and zeta potential; the morphology of the complexes. Then, the peptide/siRNA 
complexes with certain combinations of peptide and siRNA concentrations were further 
tested on their cellular uptake, cytotoxicity and their in vitro therapeutic effect on several 
cell lines. Potential immune side effects of these peptides in terms of complement 
activation and cytokine activation were also addressed. Their intracellular trafficking 
mechanism was systematically studied to explore a rational design strategy for peptides 
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as siRNA carriers. This information will be critical to the next phase of in vivo studies. In 
the next step, human tumor xenografts in a nude mice model were used to conduct in vivo 
efficacy and toxicity evaluation of potential gene therapy for cancer treatment. The 
simultaneous delivery of two anticancer drugs and therapeutic siRNA was investigated in 
A549 cancer cells. Based on the results reported in this work, strategies could be 
developed to design efficient peptides to construct functional nanocarriers for in vitro 
siRNA delivery and cancer gene therapy.  
1.2 Research Objectives  
The goal of this research is to develop an efficient and safe peptide based delivery system 
for in vitro and in vivo siRNA delivery. To achieve this goal, several promising peptides 
selected from designed peptide libraries were studied for their siRNA binding ability, 
silencing efficiency and toxicity on cultured cells and a mouse model. The specific 
objectives of this thesis are listed in the following: 
(1) Design of peptide libraries that consist of novel peptides and structurally 
modified analogues of existing peptides to achieve high siRNA transfection 
efficiency and low cytotoxicity.  
(2) Characterization of peptide/siRNA complexes; This will give us a general 
understanding of their binding mode at different molar ratios, thereby providing 
information for formulating desirable siRNA/peptide complexes. 
(3) Investigation of the therapeutic efficacy, toxicity and biocompatibility of the 
complexes in vitro with several cell lines. 
(4) Evaluation of the antitumor activity of complexes in vivo on a mouse xenograft 
tumor model. 
	   7	  
(5) Study of the intracellular traffic mechanism of the complexes, providing insight 
into the design of efficient peptide based siRNA delivery system. 
(6) Exploration of the possibility to co-deliver anticancer drugs and siRNA into 
cancer cells. 
1.3 Outline of the Thesis 
The thesis consists of eight chapters. The scope of each chapter is listed as follows:  
	  	  	  	  	  	  	  Chapter 1 gives an overview of the thesis, including a brief introduction to RNA 
interference and mechanism, its potential clinical applications, existing gene delivery 
materials and the promising future of peptide based delivery system. The objectives and 
the scope of the thesis are also given in this chapter. 
      Chapter 2 provides a review of the advantages of RNAi as potential new 
pharmaceutical drugs, therapeutical applications of siRNAs and current siRNA delivery 
systems. Uptake pathways and subsequent intracellular trafficking of these cell-
penetrating peptides as siRNA delivery vector are also reviewed. 
       Chapter 3 presents a new amphiphilic cell-penetrating peptide C6. Physicochemical 
characterizations were conducted. Of particular interest is that this peptide could deliver 
large amounts of siRNA into cells, yet the knockdown efficiency is very low, probably 
due to poor endosomal escape ability.  
        In order to improve the endosomolytic ability of peptide C6, thus enhancing 
transfection efficiency, different strategies were applied to modify C6 sequence.  In 
Chapter 4, we designed a new peptide C6M1 by substituting some leucine residues in C6 
with tryptophan. In chapter 5, peptides were generated by adding pH-responsive histidine 
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residues to the sequence. Both modifications, though working through different 
endosomal escape pathways, greatly improve the knockdown efficiency of 
peptide/siRNA complexes. In vivo antitumor activity of therapeutic siRNA delivered by 
these peptides was investigated in a tumor xenograft mouse model.  
        To further explore the structure-activity relationship of cell-penetrating peptides, in 
Chapter 6, oligoarginine peptides, prominent members in CPPs, were rationally modified 
with oligohistidine and stearyl moieties (STR-). The optimal histidine/arginine ratio for 
efficient gene knockdown was determined.  
       Chapter 7 studies the possibility of simultaneous delivery the anticancer drugs and 
therapeutic siRNA into cancer cells by promising peptide. The importance of peptide to 
stabilize hydrophobic anticancer drugs hybrid nanoparticles in water was also described.  
        Chapter 8 presents the conclusions of studies in the thesis, contributions of this 
research and recommendations for future work. 
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Chapter 2 
Literature Review 	  
 
2.1 RNAi as a potential new class of pharmaceutical drugs 
2.1.1 Comparison of siRNA therapy with traditional drugs 
Most approved drugs share important features like relatively small in size (molecular 
weight< 500 Da), apolar and function by binding to proteins or altering protein function 
[35]. Although much is known about designing traditional drugs and how to modify them 
to improve their in vivo efficacy, the development of small molecule drugs is often 
marked by failure in preclinical and clinical trials even with this vast experience [36]. 
siRNA drugs are not quite similar to traditional drugs. “Traditional drug discovery was 
done by trial and error—applying materials to cells until the desired phenotype is 
obtained. Drugs discovered in this method usually are nonspecific and have extensive 
side effects. With siRNA, it’s possible to identify the reason a phenotype develops, 
validate your identification, and attack the exact location in the cell that’s responsible for 
disease with minimal side effects. RNAi’s sequence specificity allows the kind of 
specific treatment you would demand from a next-generation drug,” says Sharon Engel, 
director of genomic data at Compugen Ltd., Tel Aviv, Israel. As an alternative 
therapeutic approach, RNAi may provide solutions to the major disadvantages of 
traditional pharmaceutical drugs. Figure 2.1 compares the key features between RNAi as 
a therapeutic approach and the two major classes of traditional pharmaceutical drugs-- 
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small molecules and proteins & antibodies [12]. One principle advantage of RNAi over 
other drugs is that all targets, including “non druggable” targets for traditional therapy, 
can be inhibited with RNAi and the corresponding siRNA can be rapidly identified and 
synthesized. The identification of highly selective and potent compounds for small 
molecule drugs is a difficult and time-consuming process, and can be unsuccessful 
sometimes. For RNAi, the identification of highly selective and potent target gene is  
 
 
Figure 2.1 Comparison of the key features between RNAi as a therapeutic approach and 
the two major classes of traditional pharmaceutical drugs-- small molecules and proteins 
& antibodies.  
rapid and has been demonstrated with numerous molecular targets. With protein and 
antibody drugs, the major technical challenge is production. Acceptable cellular 
production levels are difficult to achieve for protein drugs, while the aggregation 
problems continue to be a major issue for biologics. In contrast, siRNA molecules are 
easy to produce with respect to chemical synthesis process. One shortcoming of RNAi 
therapy is that they only have antagonism effect to the specific targets, whereas the other 
two classes of drugs provide agonism as well as antagonism effect. Overall, RNA holds 
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great promise as a pharmaceutical drug that will fill in a significant gap in modern 
medicine.  
2.1.2 Therapeutic applications of RNAi 
RNAi based therapeutics has significant advantages including broad applicability, 
therapeutic precision and selectivity avoiding side effects. Recent advances in RNAi 
therapy have broadened the scope of its application for a variety of human diseases. A 
number of studies have been reported demonstrating the silencing of disease genes by 
administration of siRNAs. Figure 2.2 shows the organs in the human body for which 
RNAi proof of concept has been demonstrated [12]. Direct RNAi means local delivery of 
siRNA molecules. This has been carried out successfully to specific tissues and organs 
like eye, lung, skin, nose, the nervous system and the digestive system. Systemic RNAi 
means intravenous delivery of siRNA molecules into lung, tumors, liver and joint.  
Several different types of diseases that are very common and widely studied will be 
discussed here.  
Infectious disease 
Diseases caused by bacteria and viruses continue to be one major cause of death around 
the world. The emergence of resistant strains raises increasing concerns worldwide. The 
prominent examples are AIDS, influenza and hepatitis for virus infection and pneumonia 
and sepsis for bacterial infections [37].  Cell culture studies clearly demonstrated that 
RNAi was able to inhibit the cellular uptake or replication of infectious agents. Many 
studies have shown that siRNAs could knock down the expression of HBV gene [38,39]. 
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Figure 2.2 Organs and diseases for which the effect of RNAi has been proved [12]. 
        HBV is a DNA virus, its DNA replicates through a genomic RNA intermediate and 
uses a virally encoded reverse transcriptase during replication. It is found that the distinct 
RNAi targeting sequences on specific gene on virus exhibited various efficacies on 
inhibition of the viral DNA replication and gene expression [40–42]. Morrissey et al. 
reported a reduced serum HBV DNA concentration in mice by intravenous injections of a 
stable nucleic-acid-lipid particle (SNALP) [40].  McCaffrey et al. injected a large volume 
of plasmids encoding the HBC gene along with HBV specific shRNAs (small heparin 
RNA) into mouse liver. The HBV specific shRNAs significantly reduced viral mRNAs 
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and protein expression, thus inhibiting HBV replication in infected mice [43]. More 
examples of siRNA treatment for HBV are shown in Table 2.1. 
                               Table 2.1 Examples of siRNAs targeting HBV 
Gene Host Transfection/Delivery Results 
S, C HepG2.2.15 
cells 
Liposomes Reduction in HBsAg secretion by 
80% in cell culture 
C Mice Tail vein injection Significant reduction in HBsAg and 
HBeAg expression 
S Mice Hydrodynamic injection Three daily intravenous injections 
of 3 mg/kg day reduced serum 
P, C, S HepG2.2.15 
cells 
oligofectamine HBeAg expression decreased by 
73.8% and 72.8% after siRNAs 
targeting Pre C region 
C HuH7 and 
HepG2 cells 
oligofectamine HBeAg levels in the cell culture 
medium decreased to 4.6 fold and 
4.9 fold 
NA HepG2.2.15 
cells 
DOTAP liposomes Inhibition rate is approximately 80-
90% in treated cells 
Abbreviation: C, core antigen; S, surface antigen; P, polymerase; S, X protein; NA, not 
report; DOTAP, 1,2-dioleoyl-3-trimethylammonium propane 
      HIV was the first infectious agent targeted by RNAi, as the pattern and lifecycle of 
gene expression of HIV is well known. A number of studies have been carried out using 
siRNAs and shRNAs targeting HIV genome regions such as tat, rev, gag, pol, nef, vif, 
env, vpr, and the long terminal repeat (LTR) in infected cells and showed promising 
results to inhibit viral production [44]. Despite several successful cases, targeting the 
virus directly encounters a substantial challenge for clinical application, because the high 
viral mutant rate may lead to mutants that escape from being targeted [45]. Thus, RNAi 
mediated knockdown of cofactors associated with virus infection has become an 
alternative approach. Qin et al. successfully constructed a lentivirus-based vector to 
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deliver siRNAs against the HIV-1 co-receptor CCR5, into human peripheral blood T 
lymphocytes [46]. This resulted in up to 10-fold inhibition of CCR5 expression on the 
cell surface over two weeks, which therefore provided a substantial protection for the 
lymphocyte populations from HIV-1 virus infection, dropping infected cells by 3-7 fold. 
Kumar et al. conjugated a CD7 specific single-chain antibody to oligo-9-arginine peptide 
for T cell specific siRNA delivery in mice or CD43+ hematopoietic stem cells [47]. This 
treatment controlled viral replication and prevented the disease-associated CD4 T cell 
loss. Surabhi and Gaynor [48] addressed that siRNAs directed against NF-κB p65 subunit 
could significantly decrease the levels of the protein and thus inhibiting HIV-1 
replication. Multiplexing shRNAs or siRNAs targeting several sites in the HIV is an 
option that should be fully explored and carefully examined for efficacy, inhibition of 
viral mutants, and potential toxicity. One example of a potent combination of shRNAs 
with mixtures of non-shRNA antivirals is shown in Figure 2.3 [49]. However, the 
delivery of siRNAs to HIV infected cells is also problematic sometimes. The systemic 
delivery of siRNAs to T cells is probably not feasible owing to the immense number of 
target cells, which are primarily T lymphocytes, monocytes and macrophages. Therefore, 
the preferred method is to isolate T cells from patients. These cells are then transfected, 
expanded and reinfused into the same patients.  
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Figure 2.3 Proposed multiplexing RNA interference (RNAi) with ribozymes and decoys 
for the treatment of HIV infection. Different stages of HIV replication can be targeted 
using siRNA and combinations of other RNA based inhibitors. CD4 receptor and CCR5 
co-receptor are binding site for HIV-1. The proviral RNA is reverse transcribed into 
DNA, which will integrate randomly into the host chromosomes. The scissors represent 
targeting site for siRNA or ribozymes. The decoy for binding viral Tat or Rev is depicted 
as a barrel in the nucleus.  The virus may be attacked by siRNA or ribozymes at the 
preintegration step to block proviral DNA formation and integration. While at 
postintegration step, siRNAs can target all classes of HIV transcripts.  
Neurodegenerative diseases 
For many neurodegenerative disorders, a causative therapy is unavailable. Designing an 
inhibitor for any neurodegenerative disease that effectively suppresses the pathogenicity 
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of the disease is yet to be achieved. The challenge lies in crossing the blood-brain barrier 
(BBB) and blood-cerebrospinal fluid barrier (BCSFB) to reach the catalytic sites of the 
enzyme/protein involved in the molecular mechanism of the disease process [50]. siRNA 
holds a promising option for the development of novel therapeutic strategies for this kind 
of disease. Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), Parkinson’s 
disease, Huntington's disease are examples of relatively common age-related 
neurodegenerative disorders, each of which is characterized by the dysfunction and death 
of specific populations of neurons: Hippocampal and cortical neurons involved in 
learning and memory processes in Alzheimer’s disease, dopamine- producing neurons in 
the substantia nigra controlling body movements in Parkinson’s disease and spinal cord 
motor neurons in ALS [37].  Specific genetic mutations are responsible for a small 
percentage of cases of Alzheimer’s disease, Parkinson’s disease and ALS [51], where all 
cases of Huntington’s disease result from mutations in the Huntington protein [52]. These 
neurodegenerative disorders share some biochemical cascades that result in neuronal cell 
death, including increased oxidative stress, irregulation of cellular calcium, homeostasis 
and apoptosis. Therefore, two different strategies were proposed for preventative and 
therapeutic treatment in these diseases. One is to silence the disease-causing genes that 
are believed to initiate the neurodegenerative process. The other is to target downstream 
events in the neurodegenerative cascade. Wang et al. used siRNA directed against the 
huntington gene to repress its transgenic mutant expression in an HD mouse model [53]. 
Results showed that intraventricular injection of siRNAs at an early postnatal period 
inhibited transgenic Huntington gene expression in brain neurons and induced a decrease 
in the numbers and sizes of intranuclear inclusions in striatal neurons. Treated model 
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mice showed significantly prolonged longevity, improved motor function and slowed 
down in the loss of body weight. In Alzheimer’s disease, increased beta-secretase 
(BACE1) activity is associated with neurodegeneration and accumulation of amyloid 
precursor protein (APP) products. Therefore, the inhibition of BACE1 could be important 
in the treatment of Alzheimer’s disease. Singer et al. found that decreasing BACE1 levels 
by using lentiviral vectors with siRNAs targeting BACE1 gene reduced amyloid 
production and the neurodegenerative and behavioral deficits in mice model with 
Alzheimer’s disease [54].  In summary, in vitro cell culture experiments and in vivo 
animal studies have shown that siRNA is a highly effective tool to downregulate different 
target genes involved in the pathogenesis of neurodegenerative diseases.   
Cancer 
Cancer is one of the primary causes of death around the world and it is estimated to cause 
13.1 million human casualties in 2030 [55]. Cancer is a chronic disease that causes 
growing burden to the patients, families and society. Thus, effective and safe treatments 
are urgently needed. Current available and common cancer treatment—surgery, 
chemotherapy and radiation have made tremendous progress, but they have ample of 
limitations. Recent understanding of the genetic causes of the disease provides the 
prospective for gene therapy as an alternative approach. The antigene approaches include 
ribozymes [56], antigene oligonucleotides [57], peptide nucleic acids (PNAs) and 
antisense oligonucleotides. In contrast to antisense technology, siRNA applies a post-
transcriptional gene silencing (PTGS) mechanism. siRNAs are much better in silencing 
the target gene compared to the antisense RNA alone as the transcript of the gene is 
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rapidly degraded without accumulation. Table 2.2 compares the pros and cons of 
different gene silencing strategies [18].  
        In cancer cells, proto-oncogenes have frequently been activated by various 
mechanisms. Cancer cells are different from normal cells in that they exhibit abnormality 
in cell cycle resulting in uncontrolled growth; they are resistant to death as a result of the 
dysfunction of the proteins that mediate cell apoptosis; they gradually acquire resistance 
to many anti-cancer drugs. Therefore, the approach for siRNA in the treatment of cancer 
is downregulation of genes that contribute to tumor progression, e.g. the expression of the 
oncogenes in cell cycle and/or an anti-apoptotic gene in cancer cells. The other genes 
involved in tumor formation were also widely studied—vascular growth factor involved 
in cancer metastasis, mutated genes that contributed to the development of drug-resistant 
cancer cells.  
      This high-throughput screening technique has paved the way for loss-of-function 
studies, thus numerous genes involved in tumor formation have been identified. This has 
indeed led to a recent acceleration in the development of siRNA-based strategies for 
cancer therapy. Figure 2.4 shows different target genes and pathways for which in vivo 
animal studies have been conducted successfully [58].  
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              Table 2.2 Advantages and disadvantages of different gene-silencing strategies 
Strategy Advantages Disadvantages 
Low-molecular-
weight agents 
Easy to administrate  Often nonspecific 
 Often inexpensive May not be available  
  Off-target effects 
Antisense ODNs Easy to synthesize Only exogenous 
delivery 
 Inexpensive Protein binding  
 Modification to improve selectivity and efficacy Off-target effects 
 
 Induction of interferon 
response 
Ribozymes Simple catalytic domain  Requirement of 
specific cleavage 
triplets 
 Delivery as free molecules and by expression 
vectors 
Protein binding  
 Tissue-specific delivery if vector established   
 Administration to subcellular compartments  
DNAzymes Inexpensive Only exogenous 
delivery 
 Good catalytic properties Off-target effects 
 Modification for systemic delivery  
RNAi Highly effective at low concentrations Off-target effects 
 
Delivery as free siRNA molecules and by short 
hairpin RNA expression vector 
Induction of interferon 
response 
 
Tissue-specific delivery if vector established  Expensiveness of 
siRNAs 
ODN: Oligodeoxynucleotide; siRNA: Short interfering RNA 
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Figure 2.4 Pathway targeting by siRNA delivery systems in cancer. Representation of 
siRNA targeted molecules used in preclinical studies to develop an anti-cancer treatment. 
Dox: doxorubicin; Doce: docetaxel. Plk1: polo-like kinase1; MAD2: mitotic-arrest 
deficient 2; EphA2: receptor of ephrins; AKT 1/2/3: KLFisoforme of serinethreonin 
kinase; PKN3: protein kinase N3; FAK: focal adhesion kinase; Bcl: B-cell lymphoma; 
Mcl-1: myeloid cell leukemia; VEGF: vascular endothelium growth factor; PAR-1: 
protease activated receptor 1; KLF-5: Kruppel-like factor 5; PLX1DC: plexin domain 
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containing 1; HIF-1a: hypoxia inducible factor 1a; CA: ceramidase acid; MDM2: murine 
double minute 2; POSTN: periostin. 
       Many studies have confirmed the therapeutic potential of RNAi in vivo by 
demonstrating the anticipated tumor inhibition effect. Table 2.3 summarizes these studies 
with detailed information [58].  
           Table 2.3 Studies based on siRNA delivery in cancer therapy 
Pathway siRNA 
target 
Cancer 
model 
Injection 
route 
Inhibition 
of tumor 
volume 
Other effects 
Cell cycle Cyclin B Prostate s.c 70%-92% 50% long 
survivial 
 PLK1 Breast s.c 70% Caspase 3 
activation 
 MAD2 Colon s.c 35% Increased 
apoptosis 
Proliferation EphA2 Ovarian i.p 55% / 
 AKT1 Prostate s.c 66% / 
 AKT2 Prostate s.c 89% / 
 AKT3 Prostate s.c 57% / 
 PKN3 Prostate Orthotopic 60% 75% for 
metastasis 
 FAK Ovarian i.p 60% / 
Cell death and 
Survival 
Bcl-2 Prostate s.c 65% / 
 Mcl-1 Breast s.c 75% no toxicity for 
max dose 
 Survivin  Prostate s.c 30% / 
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Angiogenesis VEGF Prostate s.c 87% No toxicity 
 PAR-1 Melanoma s.c 77% / 
  Melanoma 
meta 
i.v / Decreased 
metastase 
number 81% 
 CD31 Prostate Orthotopic 65% / 
 KLF-5 Lung 
carcinoma 
s.c 60% / 
  Prostate s.c 48% Prolonged 
survival 
median 
 PLX1DC Ovarian i.p 87% Increased 
apoptosis 35% 
Oncogene 
protein 
E6/7 Renal s.c 55% No synergic 
effect with 
cisplatin 
 ret/PTC1 Fibroblast s.c 90% / 
 
EWS-
FLI1 
Ewing 
sarcoma 
i.v 80% No 
inflammatory 
response 
 SS18-
SSX 
Synovial 
sarcoma 
s.c 83% / 
Hypoxy  HIF-1a Glioblastoma s.c 50% / 
Metabolism CA BT474 s.c 75% Increased 
apoptosis,non-
immunogenic 
DNA repair RecQL1 Colorectal 
meta 
Spleen 43% / 
  Pancreatic 
meta 
Spleen 31% / 
  Lung s.c 46% / 
Nuclear 
transport 
Ran Neuroblasto-
ma 
s.c 49% Increased 
apoptotic cell 
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Resistance P-gp Breast s.c 60% / 
Migration Actine B HT-1080 s.c 65% No 
inflammatory 
response 
siRNA 
concomitance 
MDM2, 
c-myc, 
VEGF 
Melanoma i.v 30% No 
inflammatory 
response 
Chemotherapy 
Concomitance 
c-myc Colon s.c 60% Increased 
apoptosis 
 c-myc, 
VEGF 
Ovarian s.c 57%-60% Increased 
apoptosis, no 
inflammatory 
response 
 POSTN Ovarian i.p 90% Increased 
apoptosis 45%, 
decreased 
proliferation 
60% 
Plk1: Polo-like kinase1; MAD2: mitotic-arrest deficient 2; EphA2: receptor of ephrins; 
AKT 1/2/3: KLFisoforme of serinethreonin kinase; PKN3: protein kinase N3; FAK: focal 
adhesion kinase; Bcl: B-cell lymphoma; Mcl-1: myeloid cell leukemia; VEGF: vascular 
endothelium growth factor; PAR-1: protease activated receptor 1; KLF-5: Kruppel-like 
factor 5; PLX1DC: plexin domain containing 1; HIF-1a: hypoxia inducible factor 1a; CA: 
ceramidase acid; MDM2: murine double minute 2; POSTN: periostin. s.c: sub-cutaneous 
injection, i.p: intraperitoneal injection, i.v: intravenous injection. 
 
However, to avoid the side effects often inccurred in traditional treatment, we should 
selectively eliminate cancer cells without damaging normal cells. To do so, the siRNA 
would be targeted to a gene specifically involved in the growth or survival of cancer 
cells, or the siRNAs would be selectively delivered into the cancer cells.  
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2.1.3 siRNA therapeutics in clinical trials 
RNAi has rapidly advanced from research discovery to clinical trials. Large amounts of 
money and effort have been invested in bringing siRNA technology to drug market. 
Initial trials have focused on well validated therapeutic targets, such as the VEGF 
pathway for the wet form of AMD, a leading cause of blindness and on the RSV genome, 
for the treatment of RSV infection, the leading cause of pediatric hospitalizations [59]. 
Phase I trials for above studies have already been completed without untoward toxicity. A 
total of 14 RNAi therapeutic programs have been reported to enter clinical trials in 2010 
[60]. Till 2013, this number has increased to 22, as shown in Table 2.4, and many more 
are still in the development pipeline [61]. However, few publications detailing these 
clinical practices have emerged currently, we can only acquire following information 
from company press releases or the US National Institutes of Health hosted database of 
ongoing and completed clinical trials. 
                      Table 2.4 siRNA based drugs in clinical trials 
Drug Target Disease Phase Company 
ALN-
VSP02 
KSP and 
VEGF 
Solid tumors I Alynylam 
Pharmaceuticals 
siRNA-
EphA2-
DOPC 
EphA2 Advanced cancers I MD Anderson 
Cancer Center 
Atu027 PKN3 Solid tumors I Silence 
Therapeutics 
TKM-
080301 
PLK1 Cancer I Tekmira 
Pharmaceutical 
TKM-
100201 
VP24, VP35, 
Zaire Ebola,  
Ebola-virus infection I Tekmira 
Pharmaceutical 
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ALN-
RSV01 
RSV 
nucleocapsid 
Respiratory syncytial 
virus infections 
II Alynylam 
Pharmaceuticals 
PRO-
040201 
ApoB Hypercholesterolaemia I Tekmira 
Pharmaceutical 
ALN-
PCS02 
PCSK9 Hypercholesterolaemia I Alynylam 
Pharmaceuticals 
ALN-
TTR02 
TTR Transthyretin-mediated 
amyloidosis 
II Alynylam 
Pharmaceuticals 
CAKAA-01 RRM2 Solid tumors I Calando 
Pharmaceuticals 
TD101 K6a (N171K 
mutation) 
Pachyonychia 
congenita 
I Pachyonychia 
Congenita 
Project 
AGN211745 VEGFR1 Age-related macular 
degeneration, choroidal 
neovascularization 
II Allergan 
QPI-1007 CASP2 Optic atrophy, non-
arteritic anterior 
ischaemic optic 
neuropathy 
I Quark 
Pharmaceuticals 
I5NP p53 Kidney injury, acute 
renal failure 
I Quark 
Pharmaceuticals 
PF-655 RTP801 Choroidal 
neovascularization, 
diabetic 
retinopathy,diabetic 
macular oedema 
II Quark 
Pharmaceuticals 
siG12D 
LODER 
KRAS Pancreatic cancer II Silenseed 
Bevasiranib VEGF Diabetic macular 
oedema,macular 
degeneration 
II Opko Health 
SYL1001 TRPV1 Ocular pain, dry-eye 
syndrome 
I, II Sylentis 
SYL040012 ADRB2 Ocular hypertension, 
open-angle glaucoma 
II Sylentis 
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CEQ508 CTNNB1 Familial adenomatous 
polyposis 
I, II Marina Biotech 
Rxi-109 CTGF Cicatrix scar 
prevention 
I Rxi 
Pharmaceuticals 
ALN-TTRsc TTR Transthyretin-mediated 
amyloidosis 
I Alynylam 
Pharmaceuticals 
ARC-520 Conserved 
regions of 
HBV 
HBV I Arrowhead 
Research 
 
As these and other trials advance through the clinic in the near future, the exciting 
potential of siRNAs may be demonstrated. Despite the obvious promise, there are several 
extracellular and intracellular challenges that currently limit the use of RNAi in the clinic. 
Important considerations for therapeutic RNAi include that gene silencing approaches 
rarely remove 100% of the mRNA, that off-target silencing can occur and that each target 
organ and tissues sometimes requires unique treatment. In some cases, the goal is to 
target every cell in the tissue, in other instances certain cell type in an organ is the 
objective. siRNA can also induce potential unwanted effects by activating the innate 
immune response, shutting off defense systems usually needed to fight against viruses. 
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2.2 Current delivery systems 
siRNA molecules must be delivered to the target cells to activate the RNAi pathway. 
Many reports have described the direct delivery of naked siRNA to tissues in vivo such as 
eye, lung and central nervous system [59]. It is still not understood why certain cells, 
other than the rest, can directly take up siRNA into cytoplasm. But in most cases, as 
siRNAs are too large and hydrophilic to pass through cell membranes by themselves, a 
delivery strategy is required to assist their uptake and protect them from degradation. 
Figure 2.5 lists the barriers the delivery system may encounter in vivo [62]. Many types 
of delivery strategy have been created therefore to solve these issues. These include some 
physical internalization method, such as hydrodynamic injection [63,64], which rapidly 
inject large volume of siRNA solution into a mouse via the tail vein; particle 
bombardment and electroporation [63,64]. Physical delivery methods have not been 
studied as extensively as chemical delivery systems, though these approaches may avoid 
possible immune system stimulations that often arise in normal chemical based delivery 
systems. Viral vectors are still the most powerful transfection tools used currently with 
respect to their high efficiency. However, viral vectors are difficult to produce in a large 
scale and more important, their inflammatory and immunogenic nature prevents them 
from clinical administration. To overcome these limitations, non-viral vectors have been 
investigated as an alternative safer way for siRNA delivery. These non-viral 
nanoparticles are preferred to viral carrier due to their relatively low immunogenicity and 
high biocompatibility. Three major types of siRNA delivery system will be discussed 
here. 
 
	   28	  
             
 Figure 2.6 In vivo siRNA systemic delivery barriers. (A) Stability in the blood stream; 
(B) transport across the vascular endothelial barrier; (C) diffusion through the 
extracellular matrix; (D) delivery into the cytoplasm by (Di) endosomal escape and (Dii) 
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direct cytosolic delivery. (Dia) The siRNAs or siRNA nanoparticles were trapped in the 
endosome and (Dib) the siRNAs were released from the endosome into the cytoplasm. 
2.2.1 Lipid based siRNA delivery system  
Since the first discovery and active research of lipid carriers in 1965, the field has 
attracted enormous interest among scientists around the world [65]. Liposomes are 
considered the most versatile supramolecular assemblies with respect to size variety, 
composition and capacity to capsulate a variety of compounds. Liposome technology has 
made significant progress in the pharmaceutical industry, especially in drug and gene 
delivery. Several liposomes have been proved efficient and safe to deliver small molecule 
drugs in patients. Doxorubicin liposome (Doxil; Orthobiotech) has received FDA 
approval for treatment of breast cancer, ovarian cancer and other solid tumors [66]. 
        The ideal liposomes for siRNA delivery will encapsulate siRNA with high 
efficiency, protect siRNA from enzymatic degradation in serum, and form a narrow size 
distribution of less than 200 nm to be able to access extravascular regions. A number of 
different lipid and lipid-like formulation methods have been developed, generating a 
variety of LNPs including liposomes, micelles, microemulsions and solid lipid 
nanoparticles [67]. Among these synthetic carriers, cationic liposomes and lipoplexes 
emerged as the most promising vehicles. Liposomes usually consist of an aqueous core 
enclosed in a phospholipid bilayer with hydrophilic drug entrapped in the aqueous phase. 
In contrast, lipoplexes are spontaneously formed through static interaction [68]. The 
interaction of lipid with siRNA is based on the electrostatic interaction between the 
positive charges of the cationic lipid and the negatively charged phosphate backbone of 
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the siRNA. Upon mixing of the two species in solution, the siRNA is condensed with 
lipid in order to neutralize negative charge. The structure of the lipid/siRNA complex 
depends on the composition of lipid, the properties of solution and the molar ratio of 
them. The structure of the cationic lipids is known to influence the transfection efficiency 
and toxicity of the lipid based delivery system [69]. Thus, the ratio of lipid and siRNA 
should be optimized before experiment to facilitate its interaction with the cell membrane 
and cellular internalization.  
         Lipid-based carriers have been successfully used to deliver siRNA into cells. 
Lipofectamine, RNAifect, Oligofectamine are commercial lipid-based delivery system 
that are routinely used in the laboratory [70]. For instance, siRNA targeting CD31 and 
Tie2 genes complexed with a mixture of cationic and fusogenic lipids can downregulate 
the corresponding mRNA and protein levels in vivo after intravenous injection [71]. 
Intraperitoneal injection of anti-TNF-α siRNA complexed with cationic liposomes 
DOTAP can inhibit LPS induced anti-TNF-α gene expression in mice [72]. 
       Although satisfactory results were obtained for lipid based siRNA delivery system, 
there are still inherent difficulties exist. The amount of lipid required for efficient siRNA 
delivery in vivo is often accompanied by severe toxicity problems [73]. Besides, lipid 
can rapidly adsorb to serum proteins and trigger immune system response in the body. 
Thus, limited successful use of lipid was reported in vivo.  
2.2.2 Polymers and dendrimer based siRNA delivery system 
Linear or branched cationic polymers, made up of repeated units of covalently bonded 
monomers is another class of widely studied siRNA delivery system. The positively 
	   31	  
charged polymers bind to siRNA through electrostatic interaction [74]. Figure 2.7 
illustrates the schematic structures of siRNA nanocarriers formed by polymers [75].  
                      
Figure 2.7 Schematic structure of various polymer based nanocarrier for siRNA delivery 
       A variety of polymers including poly(ethyleneimine)(PEI), poly-(L-lysine)(PLL) 
[76], chitosan [77], gelatin [78], poly-D,L-lactide-co-glycolide (PLGA) [79], poly 
(dimethylaminoethylme-thacrylate) (PDMAEMA) [80,81] and poly (trimethylamino-
ehylmethacrylate) (PTMAEMA) were investigated. PEI is the most widely used polymer 
for siRNA delivery. In general, a branched structure of PEI offers higher transfection 
efficiency and a high molecular weight complex leads to increased toxicity. Non-
covalently complexed PEI/siRNA could be internalized by the cells and achieve 
significant silencing effect. The systemic application of HER-2-specific gene complexed 
with PEI inhibited the growth of established tumors [82]. The intrathecal injection of 
PEI-siRNA complex targeting the pain receptor NR2B subunit decreased the mRNA 
level and its associated protein expression [83]. Dendrimers are synthetic 
macromolecules with highly branched peripheral chain ends. Although the investigation 
of dendrimers as siRNA delivery vector is still in its infancy, there are several reported 
advantages, which make it a promising versatile carrier. A novel surface neutral 
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dendrimers generated from poly(amidoamine) (QPAMAM) [84] was reported to show 
low cytotoxicity and highly organized compact ability because of its neutral surface and 
cationic inside structure.  
2.2.3 Cell-penetrating peptide based siRNA delivery system 
Cell penetrating peptides are defined by their ability to reach the cytoplasmic and/or other 
cellular compartments after internalization [85,86]. The initial discovery of cell 
penetrating peptide goes back about twenty years when the HIV-1 transactivating protein 
Tat was found to be taken up by mammalian cells [87,88]. And the following discovery 
of the homeodomain of Drosophila melanogaster transcription factor Antennapedia 
demonstrated that some “non-nature” peptides also share this property [89]. Mutation and 
deletion analyses have shown that in fact small domains within these proteins are 
responsible for the cellular uptake instead of the full-length peptide. These small peptide 
sequences are now referred to as CPPs or protein transduction domains (PTDs). Some of 
the CPPs, like Tat and penetratin, are small domains obtained from nature sequences, 
while some others are artificial designed constructs containing the critical feature of 
already known CPPs [90,91]. These CPPs share some common properties such as 
amphipathic and net positively charged at physiological pH [92]. Sometimes, siRNAs are 
linked to CPPs by expression as a fusion or by chemical coupling. Less peptide is 
required for this method. This is extremely important if peptide shows high toxicity to the 
cells. Recently, a more popular way to construct siRNA/peptide complex is allow them to 
bind each other non-covalently through mainly ionic interactions. The advantage of the 
later approach is that it does not require chemical modification of siRNAs, which 
maintain the nature structure of RNAs and reduces the purification procedures [93]. 
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Some positively charged amino acid such as arginine, lysine and histidine are often 
included in the peptide sequence for this purpose. 
        MPG, which is derived from the fusion peptide domain of HIV-1 gp41 protein and 
the nuclear localization sequence (NLS) of SV 40 T antigen, is the first peptide non-
covalently complexed with siRNA [94]. Luciferase activity was decreased by 80% after 
transfection with the complex. The derivatives MPG∆NLS and MPGα shows enhanced 
transfection efficiency and increased siRNA binding ability [95]. Further variations in 
the hydrophobic part of MPG led to pep-family [96,97]. In addition, more information on 
the recent discovered CPPs can be found in a variety of reviews [98–103]. 
   
       Figure 2.8 Principles of peptide mediated siRNA delivery [104] 
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2.3 Uptake pathways and subsequent intracellular trafficking of cell-
penetrating peptides as siRNA delivery vector 
2.3.1 Internalization mechanism of CPP/siRNA complexes 
Despite the intensive study in cell penetrating peptide, the uptake mechanisms are still 
elusive and remain a major controversy. In general, positively charged CPPs will attach 
to membrane surface through ionic interactions with negatively charged membrane 
components, i.e. heparin sulfate proteoglycans [105–107]. Subsequently, the complexes 
are internalized to cells by directly penetrating or endocytosis, depending on the uptake 
mechanism. Early study on labeled siRNA with fluorescence microscopy and flow 
cytometry showed that these peptides seemed to be internalized very rapidly within 
minutes even at 4°C, suggesting an energy-independent mechanism [108]. The secondary 
structure of peptides possibly plays an important role in cell membrane penetrating 
process. The peptides would form secondary structures as α-helix or β-sheet depending 
on the sequences and solvent. These structures would help the complex to translocate the 
cell membrane [109,110]. However, some peptides such as oligoarginine can translocate 
through cell membranes in a random coil, suggesting secondary structure is not the only 
factor that decides the uptake mechanism [111]. The recent studies that the uptake 
mechanism of CPPs also can be influenced by the kind of cargo it carries make the 
situation more complicated. For example, a Tat-GFP fusion protein was involved in 
caveolae/lipid raft-dependent process [112] while a fusion construct of Tat and Cre 
recombinase went through a macropinocytotic uptake pathway [113].  In a word, the 
mechanism of internalization strongly depends on the properties of both CPP and cargo 
as well as on the cell lines, transfection condition and even complex concentration [114]. 
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CPPs can cross the membrane bilayer directly in a non-endocytic, energy independent 
manner [115]. This occurs when the peptide are compatible with the membrane or can 
sufficiently disturb the structural integrity of the membrane. The process will be 
influenced if there are changes in membrane properties, such as fluidity and membrane 
potential. MPG and Pep-1 are reported to deliver siRNA into cells efficiently in an 
endosomal independent pathway [116,117].   
       Endocytosis is a process by which cells use to internalize solutes and fluids from the 
extracellular matrix [118]. It comprises of phagocytosis and pinocytosis. Phagocytosis 
relates to the uptake of large particles and exists in special cell types, where pinocytosis 
occurs in all cells and can be further divided into four mechanistically different pathways: 
macropinocytosis, clathrin-mediated endocytosis (CME), caveolae-/lipid-raft mediated 
endocytosis and clathrin and caveolin-independent endocytosis [119]. Figure 2.9 lists the 
uptake pathways for CPP/siRNA complexes. Extracellular molecules will be 
encapsulated in a lipid vesicle after internalization. Whether they can reach RISC in 
cytosol depends on their ability to escape the endosome before they are delivered back to 
the cell membrane for recycling or degraded by enzymes in lysosomes. Evidences have 
shown that the release of CPP-siRNA complex into the cytoplasm is a bottleneck for 
many peptide-mediated siRNA delivery systems.  
      To determine which uptake pathway the complex applys, some biological tools are 
used. These tools are usually various endocytosis pathways inhibitors, which will block 
the specific uptake of labeled complex. Tracer molecules for labeling endocytic pathway 
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                        Figure 2.9 Uptake pathways of CPP/siRNA complexes 
compartments can be use to investigate uptake mode as well [120]. Based on 
experimental results, widespread opinions favor endocytosis as major pathway for most 
CPPs while direct membrane penetration is also regarded as possible for individual CPPs.  
2.3.2 Endosomal escape strategy 
For now, the most widely used delivery strategy for macromolecules including siRNA is 
to take advantage of the endocytosis pathway. After internalized via endocytosis, the 
internalized complexes exist in endosomes with no access to the cytosol. Therefore, 
endocytosed siRNA will need to escape from the endosome to reach the cytoplasm where 
the RISC locates. The endosomal entrapment and subsequent enzymatic degradation in 
lysosome contribute to the low transfection efficiency and is a major impediment for 
most non-viral carriers. Therefore, a variety of strategies have been used to facilitate 
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endosome escape, these include the addition of pore formation or fusion in the endosomal 
membrane, pH-buffering effect (the proton sponge effect), and photosensitizers [121].  
        Liposomes represent a mature delivery system as mentioned above. The mechanism 
by which cationic lipids escape from the endosome was proposed by Xu and Szoka [122]. 
The cationic lipids can interact with negatively charged membrane lipids in early 
endosome by formation of ion-pair. The electrostatic interaction could further promote 
the formation of the inverted hexagonal phase [123]. This will lead to the fusion of the 
liposome with endosome membrane, triggering the release of siRNA into cytoplasm.  
        For many cell penetrating peptides[124], the most troublesome problem is the 
entrapment in endosome after uptake, rather than the internalization itself. Thus, these 
CPPs can be further modified to promote endosomal escape, preventing degradation and 
allowing the siRNA to reach targets in cytosol. Endosomolytic reagents that are able to 
disturb endosome membrane can be used in combination with CPPs to enhance the 
release of complex. Chemical reagent chloroquine is thought to disrupt endosomes by 
inhibiting the acidification process of the endosome [98]. Some studies have 
demonstrated that an enhancement of the silencing effect was obtained by adding 
chloroquine with CPP-siRNA complex [95,113,125]. However, chloroquine is not 
suitable for in vivo therapeutic administration.  
       As alternatives, some peptides, known as fusogenic or endosomolytic peptides can be 
utilized to destabilize the endosomal membrane. The majority of viruses such as the 
influenza and adeno virus have single integral membrane peptides that will induce 
endosomal disruption or fusion upon acidic pH of endosomes. These peptides will go 
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through conformational changes in response to acidification of the endosome [126]. HA2 
peptide, derived from influenza virus hemagglutinin [127] is the most widely used 
fusogenic peptide. Protonation of the acidic residues of HA2 when endosome 
acidification happens results in a sided α-helix with a hydrophobic and a hydrophilic 
face. The hydrophobic face will strongly interact with the endosomal membrane, thus 
destabilizing it and cause the cargo molecules released [128]. In a study, the silencing 
ability of cell-penetrating peptide penetratin fused with HA2 was examined. The results 
indicated that the fusion of HA2 to penetratin significantly improve the transfection 
efficiency of penetratin alone [129]. Similarly, the biological activity of another CPP Tat 
was also enhanced by the fusion of HA2 to it, or by the administration of HA2-Tat 
protein with Tat at the same time [127]. Covalently linking the fusogenic peptide to the 
CPP directly increases the endosomolytic property of CPP, in contrast to adding chemical 
endosomolytic reagent. 
      Photostimulation strategy can also be applied to release endocytosed molecules in a 
biologically active form from endosomal vesicles. The photosensitizer reagents used here 
can be small molecules like TPPS2a and AlPcS2a [130] or fluorescent dye [131,132]. After 
internalization, the photosensitizers are mainly localized in the endosome with trapped 
CPP/siRNA complex. The cells or tissues are then exposed to light at a wavelength close 
to the excitation of the photosensitizers. This photostimulation will trigger the generation 
of highly reactive singlet oxygen (1O2), which result in disruption of endosomal 
membranes and the release of contents into the cytosol [98]. Some experiments have 
proved that this photostimulation strategy could greatly improve siRNA silencing 
efficiency [133,134]. This photoinduced endosomal escape strategy has potential use in 
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therapeutics as a targeting method without inducing extensive cell death and with 
maintenance of the biological activity of the released cargos.  
       The “proton sponge ” effect is mediated by agents with high buffering ability and the 
flexibility to swell when protonated. In this approach, proton absorbance by buffering 
agents prevents acidification of endosomes, thereby increasing the ATPase-mediated 
influx of protons, as well as counter ions, which enter endosomes to balance the proton 
flux. Increased ion concentrations inside endosomes will lead to osmotic swelling, 
endosomal membrane rupture and eventually leakage of the contents into cytosol [135]. 
Figure 2.10 demonstrates the endosomal escape process via “proton sponge” effect [136]. 
         
                   Figure 2.10 Endosomal escape process via “proton sponge” effect 
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        With the aim to increase the endosomal escape of siRNAs after peptide-mediated 
delivery, we can rationally include some agents with buffering effect when we design the 
cell-penetrating peptide, such as histidine residues. The imidazole group of histidine has a 
pKa of around six and can absorb protons in the acidic environment (pH5-6.5) of the 
endosome, leading to osmotic swelling, membrane disruption and eventually cargos 
escape [137]. Lundberg has reported a new peptide EB1 derived from penetratin by 
replacing two basic amino acids with histidines and the N-terminal addition of six amino 
acids [129]. This peptide will undergo a pH-dependent conformational change to a higher 
degree of helicity. The followed transfection experiment demonstrated that this modified 
peptide had better silencing effect than penetratin. Other examples of histidine containing 
peptide improving the transfection efficiency of peptide are also reported in literatures 
[138,139].  
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Chapter 3 
A New Amphipathic Peptide as siRNA Delivery Carrier: 
Physicochemical Characterization and Cellular Uptake* 
 
3.1 Introduction  
The recent discovery of RNA interference (RNAi) is considered to be the most important 
and exciting discovery of the past multiple decades [140]. RNAi is a natural regulatory 
process where small, double-stranded RNA molecules (typically 21-25 nucleotides) turn 
off specific genes in a biological cell [4]. Because RNAi is highly specific and efficient, 
it has become a widely used tool to dissect signaling pathways, discover important genes 
to embryonic development, and elucidate the function of novel genes in various 
fundamental biological processes—functional genomics [1,141]. However, the real 
payoff of RNAi lies in new therapies—short interfering RNAs (siRNAs)—which could 
yield more efficient drugs to fight cancer, HIV, influenza, and other diseases where 
conventional therapies fail. Rather than blocking the effects of specific proteins, which is 
what most conventional drugs do, an RNAi-based therapy could, in theory, stop the 
proteins from being made in the first place.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  *	   	   This chapter is based on a paper M. Jafari, W. Xu, S. Naahidi, B. Chen, P. Chen, A new 
amphipathic, amino-acid-pairing (AAP) peptide as siRNA delivery carrier: physicochemical 
characterization and in vitro uptake, J. Phys. Chem. B. 116 (2012) 13183–13191. M. Jafari and 
W. Xu contribute equally to this paper.	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  However, despite abundant promise, the translation of RNAi to realistic therapeutics 
has faced serious obstacles. The large size and polyanionic nature of free siRNAs prevent 
them from translocating across the negatively charged cell membrane. Moreover, without 
protection, siRNAs are subject to enzymatic degradation under physiological conditions. 
These highlight the importance of developing an efficient siRNA delivery system. In 
light of the safety concerns and efficacy issues with current drug delivery systems, cell-
penetrating peptides (CPPs), net positively charged peptides with fewer than 30 amino 
acids, have been widely applied to deliver cargos into cells. We have been studying a 
class of peptides, the self-assembling/co-assembling peptides, which can be used as drug 
or gene delivery vehicles [34]. These peptides have been successfully used to encapsulate 
a model anticancer drug and deliver it across the cell membrane in a controlled manner 
[142]. Encouraged by these results, we generated libraries of peptides that have potential 
to deliver siRNAs into cells. After high throughput screening from the first library of 
designed peptide [143], we have discovered a promising peptide C6 that is able to form 
stable non-covalent complexes with siRNA and deliver into cells efficiently. Considering 
the amphiphilic nature of the cell membrane, most CPPs possess both hydrophilic and 
hydrophobic moieties. C6 is amphiphilic, as the hydrophilic side interacts with the 
hydrophilic drugs/gene through electrostatic interaction, whereas the hydrophobic side is 
anchored in the hydrophobic core of the bilayer, triggering the endocytosis pathways or 
assisting the direct translocation of peptide-cargo to the cytosol. The amphiphilicity of 
the peptides may evolve from their primary structure, for example, MPG [144], or 
secondary structure, for example, penetratin, where the peptide needs to adapt a helical 
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structure to organize hydrophilic and hydrophobic moieties at different sides of the 
peptide.  
      Three types of amino acids were incorporated in the design of C6 peptide (Ac-
RLLRLLLRLWRRLLRLLR-NH2): (1) seven arginine residues were incorporated to 
interact with siRNA and cell membrane. Positively charged arginine residues can interact 
with the negatively charged phosphate groups on the siRNA backbone via ionic 
interactions. These basic residues also interact with negatively charged cell surface 
proteoglycans to initiate their cellular uptake [145]. CPPs with six to nine arginine 
residues have been reported to have the highest translocation efficiency [146]. (2) Ten 
leucine residues were incorporated to induce the amphiphilicity and helicity to the 
peptide structure. These hydrophobic residues are found abundantly in the helical regions 
of proteins [147]. They also interact with hydrophobic tails of lipid bilayer and facilitate 
the translocation of peptide [148]. (3) An aromatic tryptophan residue in the middle of 
the sequence was incorporated to use as an intrinsic fluorescence probe to study the 
structural change of peptide upon changing the environment or interaction with siRNA. 
        Because each turn of a peptide helix includes 3.6 residues, arginine residues were 
distributed along the peptide sequence in three or four residue intervals, so when a helical 
structure was formed, they all faced the same side of the helix (Figure 3.1). This induces 
amphiphilicity to the peptide structure as polar (R) and nonpolar (L, W) residues face 
opposite sides when peptide adopts a helical structure. The presence of all arginine 
residues on hydrophilic face of the helix facilitates ionic interaction of positively charged 
residues with siRNA backbone, maximizing the loading capacity of the peptide. 
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Figure 3.1 Helical wheel projection of peptide C6. A downward cross-sectional view of 
the α helix axis, orthogonal to the paper plane, is shown. The bigger the circle is, the 
upper turn the residue is located at, when viewing from the top. R (green), L (yellow), 
and W (blue) represent arginine, leucine and tryptophan residues, respectively. 
 
The chapter will be focused on physicochemical characterization of C6 and its 
coassembly/complex with siRNA as well as C6-mediated cellular uptake of siRNA using 
several biophysical, spectroscopy, and microscopy approaches. 
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3.2 Materials and Methods 
3.2.1 Peptide and siRNA  
The C6 peptide (Ac-RLLRLLLRLWRRLLRLLR-NH2, MW 2470.2 g/mol) was 
purchased from CanPeptide (Montreal, Canada). High performance liquid 
chromatography (HPLC) analysis indicated that the synthetic peptide was at least 98% 
pure. SilencerTM GAPDH siRNA  (Life Technologies, Carlsbad, USA) was used as 
siRNA targeting the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene. The 
SilencerTM Cy3-labeled GAPDH siRNA (Life Technologies, Carlsbad, USA) was used in 
fluorescence microscopy and Fluorescence Activated Cell Sorting (FACS). The siRNA 
used in agarose gel electrophoresis and fluorescence spectroscopy is eGFP siRNA, which 
was purchased from Dharmacon with an extinction coefficient of 362408 L/mol cm. The 
sense sequence is GACGUAAACGG CCACAAG UUC and antisense sequence is 
ACUUGUGGCCGU UUACGUCGC.	  The negative control siRNA (Life Technologies, 
Carlsbad, USA) used in the experiment was siRNA with scrambled sequence. 
3.2.2 Cell Culture  
CHO-K1 (Chinese hamster ovary) cells were purchased from American Type Culture 
Collection (ATCC, Manassas, USA). Cells were cultured in F-12K medium (Thermo 
scientific, Ottawa, Canada) supplemented with 10% fetal bovine serum (FBS) (Sigma, 
Oakville, Canada). All of the cells were incubated at 37°C in a humidified atmosphere 
containing 5% CO2. 
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3.2.3 Preparation of Peptide/siRNA Coassembly/Complex 
The C6 peptide was prepared by dissolving peptide powder in RNase-free water. A stock 
solution of 1 mM was made and diluted at desirable concentrations for various 
experiments. The solution was vortexed for 10 s and sonicated for 10 min in a tabletop 
ultrasonic cleaner (Branson, model 2510, Danbury, USA). siRNA was diluted in RNase-
free water to a concentration of 50 µM. Peptide/siRNA complexes were formed by 
adding peptide solution into siRNA in proportion according to the designed experiment. 
The complexes were incubated for 20 min at room temperature before each experiment. 
3.2.4 Atomic Force Microscopy (AFM) 
 The nanostructures of peptide C6 (40 µM) and C6/siRNA (molar ratio of 40/1) 
complexes were characterized by AFM. The sample solution (10 µL) was placed on a 
freshly cleaved mica surface, fixed on a glass slide, and incubated for 30 min at room 
temperature to allow the sample to adhere onto the mica surface. The mica was then 
rinsed five times with Milli-Q water to remove any unattached particles, followed by air-
drying overnight. The mica surface was analyzed by a PicoScan AFM (Molecular 
Imaging, Phoenix, USA) at room temperature using the tapping mode with silicon single-
crystal tips (NCL type, Molecular Imaging, Ann Arbor, USA), with a typical tip radius of 
10 nm and resonance frequency of <170 kHz. A scanner with the maximum scan size of 
5 µm × 5 µm was used. All AFM images were obtained at a resolution of 512 × 512 
pixels on a scale of 2 µm × 2 µm. 
3.2.5 Agarose Gel-Shift Assay and Heparin Competition Assay 
The ability of C6 to coassemble with siRNA was investigated by agarose gel (1.2 wt %/ 
	   47	  
vol) shift assay. siRNA was incubated for 30 min at 37 °C in RNase-free water with 
different concentrations of C6 to obtain peptide/ siRNA molar ratios ranging from 1/1 to 
80/1. The samples (10 µL containing 0.3 µg of siRNA per well) and loading dye were 
loaded to each well, and electrophoresis was carried out at a constant voltage of 55 V for 
1.5 h in TBE buffer (4.45 mM Tris−base, 1 mM sodium EDTA, 4.45 mM boric acid, pH 
8.3) containing 0.5 µg/mL ethidium bromide. 
      In the case of heparin competition assay, different amounts of heparin corresponding 
to final concentrations from 0.5 to 10 µg heparin per 10 µL of complex were added to 
C6/siRNA complexes at molar ratios of 15/1, 40/1, 60/1, and 80/1. Ten microliters of 
each sample, corresponding to 50 pmol of siRNA, was then analyzed by electrophoresis 
on agarose gel (1.2 wt %/vol) stained with ethidium bromide. 
3.2.6 Peptide mediated siRNA transfection in cultured cells 
CHO-K1 cells were seeded in F-12K medium with 10% FBS without antibacterial agents 
in a 24 well plate, 24 hrs before transfection. Overlay the cells with 100 ul of preformed 
complexes after rinse the cells with PBS, incubate for 3–5 minutes, and then 200 µl of 
Opti-MEM (Life Technologies, Carlsbad, USA) were added. After 4 hours of incubation 
in 37°C, 300ul of media containing 20% FBS was added to obtain a final FBS 
concentration of 10%. For siRNA uptake experiment, cells were harvested after 3 hours 
while for knockdown experiments, cells were collected after 48 hours.  
3.2.7 Fluorescence-Activated Cell Sorting (FACS) 
The amount of Cy-3 labeled siRNA uptaken by the cells was studied by Flow Cytometry 
(type BD Biosciences, BD FACSVantage SE Cell Sorter, Franklin Lakes, USA). 
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Approximately 50000 CHO-K1 cells were seeded in a 24-well cell culture plate 24 h 
before treatment. Cy3-labeled GAPDH siRNA was complexed with C6 peptide at molar 
ratios of 15/1, 25/1, and 40/1 and incubated at room temperature for 20 m. Lipofectamine 
2000 (Life Technologies, Carlsbad, USA) was complexed with labeled siRNA according 
to manufacturer’s protocol and used as a positive control. The complexes were added to 
cells with a final siRNA concentration of 50 nM per well and incubated at 37 °C for 3 h 
in Opti-MEM. The medium was removed by aspiration, and the wells were washed with 
heparin (10 U/mL, three times total for 1 h at 37 °C). After washing, the cells were 
detached from the plate by adding trypsin-EDTA and resuspended in fresh 4% 
paraformaldehyde (PFA) in phosphate-bufferred saline (PBS) and collected in FACS 
tubes for analysis.  
3.2.8 mRNA level measurement 
Approximately 4x104 CHO cells were plated in a 24-well cell culture plate. 24 h later, the 
medium was replaced by Opti-MEM. GAPDH siRNA or scrambled siRNA complexed 
with C6 at different molar ratios were prepared in Opti-MEM medium and added to the 
cells. Three hours later, growth medium with 20% FBS was added, followed by 48 h 
incubation at 37 °C in a 5% CO2 atmosphere. The cultures were then washed with PBS. 
Total RNA was extracted from the cells with TRIzol reagent (Life Technology, Carlsbad, 
USA), then treated with chloroform (Sigma, Oakville, Canada) and 2-propanol (Sigma, 
Oakville, Canada) as recommended by the manufacturer. RNA concentrations were 
measured by Nanodrop spectrophotometer ND-1000 (Thermo scientific, Ottawa, 
Canada). All RNAs were reverse transcribed with Bio-Rad iScript cDNA synthesis kit. 
The cDNA synthesis was primed with a unique blend of oligo (dT) and random primers. 
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The following pairs of primers were used for PCR: 5ʹ′-TTGCTGTTGAAGT- 
CGCAGGAG-3ʹ′, 5ʹ′-TGTGTCCGTCGTGGATCTGA-3ʹ′ (Sigma, Oakville, Canada). 
Here, the housekeeping gene cyclophilin was chosen as an internal control to normalize 
the GAPDH gene. The normalization was performed by the amplification of mouse/rat 
cyclophilin mRNA with the following primers: 5ʹ′-AGGGTTTCTCCACTTCGATCT- 
TGC-3ʹ′ and 5’-AGATGGCACAGGAGGAAAGAGCAT-3ʹ′ (Sigma, Oakville, Canada). 
PCR reaction was performed with Brilliant II Fast SYBR Green QPCR Master Mix 
(Agilent Technologies, Wilmington, USA) on an Mx3005P™ Real-Time PCR System 
(Agilent Technologies, Wilmington, USA). 
3.3 Results and Discussion 
3.3.1 Morphology of C6/siRNA complex  
The particle size and charge significantly affect its circulation in the bloodstream, 
biodistribution, and uptake by the cells. The particle size ranging from 100 to 500 nm 
would be ideal for passive targeting to solid tumors through the enhanced permeability 
and retention (EPR) effect [149]. Therefore, engineering the nanoparticle to obtain 
appropriate physical properties could significantly enhance its therapeutic effect. The 
particle size and zeta potential of C6/siRNA complex were first studied by dynamic light 
scattering and zeta potential. As reported [150], the majority of C6/siRNA coassemblies 
at molar ratios of 10/1 to 20/1 had an average size of ∼50 nm. However some larger 
particles (∼200 nm) were also observed. The size of complexes was increased by adding 
more peptides, because the extra peptides added layers to the initially formed 
peptide/RNA cores. This finding was in agreement with AFM images (Figure 3.2b), 
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which show high population of small nanoparticles (∼50 nm) as well as the presence of 
larger complexes (∼100−200 nm). At molar ratio of 40/1, the complex became more 
uniform as the intensity and number-based DLS results showed the average size between 
150 and 250 nm. The peptide only sample formed globular structures with an average 
diameter of ∼45 nm, eventually organized to form a network of strings of nanospheres, 
shown in Figure 3.2b. The formation of these globular structures was derived by 
hydrophobic attraction between leucine residues, distributed along the peptide sequence. 
 
Figure 3.2 AFM images of (a) C6 peptide aggregates/assemblies (40 µM) and (b) 
C6/siRNA complex (MR = 40/1). The sample solution (10 µL) was placed on the mica 
surface and incubated for 30 min at room temperature. The mica was then rinsed five 
times with Milli-Q water, followed by air-drying overnight. The scan size of the images 
is 2 × 2 µm2. The scale bar denotes 200 nm.  
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Because there was not such a template for nanoparticles in solution in DLS experiment to 
form the network, they aggregated, instead, as larger particles to minimize the interaction 
of hydrophobic residues and water molecules. This self-assembly/aggregation process is 
thermodynamically favored by minimizing Gibbs free energy through limiting the 
exposure of hydrophobic residues to the aqueous environment and having mostly charged 
arginine residues on the surface of globules. 
      The surface charge of C6/siRNA complex at molar ratio of 10/1 was slightly 
negative, which implies that siRNA molecules were not fully saturated by peptides. 
Considering seven positively charged arginine groups of the peptide C6 and 21 pairs of 
negatively charged nucleotides in a siRNA molecule, it was theoretically expected to 
neutralize the negative charge of siRNA at molar ratio of 6/1; however, at a higher molar 
ratio, that is, 15/1, the zeta potential of the complex jumped to +30 mV, indicating that 
peptides fully covered the surface of the complex. With the increasing concentration of 
peptide at the same siRNA concentration, the positive value of the surface charge of the 
complexes increased from +30 (MR = 15/1) to +60 mV (MR = 40/1) due to the increase 
in the number of positively charged arginine residues. The net positive charge of the 
particles is crucial because it inhibits particle aggregation and enhances electrostatic 
interaction with the negatively charged phospholipids of the cell membrane upon siRNA 
delivery. 
        The helical structure of C6 was also confirmed by CD spectroscopy. C6 in water 
showed a small content of a random coil conformation with a minimum at 203 nm. By 
adding a small amount of siRNA (MR of 40/1), a clear shift in the spectrum minimum 
from 203 to 208 along with a maximum around 190 nm was observed, which represents a 
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typical helical conformation. The absolute values of the minima at 208 and 222 nm and 
the maximum at 190 nm were increased by adding more siRNAs to MR of 10/1, which 
indicates the increase in helical content in secondary structure of the peptide at a higher 
concentration of siRNA. Adding further siRNA beyond the MR of 10/1 did not 
significantly change the secondary structure of the peptide. Considering the nature of C6 
and siRNA interaction, that is, ionic interaction, the charge neutralization of seven 
arginine residues in the peptide sequence may decrease the repulsion between them, 
which eventually facilitated the peptide adoption to a helical conformation. 
 
3.3.2 Agarose gel-shift assay and heparin competition assay 
Agarose gel shift assay was used to detect the interaction between siRNA and peptide 
molecules and the stability of the formed complex in the presence of heparin. Peptide can 
interact with siRNA through noncovalent interactions such as Coulombic forces and 
hydrogen bonding. In particular, basic amino acids such as lysine, arginine, or histidine 
can interact with the negatively charged phosphate groups on the siRNA sugar rings 
through electrostatic interactions. Free siRNA molecules could move toward the positive 
electrode when the voltage is applied, whereas the inability of peptide/siRNA complexes 
to enter the agarose gel suggests the formation of stable complex with no free siRNAs to 
be shown in siRNA bands. As shown in Figure 3.3a, the effective formation of the 
C6/siRNA complex started at molar ratio of as low as 5/1 because the band was less 
bright than that of siRNA only. At the molar ratio of 10/1, siRNA molecules were almost 
completely associated with peptide C6 because a very small amount of free siRNA was 
observed on siRNA band. This band completely disappeared at the molar ratio of 15/1. 
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This finding suggests that excess peptide molecules are needed to obtain stable 
peptide/RNA complexes, as six molecules of peptides are theoretically required to 
neutralize electrostatically one molecule of siRNA. Further experiments showed that the 
excess peptide molecules could provide a shield to protect siRNA molecules against 
degradation and also interact with cell membrane to initiate the peptide/siRNA cellular 
uptake. 
 
Figure 3.3 (a) Formation of C6/siRNA complexes at different molar ratios, indicated by 
agarose gel. siRNA was incubated with different concentrations of C6 corresponding to a 
molar ratio ranging from 1/1 to 80/1. Lane 1 refers to siRNA control in the absence of 
C6, and lanes 2−8 refer to different molar ratios. (b) Stability of C6/siRNA complex 
indicated by heparin competition assay. Different amounts of heparin corresponding to 
final concentrations of 0.5 to 10 µg heparin per 10 µL of complex were added to 
C6/siRNA complexes at different molar ratios. The stability of complexes was analyzed 
by electrophoresis on agarose gel (1.2 wt %/vol) stained with ethidium bromide. For 
better comparison, the siRNA bands of four independent gels were put in the same image.  
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          The stability of C6/siRNA complexes at different molar ratios in the presence of 
heparin was also analyzed by gel electrophoresis. As shown in Figure 3.3b, C6/siRNA 
complexes were stable in the absence of heparin (second well from left), and no free 
siRNA was shown in siRNA bands at all MRs. The complex at MR of 15/1 was stable at 
very low concentration of heparin, that is, 0.5 µg per 10 µL of sample, but dissociated at 
higher heparin concentration. The minimum concentration of heparin required for 
dissociation of the complex increased by increasing the MR up to 60/1. However, the 
complex at the molar ratio of 80/1 was completely stable even at high heparin 
concentration (10 µg in 10 µL of loaded sample). 
 
3.3.3 Subcellular distribution of C6/Cy-3 siRNA  
To study the cellular uptake, distribution, and localization of siRNA complexed with C6, 
we transfected CHO cells with Cy3-labeled siRNA alone or in complex with C6 or 
lipofectamine 2000. CHO cells were incubated with or without complexes for 3 h and 
observed under a fluorescence microscope (Figure 3.4). 
      As expected, Cy-3 siRNA alone was not able to enter the cells by itself due to the 
negative charge and lack of an appropriate delivery vector (Figure 3.4b). siRNA 
internalization happened within 3 h of incubation at the presence of transfection reagent, 
Lipofectamine 2000, as shown as small red dots in the cytosol of most of the cells (Figure 
3.4d). In the cells treated with C6/siRNA complexes (Figure 3.4e, f), siRNA was 
localized to regions in close proximity to the nuclear membrane. siRNAs delivered by C6 
	   55	  
showed a punctual nonhomogeneous distribution pattern around the periphery of the 
nucleus inside the cell, which indicated the possibility of endocytosis pathways [95].     
      C6/siRNA complexes at high molar ratios 40/1 may form high-molecular-weight 
complexes or aggregate, as previously documented for other CPPs. These large 
complexes may be internalized through the macropinocytosis pathway, which can include 
all pinosomes larger than 200 nm. However the uptake of large aggregates by fluid phase 
endocytosis may not result in the effective release of siRNA into the cytoplasm and 
eventually significant gene knockdown. Thus, precautions should be taken into account 
when increasing the molar ratio because the large aggregates might have problems 
dissociating and releasing siRNA in the cells, eventually decreasing the knockdown 
efficiency of the complex. 
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Figure 3.4 Subcellular distribution pattern of Cy3-labeled siRNA 3 h post-treatment. 
Cy3-labeled GAPDH siRNA (red) was transfected to CHO-K1 cells with positive control 
reagent and different molar ratio of C6 at a siRNA concentration of 50 nM. Cells were 
analyzed by fluorescence microscopy 3 h after transfection (magnification, 40×). Nuclei 
were stained with DAPI (blue). (a) Nontreated cells and (b) cells treated with 50 nM 
siRNA only, (c) with C6 peptide only, (d) with Lipofectamine 2000 as positive control, 
and (e) with siRNA complexed with C6 at molar ratio of 15/1 and (f) molar ratio of 40/1. 
3.3.4 Cellular uptake of peptide/siRNA complex 
The efficiency of C6 to deliver siRNA into CHO-K1 cells was evaluated using FACS. As 
shown in Figure 3.5, cellular uptake efficiency of siRNA was correlated to the molar ratio 
of C6/siRNA. Even though a 15/1 molar ratio was sufficient to deliver an even higher 
amount of siRNA into cells compared with Lipofectamine 2000, the intracellular 
fluorescence intensity increased with increasing molar ratio (MR 25/1 and MR 40/1). 
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Figure 3.5 Flow cytometry results for Cy3-labeled siRNA delivered by Lipofectamine 
2000 and C6 at different molar ratios (MRs).  
3.3.5 Gene silencing efficiency of C6/siRNA complexes 
As GAPDH siRNA can be effectively delivered to CHO-K1 cells, next we want to see 
whether this delivered siRNA is able to perform RNAi and decrease the expression level 
of GAPDH mRNA. As shown in Figure 3.6, the positive control Lipo2000/siRNA 
complex demonstrates around 80% knockdown efficiency of GAPDH mRNA.  
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Figure 3.6 Gene silencing efficiency of C6/siRNA complex on CHO-K1 cells. Relative 
GAPDH mRNA level in CHO-K1 cells after transfected with C6/GAPDH siRNA 
complexes was measured by qRT-PCR method. All the data were normalized to another 
house keeping gene cyclophilin and compared to scrambled siRNA control. The results 
correspond to an average of at least three separate experiments. 
 
We expected that C6/siRNA complex would show similar transfection efficiency as 
Lipo2000, since the internalization efficiency is similar. However, C6/siRNA complexes 
only showed 20% knockdown efficiency at most with MR 40/1. This great discrepancy 
was very likely caused by the entrapment of C6/siRNA complexes in the endosomes after 
internalization. In order to increase the silencing efficiency of peptide/siRNA complexes, 
we should improve the endosomolytic ability of peptide C6 itself.  
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3.4 Conclusions 
C6, an amphipathic peptide, was introduced as a safe and efficient carrier for siRNA 
delivery in vitro. The noncovalent interaction/coassembly between C6 and siRNA and the 
physicochemical properties of the resulting coassemblies were studied. C6 alone showed 
a random coil secondary structure in water but adopted a helical conformation upon 
binding to siRNA. The gel electrophoresis and AFM results confirmed stable C6/siRNA 
complex formation in the molar ratios from 10/1 to 40/1. The flow cytometry data and 
fluorescence microscopy images also indicated the high cellular uptake and cytoplasmic 
localization of siRNA delivered by C6. However, in contrast to the high uptake 
efficiency, the silencing efficiency of C6/siRNA is very low at various molar ratios, 
probably due to endosome entrapment of this complex after being internalized into cells 
through endocytosis pathway. Thus, in the following experiments, we try to improve the 
silencing efficiency of C6/siRNA complex by modifying C6 sequence with the addition 
of endosomolytic moiety.  
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Chapter 4 
In vitro and in vivo therapeutic siRNA delivery induced by a 
tryptophan-rich endosomolytic peptide 
 
4.1 Introduction  
RNA interference (RNAi) is considered one of the most important and exciting 
discoveries in biology of the past decade [151]. Only over ten years following its 
discovery, RNAi has already become a widely used tool in biology and medicine, and is 
poised to catalyze development of the next major class of pharmaceutical drugs. Rather 
than blocking the effects of faulty proteins, which is what most conventional drugs do, an 
RNAi-based therapy would, in theory, stop the proteins from being made in the first 
place. Despite abundant promise, several sizable challenges remain in the way of siRNA-
based therapeutics. The most important concern is the effective delivery of siRNA to its 
site of action in the cytoplasm. Some unfavorable physicochemical properties impede the 
uptake of siRNA into the cells, particularly following systemic administration [25], 
including: a relatively large molecular weight, negatively charged surface, hydrophilicity, 
sensitivity to nuclease degradation, and instability (plasma half-life of less than ten 
minutes) [24]. The application of therapeutic siRNA for the targeted silencing of specific 
genes to most tissues and organs requires clinically suitable, efficient and safe delivery 
systems. 
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      Although demonstrated to have high transfection efficiency in vitro, the application of 
some lipids (e.g., Lipofectamine 2000) and polymers (e.g., PEI) [21] as siRNA vectors in 
vivo is limited due in large part to high toxicity [73] and a tendency to induce the immune 
response [32,33]. Among non-viral delivery systems, cell-penetrating peptides (CPPs) are 
emerging as one of the most promising to facilitate cellular uptake of various 
biomolecules, including siRNA. By comparison, CPPs mediated internalization is highly 
efficient and often harmless to the cell in therapeutic dosages, avoiding severe cell 
membrane destabilization [152]. Most well characterized cell penetrating peptides to date 
are derived from known transduction domains of proteins that interact with cell 
membranes, e.g., TAT(-YGRKKRRQRRR-) from HIV-1 TAT protein [153], penetratin 
from the homeodomain of the Antennapedia protein of Drosophila [154], and CADY 
from fusion peptide JTS1 [155]. These peptides usually consist of 30 or less amino acids 
and share some common characteristics, such as amphipathicity and a positive charge at 
physiological pH.    
      In previous chapter, we have reported a new cell penetrating peptide C6 
(RLLRLLLRLWR RLLRLLR) that can form stable complexes with siRNA and deliver 
them into cells in a highly efficient manner [156]. However, the knockdown efficiency of 
the complex is low, probably due to the poor endosome escape ability. siRNA that 
remains entrapped within endosomes cannot display biological activity, as it can not 
reach cytoplasm where RNAi happens. In order to optimize delivery, we modified the C6 
sequence by replacing some amino acids to increase its endosomolytic property. Among 
derivatives, C6M1 is one of the peptides showing potent therapeutic siRNA delivery 
ability. This new peptide, C6M1 (Ac-RLWRLLWRLWRRLWRLLR-NH2) maintains the 
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seven arginine residues in C6, in accordance with reports that peptides with six to nine 
arginine residues have the highest translocation efficiencies [146]. These positively 
charged arginine residues can interact with the negatively charged phosphate groups on 
the siRNA sugar rings through electrostatic interaction and increase the affinity of the 
complex with negatively charged head groups of plasma membrane [157]. Some of the 
leucine residues were kept from C6, as leucine is the strongest structure forming residue 
found abundantly in the helical regions of proteins [158]. Hydrophobic residue leucine, as 
well as other hydrophobic residues, may facilitate the translocation of the peptide by 
interacting with the hydrophobic tails in the lipid bilayer [148]. To improve endosomal 
escape, we use aromatic tryptophan to substitute some leucine residues in the sequence, 
since tryptophan rich motif is found abundantly in the pore-forming toxins of bacteria 
[159,160]. Meanwhile, tryptophan is able to interact with lipids/cholesterols within the 
cell membrane and have therefore been shown to play an essential role in the cellular 
uptake of many cell-penetrating peptides [109,154]. We arrange the amino acid residues 
in alternating order in the sequence that if the peptide adopts α-helical structure, it has an 
amphiphilic helical structure with one side of the helix contains mainly hydrophilic 
amino acid residues, while the other side contains mainly hydrophobic ones. This 
amphiphilic helical structure is widely found in antimicrobial peptides [161,162], which 
have high affinity for cell membrane. Viewed from the top, C6M1 displayed an α-helical 
secondary structure with three distinct sections, see Figure 4.1a. When folded, the 
ordered segregation of polar (R) and nonpolar (L, W) amino acids on different sides of 
the helix constitutes a secondary amphiphilic structure.  
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Figure 4.1 Predicted helical structure of peptide C6M1. (a) Helical wheel projection of 
C6M1 peptide. R represents arginine, L represents leucine, W represents tryptophan. (b) 
3D molecular structure of C6M1. Positively charged functional groups are denoted in 
blue. (c) Formulation strategy for siRNA and C6M1 molecules. Double helix represents 
siRNA.  (d) The final nanocomplex of siRNA and peptides. The figures b-d were 
generated using Hyperchem (Hypercube, Inc.) 
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The hydrogen bonding between C=O and N-H groups in the backbone of the peptide is 
involved in the formation of the helical structure. Also, the role of electrostatic, π-π 
stacking, hydrogen bonding, and hydrophobic interactions between side chains in 
stabilizing the helices has also been reported [163,164]. The unique arrangement of 
amino acids in C6M1 helical structure facilitates hydrophobic interaction between leucine 
residues, π-π stacking between tryptophan residues, and hydrogen bonding between 
arginine residues, which eventually stabilize the helical conformation of the peptide. By 
concentrating the positive charge on one side of the helix (see Figure 4.1b), the loading 
capacity of the peptide may be maximized, enabling it to more easily neutralize siRNA 
molecules, which may subsequently reduce the dose required for effective delivery, 
Figure 4.1c. Theoretically, around 10 molecules (7 being minimum) of the peptide are 
needed to neutralize one siRNA molecule in the formation of peptide-siRNA complexes. 
These monomers will then further aggregate to form nanocomplex that can be 
internalized by cells, see Figure 4.1d.  
       Here, we characterized this peptide-siRNA complex/nanocomplex and determined 
the optimal transfection condition. The amount of the complexes taken up by cells was 
determined by flow cytometry. Quantitative RT-PCR was applied to measure the mRNA 
level of cells treated with C6 and C6M1. Our results show that the substitution of 
tryptophan for leucine in C6 sequence significantly increases transfection efficiency. In 
addition, the complex could significantly inhibit tumor growth in a xenograft mouse 
tumor model without causing toxicity effect, suggesting potential therapeutic application.  
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4.2 Materials and Methods 
4.2.1 Materials 
Peptide and siRNA: The C6 and C6M1 peptides were synthesized in bulk by CanPeptide 
Inc (Montreal, Canada). High performance liquid chromatography (HPLC) analysis 
indicated that the synthetic peptide was at least 95% pure. SilencerTM GAPDH siRNA  
(Life Technologies, Carlsbad, USA) was used as siRNA targeting the glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) gene. The SilencerTM Cy3-labeled GAPDH siRNA 
(Life Technologies, Carlsbad, USA) was used in fluorescence microscopy and 
Fluorescence Activated Cell Sorting (FACS). For experiments involving A549 cells, 
siRNA targeting Bcl-2 oncogene (Sigma, Oakville, Canada) was used, with a sense 
sequence of GUGAAGUCAACAUGCCUGCdTdT and antisense sequence of 
GCAGGCAUGUUGACUUCACdTdT. The negative control siRNA (Life Technologies, 
Carlsbad, USA) used in the experiment was siRNA with scrambled sequence.  
4.2.2 Cell culture 
CHO-K1 (Chinese hamster ovary) cells were purchased from American Type Culture 
Collection (ATCC, Manassas, USA). Cells were cultured in F-12K medium (Thermo 
scientific, Ottawa, Canada) supplemented with 10% fetal bovine serum (FBS) (Sigma, 
Oakville, Canada). The non-small lung carcinoma A549 cells were obtained from 
American Type Culture Collection (ATCC, Manassas, USA), and cultured in Dulbecco’s 
Modified Eagle Media-high glucose  (Life Technologies, Carlsbad, USA) with 10% heat-
inactivated FBS. All of the cells were incubated at 37°C in a humidified atmosphere 
containing 5% CO2.   
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4.2.3 Preparation of peptide/siRNA complex 
 The peptides were prepared by dissolving peptide powders in RNase free water. The 
solution was vortexed for 5 sec and sonicated for 10 min in a tabletop ultrasonic cleaner 
(Branson, model 2510, USA). siRNA was diluted with RNase free water. Peptide/siRNA 
complexes were formed by adding peptide solution into siRNA in proportion according 
to the designed experiment. The complexes were incubated for 20 min at room 
temperature before characterization and transfection.  
4.2.4 Agarose gel-shift assay 
 siRNA was incubated for 30 min at 37°C in RNase free water with different 
concentrations of C6M1 corresponding to a peptide/siRNA molar ratio ranging between 
1/1 and 80/1. Each well contains 300 ng of siRNA. The preformed complexes were then 
analyzed by electrophoresis in agarose gel (1.2% wt/vol) stained with ethidium bromide.  
4.2.5 Particle size and zeta potential 
The hydrodynamic diameter of C6M1/siRNA complexes were measured on a Zetasizer 
Nano ZS (Malvern Instruments, Malvern, UK) equipped with a 4 mW He-Ne laser 
operating at 633 nm. Samples at molar ratios of 40/1 with final siRNA concentrations of 
100 nM were prepared as mentioned above. A quartz microcell (45 µL) with a 3 mm light 
path was used and the scattered light intensities were collected at an angle of 173°. Zeta 
potential measurements were also performed on the same machine using clear disposable 
zeta cells. Three measurements were performed to generate the intensity-based size and 
zeta potential plot reported herein. 
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4.2.6 Circular Dichroism (CD) 
 Spectra from 190 to 250 nm with spectral resolution and pitch of 1 nm and scan speed of 
200 nm/min were recorded by a J-810 spectropolarimeter (Jasco Europe, Cremella, Italy). 
A 40 µM C6M1 sample was measured in a 1 mm long quartz cell and maintained at 
25°C. Spectra reported herein are the averages of three replicates. The raw CD ellipticity 
(in millidegrees) was converted to residue molar ellipticity (deg.cm2.dmol-1.residue-1). 
4.2.7 Transmission electron microscopy (TEM) 
 An electron micrograph of the C6M1/siRNA complex was acquired using a transmission 
electron microscope. A 10 ul sample of 300 nM siRNA at a peptide/siRNA ratio of 40/1 
was applied to a 400 mesh Formva coated copper grid (Canemco-Marivac, Canton de 
Gore, Canada) for 3-5 min. The sample was then washed using 5 successive wash steps 
(RNase free water) and dried overnight. The complex was stained with uranyl acetate 
(Electron Microscopy Sciences, Hatfield, USA) and analyzed using TEM (Philips CM10 
TEM, Amsterdam, the Netherlands).  
4.2.8 Confocal and Fluorescence microscopy  
Approximately 50,000 CHO cells were plated in a 24-well cell culture plate 24 h before 
transfection. Cy3-labeled GAPDH siRNA was mixed with C6M1 peptide at a 
peptide/siRNA molar ratio of 40/1 for 20 min. The complexes were added to cells to 
reach a final siRNA concentration of 50 nM per well. Treated cells were incubated at 
37°C for 3 h with Opti-MEM medium. For endosome labeling, the cells were incubated 
with 50 nM Lysotracker Green (Life Technology, Carlsbad, USA) for 30 min before 
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fixing. The wells were then washed with heparin (15 U/ml, a total of three times for one 
hour at 37°C) and fixed with 500 ul/well of fresh 4% Paraformaldehyde (PFA) in 
phosphate buffer saline (PBS) at 37°C for 30 min. The fixation agent was aspirated, and 
the cells were washed twice with PBS before they were covered with Fluoroshield with 
DAPI mounting medium (Sigma, Oakville, Canada). Carl Zeiss LSM 700 Confocal laser 
scanning microscopy (Zeiss, Jena, Germany) was used to visualize the cells. The 
microscope was equipped with Plan-Apochromat 60x/1.4 NA oil immersion objective 
lens. The images were analyzed with LSM Zen 2009 software. For fluorescence 
microscope, the samples were visualized on a Zeiss Observer Z1 microscope with a 40x 
objective lens. Images were analyzed using AxioVision software.  
4.2.9 Fluorescence-activated cell sorting (FACS) 
 Cellular uptake of Cy-3 labeled siRNA was studied using Flow Cytometry (type BD 
Biosciences, BD FACSVantage SE Cell Sorter, Franklin Lakes, USA). Cells were 
transfected with peptide/siRNA complexes according to the protocol listed above. 
Untreated cells and naked siRNA served as a negative control. Lipofectamine 2000, a 
commercial transfection reagent, was used as a positive control. After 3 h incubation, the 
culture medium was discarded and cells were washed with PBS, Trypsin-EDTA was then 
added to detach the cells from the plate; cells were suspended in 4% PFA solution and 
collected.  
4.2.10 mRNA level measurement 
Approximately 40,000 CHO cells were plated in a 24-well cell culture plate. 24 h later, 
the medium was replaced by Opti-MEM. GAPDH siRNA or scrambled siRNA 
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complexed with C6M1 at different molar ratios were prepared in Opti-MEM medium and 
added to the cells. Three hours later, growth medium with 20% FBS was added, followed 
by 48 h incubation at 37 °C in a 5% CO2 atmosphere. The cultures were then washed 
with PBS. Total RNA was extracted from the cells with TRIzol reagent (Life 
Technology, Carlsbad, USA), then treated with chloroform (Sigma, Oakville, Canada) 
and 2-propanol (Sigma, Oakville, Canada) as recommended by the manufacturer. RNA 
concentrations were measured by Nanodrop spectrophotometer ND-1000 (Thermo 
scientific, Ottawa, Canada). All RNAs were reverse transcribed with Bio-Rad iScript 
cDNA synthesis kit. The cDNA synthesis was primed with a unique blend of oligo (dT) 
and random primers. The following pairs of primers were used for PCR: 5ʹ′-
TTGCTGTTGAAGT- CGCAGGAG-3ʹ′, 5ʹ′-TGTGTCCGTCGTGGATCTGA-3ʹ′ (Sigma, 
Oakville, Canada). Here, the housekeeping gene cyclophilin was chosen as an internal 
control to normalize the GAPDH gene. The normalization was performed by the 
amplification of mouse/rat cyclophilin mRNA with the following primers: 5ʹ′-
AGGGTTTCTCCACTTCGATCTTGC-3ʹ′ and 5’-AGATGGCACAGGAGGAAAGAG 
CAT-3ʹ′ (Sigma, Oakville, Canada). PCR reaction was performed with Brilliant II Fast 
SYBR Green QPCR Master Mix (Agilent Technologies, Wilmington, USA) on an 
Mx3005P™ Real-Time PCR System (Agilent Technologies, Wilmington, USA). The 
Bcl-2 mRNA levels in A549 cells were also measured using the method described above. 
The primers for PCR were: 5ʹ′-GGATTGTGGCCTTCTTTGAG-3ʹ′ (sense), 5ʹ′-
CCAAACTGAGCAGAGTCTTC-3ʹ′ (antisense). 
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4.2.11 pH dependent membrane disruption  
8,000 CHO-K1 cells were plated on 96-well plates and incubated overnight in 200 µL of 
F-12K medium containing 10% FBS. The cell culture medium was removed and replaced 
by Opti-MEM medium with PH 7.4, PH 6.3 and PH 5.2, respectively. Peptides were then 
added accordingly. After incubation at 37 °C for 3 h, the plates were centrifuged. 50 µL 
of aliquots in each well were collected for the LDH assay. The LDH activity in these 
samples was determined using a CytoTox 96 Non-Radioactive Cytotoxicity Assay kit 
(Promega, Madison, USA) according to the manufacturer’s protocol, which determined 
the LDH activity from the amount of produced red formazan product by a colorimetric 
assay. The amount of formazan produced was assessed by measuring the absorbance at 
490 nm with a FLUOstar OPTIMA microplate reader (BMG Labtech, Ortenberg, 
Germany). Percentages of the LDH activity in each well were calculated from a raito of 
the obtained value to the control well containing 10 µL lysis buffer.  
4.2.12 Cytotoxicity assay 
CHO cells were plated in to 96-well plates (5,000/well) in F-12K medium with 10% FBS 
in the presence of the C6/siRNA and C6M1/siRNA complexes formed at different molar 
ratios: 20/1, 40/1, 60/1. After 48 h, MTT dissolved in PBS (5 mg/ml) was added to each 
well. Cells were incubated with MTT for 4 h, followed by the addition of 100 ul MTT 
solubilization solution (Sigma, Oakville, Canada). Cell viability was assessed by 
measuring the absorbance at 570 nm with a FLUOstar OPTIMA microplate reader (BMG 
Labtech, Ortenberg, Germany) and expressed as the ratio of the cells treated with 
C6M1/siRNA over the nontreated cells (negative control). 
	   71	  
4.2.13 In vivo experiment ∗  
Six-week-old male BALB/c nude mice were obtained from the B&K Universal Group 
Limited (Shanghai, China). The mice were maintained under a 12 h light/dark cycle at 
25°C and a humidity of 60 ± 10%. In order to generate the xenograft tumor model, the 
mice were inoculated subcutaneously with 5×106 A549 cells at the right armpit. When 
the tumor volume reached 100-200 mm3, Bcl-2 siRNA complexed with C6M1 at molar 
ratio 60:1 was injected directly into the tumor. Treatment was administered every 3 d for 
a total of nine treatments at the siRNA dose of 160 µg/kg. Mice were sacrificed on day 
27. Tumor diameters were measured every day and the volume was calculated as follows: 
tumor volume=0.5×(width)2×length. Mouse body weight was also monitored. All the 
procedures and care administered to the animals have been approved by the institutional 
ethics committee, under a permit of animal use (Approval ID: (2012) 005) in No.3 
People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine, 
compliance with the Experimental Animal Regulation by the National Science and 
Technology Commission, China.  
4.2.14 Western blot 
Proteins were extracted using a total protein extraction kit (Kangchen Biotechnology, 
Shanghai, China) according to the manufacturer’s instructions. The total protein was 
stored at -20°C until use. The antibodies used included Bcl-2 rabbit polyclonal IgG 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
∗	  The in vivo experiments were designed by us and performed in 
NO.3 people’s hospital affiliated to shanghai Jiao Tong University School of Medicine 	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(Santa Cruz Biotechnology, Dallas, USA), horseradish peroxidase (HRP) conjugated goat 
anti-rabbit IgG (Kangchen Biotechnology, Shanghai, China) and goat anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Kangchen Biotechnology, 
Shanghai, China). Protein samples were separated by 12% SDS-PAGE gels and then 
transferred to nitrocellulose (NC) membranes. After blocking with blocking buffer for 2 
h, the membranes were incubated with polyclonal rabbit anti-Bcl-2 (1:1000, overnight at 
4°C). HRP-goat anti-rabbit IgG (1:2000, 2 h) conjugate was used as a secondary 
antibody. The bound secondary antibody was detected by enhanced chemiluminescence 
(Pierce Biotechnology, Rockford, USA). The housekeeping gene, GAPDH, was used as 
an internal standard.  
4.2.15 Statistical analysis 
 Results were expressed as mean values ± SD. Data were analyzed by two tailed T test 
and only p-values < 0.05 were considered statistically significant.  
 
4.3 Results and Discussion 
4.3.1 Characterization of C6M1/siRNA complexes 
Circular Dichroism (CD) result confirmed the secondary structure of C6M1 peptide. As 
shown in Figure 4.2a, C6M1 showed a CD spectrum with two minima at 208 and 222 
nm, confirming a typical helical structure.  
       Agarose gel shift assay was applied to detect the interaction between siRNA and 
C6M1 molecules. Basic amino acids such as lysine, arginine and histidine can interact 
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with the negatively charged phosphate groups on siRNA sugar rings through electrostatic 
interactions. C6M1 is designed to contain seven positively charged arginine residues so 
as to strongly bind siRNA molecules. Complex formation between siRNA and increasing 
amounts of peptide C6M1, from molar ratios 1/1 to 80/1, was followed by agarose gel 
electrophoresis of the mixture. Free siRNA will move toward the positive electrode when 
voltage is applied. Results shown in Figure 4.2b indicate that the formation of a stable 
peptide-siRNA complex began at a relatively low molar ratio, since the band produced by 
molar ratio 1/1 was less bright than band produced by siRNA alone. At molar ratios 
above 15/1, siRNA molecules complexed completely with C6M1, as no free siRNA was 
detected on the agarose gel at these ratios. This suggests that C6M1 at molar ratios higher 
than 15/1 is sufficient to neutralize and form a complex with siRNA.  
      The interaction was also confirmed by zeta potential measurements of C6M1/siRNA 
complexes at different molar ratios, Figure 4.2c. Naked siRNA alone in solution had a 
large negative zeta potential (-37 mV), reflecting the contribution from the negative 
charges on the phosphate group. Increasing the C6M1/siRNA molar ratio gradually 
neutralized the negative charge of siRNA. The increase in zeta potential was most 
pronounced when the molar ratio reached 15/1 (+51.67 mV); however, its value increased 
consistently as the peptide content increased. Thus, molar ratios above 15/1 can be used 
in the following transfection experiment. Resulting complexes were stable, as zeta 
potential obtained for molar ratios 15/1, 20/1, 40/1, and 80/1 were all around 50 mV. As a 
general rule, particles with zeta potentials more positive than +30 mV or more negative 
than -30 mV are normally considered stable [165].  
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Figure 4.2 (a) Secondary structure of peptide C6M1 (40 µM) was obtained by far-UV 
CD spectroscopy. (b) The formation of siRNA-peptide complex indicated by agarose gel. 
The preformed C6M1/siRNA complexes were analyzed by electrophoresis on agarose gel 
(1.2% wt/vol) stained with ethidium bromide. The siRNA targeting eGFP gene was 
incubated with different concentrations of C6M1 corresponding to molar ratios ranging 
between 1/1 and 80/1. Lane 1 refers to siRNA only control in the absence of C6M1, and 
lanes 2–8 to molar ratios of 1/1, 5/1, 10/1, 15/1, 20/1, 40/1, and 80/1, respectively. 300 ng 
of siRNA per well was used here. (c) Zeta potential of C6M1/siRNA complexes at 
different molar ratios. Error bars represent the standard deviation from three replicates. 
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      The size and morphology of the complex formed in transfection medium OPTI-MEM 
at a peptide to siRNA molar ratio of 40/1 was examined by transmission electron 
microscopy and dynamic light scattering, shown in Figure 4.3. The electron micrograph 
exhibited isolated particles of nanometric size and irregular shape, with an average 
diameter of about 100 – 200 nm (Figure 4.3a). This is the optimal size for cellular 
internalization through clathrin- and caveolae- mediated endocytosis [166]. Smaller 
complexes, depending on their surface properties, can directly penetrate the cell 
membrane, but are quickly removed from the blood [167]. Larger particles, on the other 
hand, can be easily recognized and removed by phagocytic cells [168]. The diameter of 
the complex, around 200 nm, was consistent with the DLS results shown in Figure 4.3b. 
Peptide C6M1 was able to condense siRNA into positively charged nanosized particles 
suitable for intracellular delivery.   
 
Figure 4.3 The complexes have a particle size suitable for transfection. (a) Transmission 
electron micrograph of C6M1/siRNA complexes (examples pointed by arrow) containing 
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300 nM siRNA at molar ratio 40/1 in OPTI-MEM medium. (b)	   Size distribution of 
C6M1-siRNA complex at molar ratio 40/1. 
 
4.3.2 C6M1/siRNA complexes silence gene expression in vitro 
It is widely accepted that the main prerequisite for an optimal siRNA delivery system is 
the ability to deliver siRNA into cells and then release it into the cytoplasm, where it can 
guide sequence specific mRNA degradation. We next used fluorescently labeled siRNA 
molecules to evaluate the efficacy of C6M1 to delivery siRNA molecules into cultured 
cells. Internalized siRNA is reported to selectively localize in the cytoplasm or 
translocate into the nucleus, depending on the target RNA residues [169]. To study 
cellular uptake, distribution, and localization of the C6M1/siRNA complex, we 
transfected the Chinese hamster ovary (CHO) cells with Cy3-labeled siRNA for 
visualization under fluorescent microscope and confocal microscope. CHO cells were 
treated with or without the complex for 3 hours and observed. To eliminate the effect of 
extracellular complexes on the image [170], cells were washed with 15 U/ml heparin in 
OPTI-MEM three times at 37°C to remove extracellularly bound complexes [95]. This 
ensures that the fluorescent siRNA we observed is indeed inside the cells and not 
attached to the cell membrane. Figure 4.4a and b show a typical fluorescence microscope 
image of CHO-K1 cells treated with siRNA alone and siRNA complexed with peptide 
C6M1, respectively. As expected, uncomplexed Cy3-labeled siRNA could not enter the 
cells. siRNA internalization occurred within three hours of incubation, and only in the 
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presence of peptide C6M1. The red fluorescence signal can be found in almost every cell. 
 
Figure 4.4 Uptake of C6M1/siRNA complexes in CHO cells. Fluorescent microscopy 
analysis of CHO cells 3 h after transfection with Cy-3 labeled GAPDH siRNA alone (a) 
or Cy-3 siRNA/C6M1 complexes (b), respectively.  Panel i. Cy3-labeled siRNA (red); 
Panel ii. Nuclei were stained with DAPI (blue); Panel iii. Differential interference 
contrast (DIC); Panel iv. Merged image. Scale bar stands for 10 um. 
 
       To visualize subcellular localization, we applied peptide/siRNA complexes to CHO-
K1 cells and visualized intracellular trafficking via confocal microscopy. As can be seen 
in Figure 4.5, siRNA delivered by C6 and C6M1 were localized to regions in close 
proximity to the nuclear membrane, but not in the nucleus. Labeled siRNA was delivered 
only to the cytosol, where it will bind to RNA-induced silencing complex (RISC) and 
then initiate RNA interference.  
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Figure 4.5 Intracellular trafficking of C6/siRNA and C6M1/siRNA nanocomplexes. 
CHO-K1 cells were transfected with peptides carrying 50nM Cy-3 labeled siRNA for 3 h 
and subsequently incubated with LysoTracker Green. Images were pseudocolored for 
visualization: blue = DAPI; red = Cy-3 siRNA; green = LysoTracker Green. Co-
localization of siRNA with the endosomal/lysosomal marker is in yellow. 
 
The siRNA delivered by peptides showed a punctual non-homogeneous distribution 
pattern around the periphery of the nucleus inside the cell, rather than a diffuse 
distribution, which indicated the possibility of an endocytosis pathway [95]. Meanwhile, 
the colocalization of Cy-3 labeled siRNA (red) with a marker of endosome (green) 
yielded yellow spots, suggesting that both C6/siRNA and C6M1/siRNA complexes enter 
the cells via endocytosis. Endosomal escape of Cy-3 labeled siRNA can be observed 9 
hours after treatment, see Figure 4.6. 
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Figure 4.6 Confocal microscopy images of CHO-K1 cells treated with C6M1 peptide 
carrying 50 nM Cy-3 labeled siRNA. Images were taken 9 h after treatment. Images were 
pseudocolored for visualization: blue = DAPI; red = Cy-3 siRNA; green = LysoTracker 
Green. Co-localization of siRNA with the endosomal/lysosomal marker is in yellow. To 
clearly see the intracellular location of the complexes, the merged image was enlarged. 
        Cellular uptake of labeled siRNA was quantified using fluorescence-activated cell 
sorting (FACS). As shown in Figure 4.7, labeled siRNA alone was not internalized, 
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which is in good agreement with the fluorescence microscope results. Complexing with 
C6M1 will increase cellular uptake efficiency of siRNA accordingly, depending on the 
molar ratio of C6M1/siRNA. The intracellular fluorescence intensity of siRNA delivered 
by C6M1 is stronger than that of Lipofectamine 2000.  The FACS data for peptide C6 has 
been reported previously [156], indicating high cellular uptake. 
 
Figure 4.7 Cellular uptake of C6M1/siRNA complex in CHO-K1 cells. C6M1 delivered 
siRNA into cells in a molar ratio dependent manner. C6M1/siRNA complexes were 
formed at different molar ratios (40/1 and 60/1) and then added to CHO cells. Cells were 
then washed, trypsinized, and fixed. Fluorescent cells were counted by FACS. 
 
        In order to evaluate whether the amino acid change in sequence improved the 
biological effect of the delivered siRNA, RT-PCR measurement of GAPDH mRNA 
levels in the CHO-K1 cell line was used as a gene knockdown assay. The GAPDH 
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mRNA level in each sample was compared to the level measured in cells treated with a 
scrambled siRNA (negative control). Quantitative real-time PCR results revealed a 
spontaneous decrease in GAPDH mRNA levels in C6M1/siRNA transfected cells over 
the 48 h testing period, while steady state levels of another housekeeping gene, 
cyclophilin, remained relatively stable. As shown in Figure 4.8a, C6M1 mediated siRNA  
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Figure 4.8 Gene silencing efficiency of C6/siRNA and C6M1/siRNA complexes in 
CHO-K1 cells. (a) Relative GAPDH mRNA level in CHO cells after transfected with 
peptides/GAPDH siRNA complexes. Black and white bar denote C6/siRNA and 
C6M1/siRNA complexes separately. (b) Silencing effect of C6M1/siRNA targeting Bcl-2 
gene in A549 cells. 
delivery resulted in a significant GAPDH mRNA decreases in a molar ratio dependent 
manner. A notable mRNA level reduction was initiated at a molar ratio of 20/1 at 50 nM 
siRNA concentration. Compared to untreated cells, C6M1/siRNA complexes at molar 
ratio 40/1 and 60/1 reduced mRNA levels by 54 ± 5.4% and 58 ± 6.2%, respectively, 
much higher than cells treated with C6/siRNA complexes, which only showed 20% 
knockdown. The knockdown efficiency of C6M1/siRNA complex was also evaluated on 
cultured A549 cancer cells before further in vivo study. The result showed similar 
silencing effect (Figure 4.8b). 
       MTT assay was performed to evaluate the cytotoxicity of 50 nM siRNA complexed 
with C6 and C6M1 at various concentrations. Lipofectamine 2000 was used as a control. 
As shown in Figure 4.9a, cell survival was not significantly impacted by the treatments of 
peptide C6M1. 48 h after transfection, CHO cells showed more than 85% viability even 
at the highest molar ratio, much higher than that of control Lipofectamine 2000, which 
achieved only 70% cell viability. Compared to C6, which showed slightly lower cell 
viability, the change in amino acid sequences also helped to improve the cytotoxicity.  
       The FACS data showed similar uptake amounts of C6/siRNA and C6M1/siRNA 
complexes. In direct contrast, quantitative PCR revealed a significant difference in 
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knockdown efficiency, indicating better release of siRNA delivery by C6M1. Therefore, 
the modification with tryptophan must have an impact on the endosomal membrane since 
both peptides are internalized via endocytosis. We next sought to directly evaluate the 
membrane disruption ability of peptides to CHO-K1 cells. This was realized through a 
colorimetric LDH assay, which estimate the membrane destabilizing capacity of peptides 
by measuring the activity of extracellular lactate dehydrogenases (LDH) liberated from 
disrupted cell membrane [171]. Medium with pH 7.4, 6.3 and 5.2 were used respectively 
to mimic the pH drops along the endocytic pathway, from extracellular pH 7.4 to pH 6.0-
6.5 in early endosomes to pH 4.5-5.5 in late endosomes [172]. As clearly seen in Figure 
4.9b, peptide C6M1 induced LDH release was critically enhanced by decreasing the 
environmental pH from neutral to acidic at both concentrations. These date suggested a 
strong capacity of C6M1 to destabilize cell membrane as well as endosomal membrane 
with the decrease of pH. Though peptide C6 also showed the trend to trigger cytosolic 
release of LDH when pH decreased, it is not so obvious compared to C6M1. Apparently, 
the increase in the membrane disruption ability under acidic condition corresponds to the 
enhanced transfection efficiency of C6M1. Therefore, the substitution of tryptophan for 
leucine indeed improves the endosomolytic property of the peptide. The role tryptophan 
played in the endosomolytic activity is not conclusive. Considering the absence of 
protonable residues in tryptophan at physiological pH, the “proton sponge” hypothesis 
[121] does not apply here. It is possible that tryptophan residues which are crucial for 
pore formation [173] disrupt the endosome membrane, causing endosomal/lysosomal 
leakage. The α-helical component of C6M1 may also play a crucial role in endosomal 
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membrane destabilization. The endosomolytic property of a series amphiphilic α-helical 
structural peptides such as HA2 and GALA have been reported [174].  
 
Figure 4.9 Cytotoxicity assay and pH dependent membrane disruption of C6/siRNA and 
C6M1/siRNA complexes in CHO cells. (a) Cytotoxicity of Lipofectamine 2000/siRNA 
and peptide/siRNA complex and at different molar ratios for CHO cells.  Experiments 
were performed in quintuplicate each time. Results correspond to the average of three 
separate experiments and compared to untreated cells cultured in the same condition. (b) 
The activity of lactate dehydrogenase released from CHO cells upon interaction with 
peptides at different pH.  
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4.3.3 C6M1/siRNA complexes inhibit cancer cell proliferation in vivo 
siRNA has widely been used to interfere with oncogene activity in mouse tumor models. 
In recent years, many studies have investigated the efficacy of liposomes as in vivo gene 
delivery agents [175–177], while the application of peptides in this area were rarely 
reported. Although some siRNA carriers can achieve high transfection efficiency in vitro, 
in vivo delivery presents unique challenges, such as the extracellular matrix barrier, 
serum degradation, and immune response, which limit their utility as clinical therapeutic 
agents. Thus, in an effort to demonstrate its clinical potential, we investigated the 
antitumor activity of the C6M1/siRNA complex in a mouse xenograft tumor model.  
        The Bcl-2 protein is an attractive target for gene therapy because it regulates the 
mitochondria-mediated apoptosis pathway [178]. A drug designed to reduce the level of 
this protein is expected to promote apoptosis and therefore inhibit tumor growth. The 
experimental results showed that Bcl-2 siRNA complexed with C6M1 at molar ratio 60/1 
suppressed the tumor cell proliferation throughout the experimental period, even at low 
siRNA dose (160 µg/kg) (Figure 4.10a). After treatments, the tumor tissues were 
separated and weighed (Figure 4.10b). The average tumor volume was 1113 mm3 in the 
control group and 459 mm3 in the C6M1/siRNA group. The tumor weight of 
C6M1/siRNA group (0.5176 g) is significantly lower than that of untreated control (1.12 
g) and saline treated control (1.24 g) groups, indicating a tumor inhibition rate of 53.7%. 
Reduced tumor volumes were due to decreased tumor cell proliferation. Moreover, the 
complexes showed minimal toxicity; all mice survived the 27 day treatment period 
without incurring severe side effects and none of the treatment groups demonstrated 
significant changes in body weight (Figure 4.10c), suggesting the complexes are 
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relatively safe to use.  
 
 
Figure 4.10 Local treatments with C6M1/siRNA complexes inhibit tumor growth in a 
mouse xenograft tumor model. (a) Antitumor activity of C6M1/siRNA complex in a 
mouse tumor model. The complexes were administered intratumorally in mice model 
bearing A549 cancer cells xenografted under the skin. The tumor sizes were measured 
everyday. Data shown is the mean value of eight mice in each group. S.D. of the data 
points is not shown for clarity. ** p＜0.01 versus model group (n=8). (b) Dissected 
tumor tissues after treatment. Mice were killed by cervical dislocation on the 27th day. 
Tumors were then separated. Representatives of five treatment groups: model, saline, 
C6M1 peptide, naked Bcl-2 siRNA and C6M/siRNA complex. (c) The body weight of 
each group. Body weights of the mice were measured everyday during the treatment. 
Data shown is the mean value of eight mice in each group (n=8). (d) Inhibition of Bcl-2 
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protein expressions by C6M1/siRNA in CHO cells. Tumor tissues were dissected after 
treatment and total proteins were extracted. Bcl-2 levels in five treatment groups: model, 
saline, C6M1, naked siRNA, C6M1/siRNA were analyzed by western blot.  
 
       Western blot analysis was used to detect Bcl-2 protein expression in tumor tissue 
specimens. The analysis revealed specific downregulation of Bcl-2 protein in the 
C6M1/siRNA complex treated group and the housekeeping protein GAPDH remained 
unchanged. From Figure 4.10d, we conclude that, compared to untreated and saline 
control treated groups, the C6M1/siRNA complex can significantly inhibit Bcl-2 protein 
expression in cancer cells. 
 
 
4.4 Conclusions 
Peptide delivery systems have recently emerged as an alternative means to transport the 
therapeutic genes into targeted cells. Our study reported the silencing of an endogenous 
gene in tumor tissues using unmodified siRNA delivered by a novel peptide. C6M1 was 
rationally designed to improve the endosome escape ability of cell penetrating peptide 
C6. C6M1 adopts a helical structure that aligns all positive charges along one side. C6M1 
demonstrated significant gene knockdown efficiency, both on CHO-K1 cells and A549 
cells, compared to unmodified C6, though similar cellular uptakes were observed. We 
conclude that the enhanced membrane disruption of C6M1 at acidic pH improved the 
endosomal escape ability of the complexes, inducing obvious silencing effect. Our novel 
peptide delivery system is not only able to deliver siRNA into cultured cells, but also to 
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tumor cells via intratumoral injection in a xenograft mouse tumor model. In vivo results 
suggest that Bcl-2 siRNA complexed with peptide C6M1 specifically inhibited tumor 
growth, as treated animals showed a significant reduction in tumor size compared with 
untreated and saline control groups. The toxicological analysis showed that the treatment 
was well tolerated at therapeutic dosage both in vitro and in vivo. Results obtained here 
not only shed light on the development of a new peptide vector for siRNA delivery, but 
also on the new system as a practicable anticancer therapy strategy in clinical application.  
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Chapter 5 
Design and evaluation of endosomolytic biocompatible 
peptides as carrier for siRNA delivery  
	  
5.1 Introduction	  	  
A new class of drugs that can silence specific gene expression, such as small interfering 
RNAs (siRNAs), has the potential to transform modern medicine [12]. In RNA 
interference (RNAi), which is induced by a particular siRNA, target mRNA is degraded 
by enzyme, leading to decreased expression of corresponding protein [179]. In principle, 
siRNA therapy could selectively downregulating pathological proteins, including those 
that are difficult to modulate with traditional drugs, with less extensive systemic toxicity 
[180]. Numerous research labs and pharmaceutical companies have already been 
developing siRNA drugs for age-related macular degeneration [181], cancer [67] and 
HIV infection [182], among other diseases. Although very promising, efficient in vivo 
siRNA delivery to the target site encounters many obstacles, including incapacity of 
highly negatively charged siRNA to cross cell membrane efficiently and vulnerability of 
siRNA to nuclease degradation in serum [183]. Therefore, an appropriate delivery 
formulation is required for siRNA treatment in order to transform the breakthrough 
science of RNAi into a new class of clinical therapy. Cationic liposomes [184] and 
polymers [27] are some of the more popular delivery method among non-viral carriers. 
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They facilitate delivery by encapsulating or condensing siRNA into nano-sized particles, 
which can be taken up by cells in a highly effective manner. Yet, when applied in vivo 
these approaches sometimes suffer from limitations such as cytotoxicity and 
immunogenicity [185–187]. 
       Alternative strategies are necessary and one possibility is cell-penetrating peptides 
(CPPs). CPPs are a class of amphiphilic and positively charged short peptides that are 
able to penetrate cell membranes and translocate different cargoes [90]. The first 
discovery of CPPs dated back to 1988, when trans-activating transcriptional activator 
(TAT) [87] from human immunodeficiency virus 1 (HIV-1) was found to be taken up 
efficiently by various cells. After more CPPs were found in the following studies, they 
have been used to transport a wide range of cargoes into cells, including active proteins 
[188], quantum dots [189] and oligonucelotides [190]. With respect to siRNA delivery, 
TAT, penetratin and transportan [191] have been covalently linked to siRNA and 
successfully delivered them to various cell types. Other CPPs can form stable 
noncovalent complexes with siRNA. In this category, MPG [144], Pep-1 [96], as well as 
CADY [192], are among the best characterized. A well-designed CPP carrier should 
promote cellular uptake as well as intracellular release of the cargo. The endocytosis 
pathway is one major internalization mechanism for biological molecules [193]. These 
agents become entrapped in endosome and are degraded by enzymes in the lysosome if 
they are not able to escape in time. Thus, a key step in achieving effective biological 
function of siRNA is to facilitate the endosomal escape and ensure cargos reach cytosol 
where RNAi happens. The mechanisms by which siRNA carriers manage to escape 
endosome are extensively studied in recent years. In general, several mechanisms such as 
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pore formation in the endosomal membrane, pH-buffering effect of protonable groups 
(pH sponge effect) and fusion into the lipid bilayer of endosomes have been proposed 
[121].  
       In our laboratory, we focus on the study of cell penetrating peptides derived from 
peptide C6, a peptide that has been reported to delivery large amount of siRNA into cells 
but with low knockdown efficiency due to poor endosomal escape ability [150]. C6 
consists of amino acids arginine, leucine and tryptophan. The seven positively charged 
arginine residues would interact with siRNA that carries negatively charged phosphate 
groups and provide extra charge for cell membrane interaction. These amino acids were 
arranged alternatively in the sequence so that when adopt a helical structure, polar (R) 
and nonpolar (L, W) residues would face opposite to form a secondary amphiphilicity 
structure [161]. However, for efficient siRNA delivery, we need to enhance the 
endosomolytic property of peptide C6. Thus, we first designed a peptide C6M1 by 
replacing certain hydrophobic leucine with tryptophan residues. The modified peptide 
showed significant membrane disruption ability with the decrease of pH, promoting the 
release of siRNA from endosome [194]. In this paper, an alternative modification applied 
to facilitate endosomal escape and ensure cytosolic delivery of siRNAs will be discussed. 
The incorporation of histidine residues is a common way to introduce protonable groups 
into peptide or polymer sequences [195]. The accumulation of histidine residues inside 
acidic endosomes causes influx of protons, which increases osmolarity, leading to 
swelling and hence disruption of the endosome membrane, according to proton sponges 
effect. Therefore, in the following design, peptides C6M2-C6M8 were obtained by 
substituting some residues in C6 and C6M1 with pH responsive histidine. From C6M6 to 
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C6M8, glycine was used as the first amino acid in N-terminal, as a number of cell-
penetrating peptides have a glycine residue in the N-end, such as MPG [144], CADY 
[196], PPTG1[155] and Tat (48-60) [197]. Free N-terminal glycine was required by some 
CPPs for full membrane activity. The substitution of glycine with other amino acid would 
influence the stability and fusion activity of peptides [198]. In this study, we intended to 
elucidate whether our modifications were able to increase knockdown efficiency of C6 
mediated siRNA delivery. The physiochemical properties of several peptides were 
characterized and compared followed by in vitro activity and toxicity measurements. 
Furthermore, the particular therapeutic significance of C6 family mediated siRNA 
delivery was demonstrated by the inhibition of cancer cell proliferation in a tumor 
xenograft mouse model. The immunogenicity of siRNA delivery systems has not been 
intensively studied in the past. As some reports appear in the literature concerning 
immune response elicited by liposomes in clinical trial, it is crucial to address possible 
immune side effects of these peptides. Hence, complement activation in human serum 
and cytokines activation in macrophages by peptide C6M3 and C6M6 were examined.  
5.2 Materials and Methods 
5.2.1 Materials 
The C6 series peptides were synthesized in bulk (Pepscan, Lelystad, Netherland). High 
performance liquid chromatography (HPLC) analysis indicated that the synthetic peptide 
was at least 75% pure. Peptide sequences were shown in Table 5.1. Peptide C6, C6M3 
and C6M6 for further characterization, in vitro and in vivo experiments were synthesized 
by CanPeptide Inc (Montreal, Canada) with at least 95% purity. SilencerTM GAPDH 
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siRNA (Life Technologies, Burlington, Canada) was used as siRNA targeting the 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene. The SilencerTM Cy3-labeled 
GAPDH siRNA (Life Technologies, Burlington, Canada) was used in fluorescence 
microscopy and Fluorescence Activated Cell Sorting (FACS). For experiments involving 
A549 cells, siRNA targeting Bcl-2 oncogene (Sigma,	  Oakville, Canada) was used, with a 
sense sequence of GUGAAGUCAACAUGCCUGCdTdT and antisense sequence of 
GCAGGCAUGUUGACUUCACdTdT. The negative control siRNA (Life Technologies, 
Burlington, Canada) used in the experiment was siRNA with scrambled sequence.  
                          Table 5.1 Peptides sequences used in this study 
Peptide              Sequence                                              M. W.      Net charge in neutral PH 
C6                   RLLRLLLRLWRRLLRLLR                 2470.2                      +7 
C6M1              RLWRLLWRLWRRLWRLLR            2689.4                      +7 
C6M2              RLWRLLWHLWRHLWRLLR            2651.3                      +5 
C6M3              RLWHLLWRLWRRLHRLLR             2621.2                      +6 
C6M4              HLLRLLLRLWHRLLRLLR                2505.2                      +5 
C6M5              HLWHLLLRLWRRLLRLLR               2505.2                      +5 
C6M6              GLWHLLLHLWRRLLRLLR               2406                         +4 
C6M7              GLWHLLLHLWRRHHRHHR             2502                         +4 
C6M8              GLWHLHLHLWRRHHRLLR              2478                         +4 
Peptides were all modified by N terminal acetylation and C terminal amidation.  
5.2.2 Cell culture 
CHO-K1 (Chinese hamster ovary) cells and the non-small lung carcinoma A549 cells 
were purchased from American Type Culture Collection (ATCC, Washington DC, USA). 
	   95	  
Cells were cultured in F-12K medium (Thermo scientific, Ottawa, Canada) supplemented 
with 10% fetal bovine serum (FBS) (Sigma, Oakville, Canada). All of the cells were 
incubated at 37°C in a humidified atmosphere containing 5% CO2.   
5.2.3 Preparation of peptide/siRNA complex 
siRNA was diluted in RNase free water. The final concentration was determined by 
Nanodrop 2000 Spectrophotometer (Thermo scientific, Ottawa, Canada). All peptide 
solutions (1 mM) were made by dissolving peptide powder in RNase free water. The 
solution was vortexed for 5 sec and sonicated for 10 min with a Microson XL2000 
Sonicator (Qsonica, Newtown, USA). Peptide/siRNA complexes were made by mixing 
peptide and siRNA solution in a desired concentration. The complexes were then 
incubated for 20 min at room temperature before further experiments. 
5.2.4 Particle size and zeta-potential 
The hydrodynamic diameter of formed peptide/siRNA complexes were determined by 
dynamic light scattering on a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, 
UK) equipped with a 4 mW He-Ne laser operating at 633 nm. Samples at molar ratio of 
40/1 with final siRNA concentration 100nM were held in a quartz microcell (45 µl) with 
a 3 mm light path. The scattered light intensities of the samples at an angle of 173° were 
collected with appropriate viscosity and refractive index of water at 25 °C. Zeta potential 
measurements were also performed on the same machine using clear disposable zeta 
cells. Three measurements were performed to generate the intensity-based size and zeta 
potential plot reported herein. 
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5.2.5 Atomic Force Microscopy (AFM)  
The nanostructure of peptide/siRNA complexes was imaged on AFM. The samples were 
prepared according to the following procedures: The peptide/siRNA complex solutions 
were prepared as mentioned in 2.3. 10 µl of the sample solution (1 µM siRNA with a 
peptide/siRNA molar ratio of 60:1) was put on a freshly cleaved mica surface. The 
sample was incubated for 10 min at room temperature to allow the complexes to adhere 
onto mica surface. Mica was then washed at least five times with RNase free water to 
remove unattached complexes. After air-drying, the mica surface was analyzed by a 
Dimension Icon AFM (Bruker, Santa Barbara, USA) at room temperature using the 
tapping mode with ScanAsyst-Air tips (Bruker, Santa Barbara, USA). All AFM images 
were obtained at a resolution of 512 × 512 pixels on a scale of 2 µm × 2 µm. 
5.2.6 RiboGreen intercalation assay 
RiboGreen assay was performed to quantify the encapsulation efficiency of siRNA with 
peptides. RiboGreen working solution was prepared by diluting Quant-itTM RiboGreen 
RNA Assay Kit (Life Technologies Inc, Burlington, Canada) 1 to 32 in water. Initial 
siRNA concentration is 50 nM. Different volumes of peptide stock solution were added 
to the fixed siRNA concentration to obtain peptide/siRNA molar ratio from 1:1 to 80:1. 
Samples (60 µL) were mixed with 5 µl RiboGreen working solution and then transferred 
to a quartz cell (1 cm × 1 cm) and excited at 480 nm, The fluorescence was acquired on a 
Photon Technology International spectrafluorometer (Type LS-100, London, Canada) 
with a pulsed xenon lamp as the light source. Spectra were collected in the range of 
500−600 nm. The amount of free siRNA after peptide addition was calculated by 
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subtracting the values of RiboGreen background fluorescence from the average 
intensities of sample at 528 nm, and expressed as a percentage of the control (naked 
siRNA only) with the following equation: Free siRNA percentage = Fluorescence 
intensity of complexes/Fluorescence intensity of naked siRNA x 100% 
This percentage was then plotted versus peptide/siRNA molar ratios. 
5.2.7 Fluorescence microscopy cell imaging 
To investigate the distribution of the peptide/siRNA complexes in CHO-K1 cells, we 
used Cy-3 labeled GAPDH siRNA. Approximately 80,000 CHO cells were plated in a 
24-well cell culture plate 1 d before transfection. Cy-3 labeled siRNA was mixed with 
different peptides at a peptide/siRNA molar ratio of 40/1 for 20 min. The cells were 
transfected with complexes (final siRNA concentration 50 µM) at 37°C for 3 h in Opti-
MEM medium. The wells were washed with heparin in medium (15 U/ml, a total of three 
times for one hour at 37°C) to eliminate the effect of extracellular complexes and then 
fixed with 500 µl/well of fresh 4% Paraformaldehyde (PFA) for 30 min. After that, the 
fixation agent was aspirated, and the cells were washed twice with phosphate buffer 
saline (PBS) before they were subjected to Fluoroshield with DAPI (Sigma, Oakville, 
Canada) staining to visualize nuclei. The samples were monitored on a Zeiss Observer Z1 
microscope with a 40x objective lens. Images were analyzed using AxioVision software. 
5.2.8 Fluorescence-activated cell sorting (FACS) 
The amount of Cy-3 labeled siRNA taken up by the cells via different peptide delivery 
vector was studied using Flow Cytometry (type BD Biosciences, BD FACSVantage SE 
Cell Sorter, USA). Cells were transfected with peptide/siRNA complexes according to 
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the protocol listed above. Untreated and naked siRNA only treated cells served as 
negative controls. Lipofectamine 2000 was used as a positive control. After 3 h 
incubation, cells were washed with PBS and trypsinized for 5 min, then resuspended in 
4% PFA solution and collected. For each sample, data was acquired on 10,000 cells. The 
siRNA delivered to the cells was assessed using the FL-2 detection channel.  
5.2.9 GAPDH enzyme activity measurement  
CHO-K1 cells were seeded in a 96-well plate with 5,000 cells/well one day before 
transfection. 24 h later, the peptide/siRNA complexes containing GAPDH siRNA or 
negative control siRNA were prepared in Opti-MEM and added to each well in 
quintuplicate giving a final siRNA concentration of 50 nM. After 4 h of incubation at 
37°C, equal volume of medium with 20% FBS were added to the cells. After 48 h, the 
GAPDH enzyme activity was detected using KDalert™ GAPDH assay kit (Life 
Technologies, Burlington, Canada) according to the manufacturer’s protocol. The 
increase of fluorescence intensity was measured by a FLUOstar OPTIMA microplate 
reader (BMG Labtech, Ortenberg, Germany) with excitation wavelength at 560 nm and 
emission wavelength at 590 nm. The GAPDH gene knockdown efficiency was expressed 
as 100% - the fluorescence intensity of cells treated with GAPDH siRNA/ the cells 
treated with negative control siRNA. 
5.2.10 qRT-PCR for GAPDH mRNA measurement 
40,000 CHO-K1 cells were seeded in a 24-well plate 1 d before transfection. The 
transfection process was mentioned above. Gene knockdown efficiency was assessed 48 
h later. Total RNA was isolated from the cells using TRIzol reagent (Invitrogen, Life 
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Technologies Inc, Burlington, Canada) according to the manufacturer’s instructions. 
RNA concentration measurements and quality control were performed using Nanodrop 
spectrophotometer ND-1000. 0.5 µg of isolated RNA was reverse transcribed to cDNA 
with qScriptTM cDNA SuperMix (Quanta Biosciences, Gaithersburg, USA). A 
quantitative PCR analysis was performed using PerfeCTa SYBR Green FastMix (Quanta 
Biosciences, Gaithersburg, USA) on an Mx3005P™ Real-Time PCR System (Agilent 
Technologies, Santa Clara, USA). The primers for mouse GAPDH were: 5ʹ′-TTGCTG- 
TTGAAGTCGCAGGAG-3ʹ′, 5ʹ′-TGTGTCCGTCGTGGATCTGA-3ʹ′. The housekeeping 
gene Cyclophilin was used as an internal control. Following primers were used: 5ʹ′-
AGGGTTTCTCCACTTCGATCTTGC-3ʹ′ and 5’-AGATGGCACAGGAGGAAAGAG- 
CAT-3ʹ′. The PCR parameters consisted of an initial denaturation at 95°C for 30 s, 
followed by 40 cycles of PCR at 95°C for 5 s and 60°C for 30 s. 
5.2.11 Cell viability assay 
CHO-K1 cells (5,000 cells/well) in 200 µl F-12K medium with 10% FBS were seeded 
on 96-well plates and incubated. After 24 h, the cells were washed with PBS and 
transfected with peptide/negative control siRNA complexes formed at different molar 
ratios: 20/1, 40/1, 60/1. 4 h later, equal volume of medium with 20% FBS was added. 
After 48 h, MTT dissolved in PBS (5 mg/ml) was added to each well. Cells were 
incubated with MTT for 4 h, followed by the addition of 100 µl MTT solubilization 
solution (Sigma, Oakville, Canada). Cell viability was assessed by measuring the 
absorbance at 570 nm with a FLUOstar OPTIMA microplate reader. The absorbance of 
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control cells was set as 100% viability, and the viability of all other cells was expressed 
as a percentage relative to the absorbance of the control cells.  
5.2.12 In vitro complement activation assay 
The ELISA-based method for quantification of serum S-protein bound C terminal 
complex (SC5b-9) was performed. The test peptides C6M3, C6M6, at the concentration 
determined to be best in transfection experiment, and control compound Zymosan 
(Sigma,	  Oakville, Canada) were incubated with human serum (Quidel, San Diego, USA) 
for 1 h at 37°C. After that, the serum was diluted by specimen diluent (provided in the 
ELISA kits) at a 150-fold volume. Samples were tested for SC5b-9 levels using the 
MicroVue SC5b-9 plus (Quidel, San Diego, USA) kit following the manufacture’s 
instruction. All reactions were tested in duplicates. 
5.2.13 Cytokine activation in RAW 264.7 cells 
2.5x105 RAW 264.7 cells were seeded in a 12-well plate 1 d before experiment. 24 h 
later, peptides/siRNA complexes at transfection concentration were added to the cells. 6 h 
post treatment, RNA was extracted with the method mentioned above. qRT-PCR were 
then performed with the primers in Table 5.2.  
 
Table 5.2 Sequences of primers for qRT-PCR assay 
Gene  Primer sequence 
β-actin (F) AGAGGGAAATCGTGCGTGAC 
 (R) CAATAGTGATGACCTGGCCGT 
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iNOS (F) CAGCTGGGCTGTACAAACCTT 
 (R) CATTGGAAGTGAAGCGTTTCG 
COX-2 (F) AGAAGGAAATGGCTGCAGAA 
 (R) CTCAATACTGGAAGCCGAGC 
IL1-β (F) CCCAAGCAATACCCAAAGAA 
 (R) GCTTGTGCTCTGCTTGTGAG 
TNF-α (F) AGACCCTCACACTCAGATCATCTTC 
 (R) TTGCTACGACGTGGGCTACA 
IL6 (F) AAGTGCATCATCGTTGTTCAT 
 (R) GAGGATACCACTCCCAACAGA 
 
 
5.2.14 In vivo experiment∗ 
Tumor-bearing mice were prepared by subcutaneous injection of 5×106 A549 cells into 
the right armpit of six-week-old male BALB/c nude mice (B&K Universal Group 
Limited, Shanghai, China). Tumor diameters were measured every day and the tumor 
volume was calculated using the equation: tumor volume=0.5×(width)2×length. When 
the tumor volume reached 100-200 mm3, Bcl-2 siRNA complexed with peptides at molar 
ratio 1/60 was injected directly into the tumor. Treatment was administered every 3 d at 
the dose of 4 µg siRNA per mouse. After the 9th injection the mice were sacrificed and 
tumors were excised. Mouse body weight was also monitored during the treatments.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
∗The in vivo experiments were designed by us and performed in 
NO.3 people’s hospital affiliated to shanghai Jiao Tong University School of Medicine 
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5.2.15 Western blot 
Proteins were extracted using a total protein extraction kit (Kangchen Biotechnology, 
China) according to the manufacturer’s instructions. The cell extracts containing 60 µg of 
protein samples were loaded into a 12% SDS-PAGE gels and electrophoresis was run. 
After that, they were transferred to a nitrocellulose (NC) membrane. After blocking with 
blocking buffer for 2 h, the membranes were incubated with polyclonal rabbit anti-Bcl-2 
(1:1000, overnight at 4°C) (Santa Cruz Biotechnology, USA). HRP-goat anti-rabbit IgG 
(1:2000, 2 h) (Kangchen Biotechnology, Shanghai, China) conjugate was used as a 
secondary antibody. The bounded secondary antibody was detected by enhanced 
chemiluminescence (Pierce Biotechnology, Rockford, USA). In order to control protein 
loading, membranes were stripped and then incubated with goat anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody (Kangchen Biotechnology, Shanghai, 
China). 
5.2.16 Statistical analysis 
 Results were expressed as mean values ± SD. Data were analyzed by two tailed T test 
and only p-values < 0.05 were considered statistically significant.  
 
5.3 Results and Discussion 
5.3.1. Peptide screening with KDalert™ GAPDH assay 
To preliminarily determine the rank-order potency, all the peptides from C6 family were 
formulated with siRNA and tested by KDalert GAPDH assay kit. This kit relies on a 
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fluorescence-based assay to measure GAPDH enzyme activity in cell lysates, thus the 
amount of GAPDH protein activity was determined. By comparing GAPDH enzymatic 
activity in cells transfected with GAPDH siRNA to those transfected with a negative 
control siRNA, the level of gene silencing can be readily determined. Figure 5.1 shows 
the knockdown efficiency of GAPDH gene by GAPDH siRNA with C6 family peptides 
as carriers. Total nine peptides from C6 family were complexed with siRNA at molar 
ratio 20/1 and 40/1. The derivatives showed higher transfection efficiency than C6, 
indicating all the modifications improved the performance of their prototype C6 to some 
extent. The optimal peptides that produced an approximately 60% reduction in the 
GAPDH activity without being toxic to the cells were then selected. Apart from C6M1, 
two other peptides C6M3 and C6M6 achieved over 60% knockdown and therefore were 
chosen for further detailed study. Comparison of results obtained with C6 family shows 
that the transfection efficiency of the peptides seems not to be solely linked to the amount 
of histidine in the sequence, as peptides C6M2-C6M6 have the same number of histidine 
residues, but the efficiency varies. The location of histidine may also play an essential 
role in determining the transfection efficiency. It is reported that histidine residues have 
to be positioned in the core of peptide LAH4 and its derivatives to achieve high 
transfection efficiency [199].  
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Figure 5.1 Percent knockdown of GAPDH protein levels after treatment. After 48 h of 
transfection, the cells were disrupted in lysis buffer before adding KDalert master mix. 
The fluorescence intensity was read on a plate reader at 590 nm. The knockdown 
efficiency was calculated as mentioned in the methods. Each sample was repeated by five 
times. 
5.3.2 Insights into the characteristics and in vitro effect of peptides/siRNA 
complexes 
The abilities of these peptides to bind to siRNA were studied using a RiboGreen 
intercalation assay. This reagent is a highly sensitive fluorescent nucleic acid stain for 
siRNA quantification [200]. Plot of decreased siRNA fluorescence intensity with 
increased peptides/siRNA molar ratios was shown in Figure 5.2. The siRNA 
encapsulation efficiency of all four peptides increased along with the increase of molar 
ratio of peptide/siRNA, reaching a plateau when the molar ratio was over 40/1 for 
peptides C6, C6M1, C6M3 and over 60/1 for C6M6. C6 and C6M1 showed similar 
siRNA binding ability, since they have the same overall charges contributed by seven 
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arginine residues. C6M3 and C6M6 have six and four arginine residues separately, in 
addition to two partially charged histidine at neutral pH. Therefore, their affinity for 
siRNA is weaker.  It is obvious that at the molar ratio between 10/1 and 40/1, siRNA 
remaining free after complexed with C6M6 was significantly more than with other 
peptides, due to the less negative charges.  However, this discrepancy became much 
smaller when the molar ratio is over 60/1, where siRNA was almost all saturated by 
peptides. To ensure better transfection efficiency, we will use molar ratio higher than 
40/1 for all the peptides for in vitro and in vivo experiment.  
                 
Figure 5.2 Evaluation of siRNA encapsulation efficiency. siRNA concentration was 
determined by a Quant-iTTM RiboGreen RNA assay. Initial siRNA concentration is 50 
nM. Different volumes of peptide stock solution were added to the fixed siRNA 
concentration to obtain peptide/siRNA molar ratio from 1/1 to 80/1. 
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       Peptide/siRNA complexes at molar ratio 60/1 were imaged by AFM (Figure 5.3a and 
5.3c). The morphology of siRNA complexes with C6 and C6M1 were reported earlier 
[150]. For C6M3 and C6M6 complexed siRNA, the height and amplitude scan of a 2 × 2 
µm field revealing a scattered distribution of particles. The main particles were 
characterized by a width of 100 nm and a height around 30 nm, which were confirmed 
later by DLS results. Interestingly, different from the smooth edge of particles formed by 
other peptides, we can observe a granular morphology of C6M6/siRNA complexes 
(Figure 5.3c). A magnification of several complexes revealed that the particles were 
formed by association of smaller complex elements. C6M6 and siRNA may first form 
smaller particles, which will then aggregate to larger complexes. This shape is similar to 
another cell penetrating peptide CADY, which was reported to adopt a “raspberry” like 
structure when complexed with siRNA [201]. Zeta potential results obtained for 
C6M3/siRNA (Figure 5.3b) at molar ratio 20/1, 40/1 and 60/1 are positive, with values of 
26 ± 4.1 mV, 32± 3.5 mV and 37± 4.4 mV. The complexes are stable at these molar 
ratios, with a value of +/- 25 mV has been proposed as the arbitrary line between stable 
and unstable particles [202].  Particles with a zeta potential above +25 mV or below-25 
mV are considered electrically stable, while particles within the range tend to aggregate 
and coagulate. In contrast, C6M6/siRNA complexes at molar ratio 20/1 with a very low 
zeta potential of 15± 3.3 mV clearly indicates instability whereas a higher molar ratio of 
40/1 and 60/1 suggest stable particles. This can be explained by the fewer overall positive 
charges in C6M6 than C6M3. Apparently at molar ratio 20/1, the arginine residues in 
C6M6 are just enough to neutralize all the negative charges of siRNA. A molar ratio 
above 20/1 is needed to form stable complexes.  
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Figure 5.3 Representative AFM images and particle size of peptide/siRNA complexes. 
AFM images of 1 µM siRNA complexed with peptide C6M3 (a) and C6M6 (c) at molar 
ratio 40/1 and 60/1 respectively. Smaller images in (c) denotes enlarged AFM image of 
C6M6/siRNA complexes by DMT modulus. (b) (d) Particle size and zeta potential of 
C6M3/siRNA and C6M6/siRNA complexes at molar ratios 20/1, 40/1 and 60/1. Data are 
presented as the mean of three measurements.  
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      The cellular uptake and intracellular localization of Cy-3 labeled siRNA was 
observed by fluorescence microscopy. Successful siRNA delivery to the cells is shown in 
Figure 5.4, which depicts fluorescence microscopy images of the Cy3 labeled siRNA 
transfected cells 3 h post-transfection. As expected, uncomplexed Cy3-labeled siRNA 
could not enter the cells. siRNA internalization occurred within three hours of incubation, 
and only in the presence of peptide C6M3 and C6M6. The red fluorescence signal can be 
found in almost every cell. As can been seen in the image, siRNA was localized to 
regions in close proximity to the nuclear membrane, but not in the nucleus. Labeled 
siRNA is delivered only to the cytosol, where it will bind to RNA-induced silencing 
complex (RISC) and then initiate RNA interference. The siRNA delivered by peptides 
C6M3 and C6M6 shows a punctual non-homogeneous distribution pattern around the 
periphery of the nucleus inside the cell, rather than a diffuse distribution, which indicated 
the possibility of an endocytosis pathway [95]. 
 
    Effectiveness of carriers for siRNA delivery was determined by measuring the 
fluorescence intensity of cells after delivery of Cy-3 labeled GAPDH siRNA. Three 
peptides from the library were studied here. Fluorescence activated cell sorting (FACS) 
analysis of CHO-K1 cells, gated for live cells (Figure 5.5a) clearly showed comparable or 
higher siRNA delivery efficiency than a market leader Lipofectamine 2000. The mean 
fluorescence intensity of CHO cells (Figure 5.5b) after 3 h transfection with Cy-3 labeled 
siRNA complexed with peptides C6, C6M3, C6M6 at molar ratio 60/1 also shows a large 
amount of uptake. 
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Figure 5.4 Uptake of peptides/siRNA complexes in CHO cells. Fluorescent microscopy 
analysis of CHO cells 3 h after transfection with Cy-3 siRNA only, C6M3/Cy-3 siRNA 
complexes and C6M6/Cy-3 siRNA complexes, respectively. Nuclei were visualized by 
DAPI (blue).  
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    To confirm the delivered siRNA performed its function, quantitative RT-PCR was 
utilized to analyze GAPDH mRNA level in CHO-K1 cells. The cells were transfected 
with both the negative control siRNA (using siRNA with a nonsense / scrambled 
sequence) and GAPDH siRNA. The GAPDH mRNA level was first normalized to an 
internal control Cyclophilin mRNA and the ratio between GAPDH siRNA transfected 
samples and the corresponding negative control was used to calculate the relative 
GAPDH mRNA expression level. The result reveals that C6/siRNA complexes did not 
decrease GAPDH mRNA level at all tested molar ratios, as reported before. The modified 
peptides, C6M3 and C6M6 suppress GAPDH gene expression in a molar ratio dependent 
manner, Figure 5.5c. At molar ratio 60/1, C6M3/siRNA and C6M6/siRNA complexes 
demonstrate comparable gene knockdown efficiency, inhibiting GAPDH mRNA 
expression levels by 65% and 62%, respectively. This data was in accordance with 
KDalert results, but with smaller error bars. Given the fact that peptide C6 only shows 
20% silencing efficiency at most, it is obviously that the replacement of some arginine 
residues with histidine improves transfection efficiency of the peptides remarkably. 
Histidine contains an imidazole ring, which is a weak base with pKa of 6 [203]. Studies 
have shown that the incorporation of histidine into polymeric and peptide gene delivery 
vehicles increases the endosomal buffering capacity, improving the efficiency of 
endosomal escape [204–207]. Proton sponge effect was attributed as the mechanism for 
the endosomolytic ability of histidine. Protonation of histidine residues in acidic 
endosomes will induce an extensive inflow of ions and water, subsequently leading to 
rupture of endosomal membrane and release of the entrapped components [121].  
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      In addition, the toxicity of peptides based formulations was investigated using MTT 
assay. As reported in Figure 5.5d, almost no toxicity was detected for C6M3/siRNA 
complexes at various molar ratios tested. For C6/siRNA and C6M6/siRNA complexes, 
only 10–15% of cell death was observed at molar ratio 40/1 and less than 20% of cell 
death at molar ratio 60/1, still lower than Lipofectamine 2000, which caused around 30% 
of cell death.  
 
Figure 5.5 Peptide mediated delivery of siRNA into CHO-K1 cells. (a) Cellular uptake 
of peptide/siRNA complexes. CHO-K1 cells were incubated with the complexes of 
peptide/Cy-3 siRNA or Cy-3 siRNA alone for 3 h. The cells were then analyzed by 
fluorescence activated cell sorting (FACS) in the Cy-3 channel. (b) Mean fluorescence 
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intensity of Cy-3 siRNA in CHO cells treated with different peptides. (c) Relative 
GAPDH mRNA level in CHO-K1 cells after treatment. CHO-K1 cells were incubated 
with preformed complexes at different peptide/siRNA molar ratios (20/1, 40/1 and 60/1) 
for 3 h. 48 h later, total RNA was extracted and gene knockdown efficiency was 
determined by RT-PCR.  All the data were normalized to another house keeping gene 
cyclophilin and compared to cells treated with corresponding peptide/scrambled siRNA 
control.  (d) The toxicity of peptide/siRNA complexes was investigated by MTT assay. 
CHO-K1 cells were treated with increasing molar ratios of peptide/siRNA complexes 
ranging from 20/1 to 60/1 and cell viability was then evaluated 24 h after treatment. 
Scrambled siRNA was used here. Reported data are the average of three separate 
experiments. 
5.3.3 In vitro complement and cytokine activation assay 
The complement system is an important part of the innate immunity and serves as a first-
line of defense after the invasion of a foreign object. The complement system can be 
activated via the classical, the lectin and the alternative pathway [208]. The Terminal 
Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as 
a consequence of activation of the complement system by either the classical, lectin or 
alternative pathway. The ELISA-based method for quantification measures concentration 
of serum S-protein-bound C terminal complex (SC5b-9), thereby giving an indication of 
the status of the level of complement activation in the specimen. High levels of 
complement activation have been demonstrated in a variety of disease states.	   In Figure 
5.6a, positive control Zymosan caused significant elevation of SC5b-9 over baseline, 
compared to serum only sample. While peptides C6M3 and C6M6 at transfection 
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concentration did not exhibit SC5b-9 activation. To determine whether these complexes 
could induce pro-inflammatory cytokines, the mRNA levels of five types of cytokine in 
macrophage RAW 264.7 cells after treated with peptide/siRNA were measured by qRT-
PCR, Figure 5.6b. The RAW 264.7 murine macrophages were incubated with either 
0.1µg/ml bacterial endotoxin LPS or peptides/siRNA complexes. High induction of 
cytokines iNOS, COX-2, IL1-β, TNF-α and IL6 was observed 6 h post treatment with the 
positive control LPS. This induction of COX-2 expression was 3-fold higher than 
untreated cells and more than 100-fold higher for other cytokines. There was almost no 
significant cytokines induction from the peptide/siRNA complexes treatment in RAW 
264.7 cells. 
 
Figure 5.6 In vitro complement and cytokine activation assay. (a) SC5b-9 formation in 
human serum after incubation with peptides was quantified by ELISA assay. 5 ug/ml 
Zymosan was used as positive control. (b) Cytokine mRNA expressions in RAW 264.7 
cells, measured 6 h after treatment with 0.1 µg/ml LPS, C6M3/siRNA and C6M6/siRNA 
complexes. Housekeeping gene β-actin was used as an internal control. All cytokine 
mRNA levels were normalized to β-actin mRNA.  
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5.3.4 Anti-tumor effect of peptide/siRNA complexes in mice bearing A549 
derived tumors 
 
Bcl-2 protein, encoded by the Bcl-2 gene, is the founding member of Bcl-2 family that 
regulate cell death [209]. The Bcl-2 family comprises antiapoptotic proteins (Bcl-2, Mcl-
1, Bcl-w and A-1) and proapoptotic proteins (Bax, Bak, Bik, Bad, Bid, BMF, and 
PUMA) [210,211]. The Bcl-2 oncogene overexpression occurs in many cancer types and 
is associated with chemoresistance and radioresistance [212,213]. Inhibition of Bcl-2 will 
either restore normal apoptotic process in cancer cells or enhance the sensitivity of these 
cells to conventional chemotherapy. Thereby, Bcl-2 gene is an important therapeutic 
target in various human cancers. The potential of peptides C6M3 and C6M6 to deliver 
therapeutic siRNA in vivo was first evaluated on human non-small cell lung cancer 
A549-xenografted mice. The effect of local intra-tumoral administration of C6M3/ Bcl-2 
siRNA and C6M6/ Bcl-2 siRNA complexes on the growth of established subcutaneous 
tumors was assessed. When tumor volume reaches 100-200 mm3, four groups of mice 
were injected with saline, 4 µg (0.16 mg/kg) naked siRNA, peptide only and 
peptide/siRNA complexes at molar ratio 60/1, separately. The treatment was given every 
three days for a total of 9 times. Reduction of tumor size was observed in both 
C6M3/siRNA and C6M6/siRNA treatment group Figure 5.7a and 5.7b. In contrast, intra-
tumoral administration of saline and peptide only did not significantly reduce tumor 
growth, compared to the model group. Surprisingly, we found that naked Bcl-2 siRNA 
treated group also showed decreased tumor size, which has also been reported by other 
researchers in A549 xenograft mice [214] and other types of cancer cells [215]. The 
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mechanisms for greater uptake of siRNA into tissue cells in vivo, compared with 
ineffectiveness in cultured cells are not known, but could involve serum proteins or 
components of the complex extracellular matrices in tissues [215]. However, peptide 
C6M3 and C6M6 as carrier for siRNA could promote the anti-tumor effect further and 
provide better protection against enzymatic degradation.  On day 27, mice were sacrificed 
and tumor tissues were excised (Figure 5.7c and 5.7d). Tumor inhibition rate was 
calculated as tumor inhibition rate=(1- tumor weight of treatment group/tumor weight of 
model group)×100%. The tumor growth was reduced by 54.72% and 53.86% with 4 µg 
of Bcl-2 siRNA formulated with C6M3 and C6M6 respectively. The body weights of 
mice were monitored throughout treatment (Figure 5.7e and 5.7f). Mice exposed to 
peptide/siRNA complexes or peptide only did not suffer from weight loss for 27 days. 
Therefore, no toxicity was observed and the treatment was well tolerated. Next, we tried 
to validate that the Bcl-2 siRNA mediated inhibition of tumor growth was directly 
associated with a decrease in the level of Bcl-2 protein. Western blot analysis (Figure 
5.7g and 5.7h) using lysates from A549 tumors collected at the end of treatment revealed 
that the reduction in tumor size was directly correlated to Bcl-2 protein level, as 
evidenced by significant reduction in Bcl-2 expression with decreased tumor size. These 
data suggest silencing Bcl-2 protein expression is an effective way for inhibiting tumor 
growth.  
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Figure 5.7 Suppression of tumor growth in a non-small cell lung cancer xenograft mouse 
model by peptide based delivery of Bcl-2 siRNA. BALB/c nude mice (N=8) were 
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injected subcutaneously with 5×106 A549. When the tumor volume reached 100-200 
mm3, animals were treated by intratumoral injection of 20 µl saline solution, free Bcl-2 
siRNA (4 µg/mouse), peptide alone or Bcl-2 siRNA (4 µg/mouse) complexed with C6M3 
or C6M6 at a 1/60 molar ratio, every three days. Curves show the mean value of each 
group. (a) (b) Tumor diameters were measured during treatment. The tumor volume was 
calculated as Tumor volume=0.5×(width)2×length . ** P< 0.01 versus nontreated control. 
(c)(d) Images of tumors excised from the tumor-bearing mice on day 27 after treatments. 
(e)(f) Body weight of each mouse was monitored during treatment to evaluate toxicity. 
(g)(h) Total proteins were extracted from tumor tissues. Bcl-2 protein expression was 
detected by western blot. House keeping protein GAPDH was used as control.  
 
5.4 Conclusions 
In the present work, various numbers of histidine residues were placed in a prototype 
peptide C6 in an effort to aid in the endosomal release of siRNA, thereby improving its 
intracellular delivery. Preliminary GAPDH protein assay reveals that all the 
modifications increased the biological activity of siRNA with varying degrees. The 
transfection efficiency seems not solely depend on the number of histidine residues in the 
sequence, as peptides with same histidine numbers vary by effect in silencing efficiency. 
Two peptides C6M3 and C6M6 achieving above 60% knockdown efficiency were 
selected for further in-depth study. These two peptides could saturate all the negative 
charges of siRNA molecules at molar ratio 40/1 and 60/1, assessed by RiboGreen 
intercalation assay. The formed complexes are around 100 nm at molar ratio 60/1, with a 
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more than 30 mV surface charge enough for stability.  Subsequent experiments focused 
on the biological effect of peptide/siRNA complex reveals its strong uptake in CHO-K1 
cell line and its ability to reduce GAPDH gene expression with low cytotoxicity. In 
addition, this peptide-based delivery system is biocompatible, as it has been shown that 
no complement or cytokines were stimulated after treatment with peptides in vitro. 
Furthermore, we tried to suppress tumor growth by regulating Bcl-2 protein level, which 
enhances the growth of tumors by suppressing apoptosis. The in vivo results show that 
the reduction in Bcl-2 protein level could inhibit tumor growth in a mouse xenograft 
tumor model. Collectively, in vitro and in vivo data suggest our new carriers based on 
peptides C6M3 and C6M6 promote the delivery of siRNA into tumor cells, and might 
have therapeutic utility in a variety of diseases. 
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Chapter 6 
Rational modification of cell penetrating peptides for highly 
efficient siRNA delivery: structure-activity relationship and 
mechanism of intracellular trafficking of siRNA 
	  
6.1 Introduction 
RNA interference (RNAi)-mediated silencing offers one of the most attractive methods 
of gene therapy for many diseases. Many types of diseases including viral infections and 
cancers have been demonstrated to be potential targets for RNAi based therapy 
[59,216,217]; however efficient delivery of short interfering RNAs (20~25 base pairs) 
(siRNAs), the molecules that mediate RNAi, is still a key challenge in realizing the full 
potential of RNAi therapeutics [218]. 
       siRNAs must first enter target cells, typically by endocytosis, cross the endosomal 
membrane to be released into the cytosol, and finally get loaded onto the RNA-induced 
silencing complex (RISC) for silencing of the target gene [2,4]. However, passive 
diffusion of “naked” siRNAs across biological membranes is impeded by the 
physicochemical properties of the siRNA, including their high molecular weight, 
negative charge and hydrophilicity [219,220]. Thus, different systems have been 
developed for siRNA delivery by taking advantage of viral or nonviral vectors. Viral 
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vectors are highly efficient but they bear an inherent risk for the patient to encounter 
severe immunological responses or even develop cancer [221–223]. These problems in 
viral delivery have initiated an intense search for efficient non-viral delivery systems. 
Common non-viral siRNA delivery systems include cationic lipids and polymers. These 
vectors have various levels of efficiency and toxicity, but for most clinical indications 
still remain unsatisfactory [224–231]. Hence, the development of appropriate delivery 
systems is still an essential requirement to turn these molecules into medicine.  
        Recently, cell-penetrating peptides (CPPs), consisting of short cationic or 
amphipathic sequences of about 5-30 amino acids, have received much attention owing to 
their low toxicity, along with their ability to translocate through plasma membranes 
[85,232,233], which is a significant barrier for siRNA access to the intended targets in 
the cytoplasm. In most cases, however, the CPP/siRNA complexes were either 
internalized by the cells only in very low amounts, or the internalized CPP/siRNA 
complexes were trapped in endosomes, therefore inducing little or no gene silencing 
[98,234–236]. In terms of cellular uptake, stearyl modification of CPPs has significantly 
improved the internalization of siRNA by cells in comparison to the unmodified peptide 
[237]. For CPP/siRNA entrapments inside the endosomes, it is highly desirable to modify 
these complexes in order to facilitate their endosomal escape. Two main mechanisms are 
currently proposed to explain the escape of biologicals induced by peptides. The first is 
the “proton sponge” effect [238], that relies on protonable groups in the molecules with 
pKa values close to the endosomal/lysosomal pH. This will lead to a higher influx of 
protons, along with chloride ions and water, resulting in inevitable endosomal swelling 
and rupture. This release mechanism of contents to the cytosol has been established for 
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polyhistidine based delivery systems [238,239]. The second mechanism is pH-sensitive 
membrane disruption [240,241]. The hypothesis is that as endosomes acidify, 
endocytosed pH-sensitive peptides shift from an inactive state to an active, membrane-
disruptive state. In line with this concept, a histidine-rich peptide [242] and a 
pentadecaarginine (R15)-PLGA-PEG polymer [243] with pH-sensitive membrane 
disruption capability have been developed.   
         In this study, by taking all this knowledge into account, we undertake a rational 
design of CPP derivatives aiming to provide highly efficient siRNA delivery. First, 
oligoarginine, one group of the most widely utilized CPPs for intracellular delivery of 
biologicals, is employed as a model carrier because it can bind to the cell surface with 
high affinity [244] and is additionally more effective at entering cells than oligolysine, 
oligoornithine and arginine-rich peptides [146,245]. Second, in order to overcome the 
lack of silencing activity induced by oligoarginine [236,246], we introduce stearic acid 
and various oligohistidine modifications that are found to significantly enhance cellular 
uptake and endosomal escape of siRNA. Moreover, we hypothesize that hydrophobic 
stearyl groups conjugated to a peptide sequence would improve the co-assembly of 
peptide with siRNA in forming nanoparticles (<200 nm) in aqueous solution due to their 
hydrophobic interaction. We explore in detail the relationship between structures and 
properties of the oligoarginine based molecules with their biological activities. 
Particularly, we demonstrate that the residue number ratio of histidine/arginine in a 
stearylated peptide sequence is important for inducing pronounced gene silencing, and 
use this knowledge to deliberately design stearylated and oligohistidylated oligoarginine 
based siRNA carriers that have significantly improved efficiency compared to the most 
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commonly used benchmark delivery systems, Lipofactamine 2000 (Lipo). Finally and 
most notably, we discover the mechanism of intracellular siRNA release mediated by the 
carrier. In culmination, not only do these newly developed, highly efficient carriers 
provide practical advancement in terms of siRNA delivery, the understanding 
surrounding oligoarginine-based siRNA delivery system developments reported herein 
will provide valuable guidance for future investigation of CPP-based siRNA vectors. 
Figure 6.1 demonstrates the whole process of peptide mediated siRNA delivery, from 
peptide-siRNA binding, internalization, intracellular trafficking, to endosomal release 
and RNA interference.  
 
 
 
 
	  
 
 
Figure 6.1 Schematic diagram depicting the application of stearylated and 
oligohistidylated oligoarginine based peptide as siRNA carriers. 
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6.2 Materials and Methods 
6.2.1 Materials 
Peptides, stearylated peptides and siRNA: The R8, R15, STR-R8 and STR-H12R8 were 
synthesized in bulk (CanPeptide Inc., Pointe-Claire, Canada). The H16R8, STR-H8R8, 
H8R15, STR-H8R15, STR-H16R8 and STR-H20R8 were synthesized in bulk by Pepscan 
(Lelystad, The Netherlands). SilencerTM GAPDH siRNA (Life Technologies, Carlsbad, 
USA) was used to target the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene. 
The sense sequence was 5'-GGU CAU CCA UGA CAA CUU Utt-3' and antisense 
sequence was 5'-AAA GUU GUC AUG GAU GAC Ctt-3'. The SilencerTM Cy3-labeled 
GAPDH siRNA (Life Technologies, Carlsbad, USA) was used in confocal laser scanning 
microscopy (CLSM) and Fluorescence Activated Cell Sorting (FACS). The scrambled 
siRNA (Life Technologies, Carlsbad, USA) was used as negative control in the 
experiments.  
 6.2.2 Cell culture 
 CHO-K1 (Chinese hamster ovary) cells were purchased from American Type Culture 
Collection (ATCC CCL-61). Cells were cultured in F-12K (Thermo scientific, Ottawa, 
Canada) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich, Oakville, 
Canada). The Hela cells were obtained from American Type Culture Collection (ATCC 
CCL-2), and cultured in Eagle's Minimum Essential Medium (Thermo scientific, Ottawa, 
Canada) with 10% heat-inactivated FBS. All of the cells were incubated at 37°C in a 
humidified atmosphere containing 5% CO2. 
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6.2.3 Preparation of the complexes 
Both of the powders of the modified or unmodified peptides and siRNA were dissolved 
in RNase free water, respectively. The complexes were formed by mixing the two 
solutions at various molar ratios of arginine residues in peptides to phosphate groups of 
siRNA (R/P ratio). Lipofactamine 2000 (Lipo) (Life Technologies, Carlsbad, USA), a 
commercial transfection reagent, was also diluted in RNase free water and mixed with the 
siRNA solution to form complexes with the final concentration of 20 µL Lipo/mL. The 
final siRNA concentration was 1µM for all the samples containing complexes, which 
were incubated for 20 minutes at room temperature before characterization and siRNA 
release study. The samples were diluted further to 10% of the original concentration in 
Opti-MEM medium (Life Technologies, Carlsbad, USA) before transfection.    
6.2.4 Particle size and zeta potential 
 The hydrodynamic diameter of the complexes were measured on a Zetasizer Nano ZS 
(Malvern Instruments, Malvern, UK) equipped with a 4 mW He-Ne laser operating at 
633 nm. A quartz microcell (45 µL) with a 3 mm light path was used and the scattered 
light intensities were collected at an angle of 173°. Zeta potential measurements were 
also performed on the same machine using clear disposable zeta cells. Three 
measurements were performed to generate the intensity-based size and zeta potential plot 
reported herein. 
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6.2.5 Atomic force microscopy (AFM) 
 The nanostructure of the complexes was imaged on AFM. 10 µL of the sample solution 
containing complexes of H16R8 or STR-H16R8/siRNA with an R/P ratio of 10:1 was put 
on a freshly cleaved mica surface. The sample was incubated for 10 min at room 
temperature to allow the complexes to adhere onto mica surface. Mica was then washed 
at least five times with RNase free water to remove unattached complexes. After air 
drying, the mica surface was analyzed by a Dimension Icon AFM (Bruker, Santa 
Barbara, USA) at room temperature using the tapping mode with ScanAsyst-Air tips 
(Bruker, Santa Barbara, USA). All AFM images were obtained at a resolution of 512 × 
512 pixels on a scale of 5 µm × 5 µm and 2 µm × 2 µm. 
6.2.6 Transmission electron microscopy (TEM) 
10 µL of sample solution containing the complexes of STR-H16R8/siRNA at R/P 10 or 
STR-H16R8 only in the same concentration was applied to a 400 mesh Formvar coated 
copper grid (Canemco-Marivac, Canton de Gore, Canada) for 3-5 minutes. The sample 
was then washed using 5 successive wash steps and dried overnight. The complexes was 
stained with uranyl acetate and analyzed using a JEOL JEM 1200 EX TEMSCAN 
transmission electron microscope (JEOL, Peabody, USA) operating at an accelerating 
voltage of 80kV. The images were acquired with an AMT 4 megapixel digital camera 
(Advanced Microscopy Techniques, Woburn, USA). 
 6.2.7 siRNA loading efficiency 
RiboGreen assay was used to determine the siRNA loading efficiency using the 
manufacturer's protocol (Life Technologies, Carlsbad, USA). This assay is based on the 
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strong fluorescence of riboGreen upon intercalation with siRNA. RiboGreen solution was 
diluted to 1/30 (v/v) and then added to the samples (1:12, v/v). After 5 min, the 
RiboGreen fluorescence was measured by a QM4-SE spectrofluorometer (Photon 
Technology International, London, Canada) at excitation wavelength of 480 nm and 
emission wavelength of 525 nm. Free siRNA concentrations were obtained from the 
fluorescence using a standard curve prepared with standard siRNA solution. Peptides or 
stearylated peptides only were used as controls. The results were obtained from three 
independent experiments (n = 3). 
6.2.8 Gene silencing 
CHO-K1 cells (40,000/well) were plated in a 24-well cell culture plate in F-12K medium 
with 10% FBS. 24 h later, the medium was removed and washed with PBS, and then 300 
µL of the sample solution containing the complexes of the Peptides, stearylated peptides 
or Lipo/GAPDH siRNA or scrambled siRNA was added to the cells. 3 h later, 300 µL of 
F-12K with 20% FBS was added. In case of chloroquine and bafilomycin A1, both of 
them was dissolved in 300 µL of F-12K with 20% FBS, respectively, which was added to 
the cells 3 h after the cells were treated with the complexes. Afterwards, the cells were 
incubated for 48 hours at 37 °C in a 5% CO2 atmosphere. The cultures were then washed 
with PBS. Total RNA was extracted from the cells with TRIzol reagent (Life 
Technologies, Carlsbad, USA), then treated with chloroform (Sigma, Oakville, Canada) 
and 2-propanol (Sigma-Aldrich, Oakville, Canada) as recommended by the manufacturer. 
RNA concentrations were measured by Nanodrop spectrophotometer ND-1000 (Thermo 
scientific, Ottawa, Canada). All RNAs were reverse transcribed with Bio-Rad iScript 
cDNA synthesis kit (Bio-Rad, Mississauga, Canada). The cDNA synthesis was primed 
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with a unique blend of oligo (dT) and random primers. The following pairs of primers 
were used for PCR: 5ʹ′-TTGCTGTTGAAGTCGCAGGAG-3ʹ′, 5ʹ′-TGTGTCCGT- 
CGTGGATCTGA-3ʹ′ (Sigma, Oakville, Canada). Here, the housekeeping gene 
cyclophilin was chosen as an internal control to normalize the GAPDH gene. The 
normalization was performed by the amplification of mouse/rat cyclophilin mRNA with 
the following primers: 5ʹ′-AGGGTTTCTCCACTTCGATCTTGC-3ʹ′ and 5’-
AGATGGCACAGGAGGAAAGA- GCAT-3ʹ′ (Sigma, Oakville, Canada). PCR reaction 
was performed with Brilliant II Fast SYBR Green QPCR Master Mix (Agilent 
Technologies, Wilmington, USA) on an Mx3005P™ Real-Time PCR System (Agilent 
Technologies, Wilmington, USA).  
6.2.9 Fluorescence-activated cell sorting (FACS) 
 Cellular uptake of Cy-3 labeled GAPDH siRNA was studied using BD FACSCalibur 
Flow Cytometry (BD Biosciences, Mississauga, Canada). CHO-K1 cells were transfected 
with the cationic molecules/Cy3-labeled GAPDH siRNA complexes according to the 
protocol listed above. nontreated cells and naked siRNA served as a negative control. 
After 3 h incubation, the culture medium was discarded and cells were washed with PBS, 
Trypsin-EDTA was then added to detach the cells from the plate; cells were suspended in 
4% PFA solution and collected.  
 6.2.10 Confocal laser scanning microscopy (CLSM) 
 CHO-K1 cells (80,000/well) were plated in a Nunc Lab-Tek 4-well glass chamber slides 
(Thermo scientific, Ottawa, Canada) 24 h before transfection. CHO-K1 cells were also 
treated with the same protocol as described above. Treated cells were incubated at 37°C 
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for 3 h with Opti-MEM medium. For endosomal labeling, the cells were incubated with 
50 nM Lysotracker Green (Life Technology, Carlsbad, USA) for 30 min before fixing. 
The wells were then washed with 15 U/mL heparin (Grade I-A, ≥180 USP U/mg, Sigma-
Aldrich, Oakville, Canada) for three times in one hour at 37°C and fixed with 500 
µL/well of fresh 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) at 37°C 
for 30 min. The fixation agent was aspirated, and the cells were washed twice with PBS 
before they were covered with Fluoroshield with DAPI mounting medium (Sigma-
Aldrich, Oakville, Canada). Carl Zeiss LSM 700 Confocal laser scanning microscopy 
(Zeiss, Jena, Germany) was used to visualize the cells. The microscope was equipped 
with Plan-Apochromat 20x/0.8 NA objective lens. The images were analyzed with LSM 
Zen 2009 software. 
6.2.11 Membrane integrity assay 
 CHO-K1 cells (8,000/well) were plated on 96-well plates and incubated overnight in 100 
µL of F-12K medium containing 10% FBS. The cell culture medium was removed and 
washed with PBS. The modified and unmodified oligoarginine were dissolved in Opti-
MEM medium with pH 7.4, pH 6.3 and pH 5.5, respectively. After stand for 5 min, the 
solution was added to the cells.  After the incubation at 37°C for 3 h, the plates were 
centrifuged. 50 µL of aliquots in each well were collected for the LDH assay. The LDH 
activity in these samples was determined using a CytoTox 96 Non-Radioactive 
Cytotoxicity Assay kit (Promega, Madison, USA) according to the manufacturer’s 
protocol, which determined the LDH activity from the amount of produced red formazan 
product by a colorimetric assay. The amount of formazan produced was assessed by 
measuring the absorbance at 490 nm with a FLUOstar OPTIMA microplate reader (BMG 
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Labtech, Ortenberg, Germany). Percentages of the LDH activity in each well were 
calculated from a ratio of the obtained value to the control well containing 10 µL lysis 
buffer.  
6.2.12 pH-dependant siRNA release 
The solutions containing the complexes at R/P 10 were diluted to 10% of the original 
concentration in a serial dilution of heparin in PBS, pH7.4 or 5.5, respectively. 15 min 
later, the released siRNA was determined by the RiboGreen method as described above 
in “siRNA loading efficiency”. 
6.2.13 Cytotoxicity assay 
 CHO cells were plated in to 96-well plates (8,000 cells/well) in F-12K medium with 
10% FBS. 24 h later, the medium was removed and washed with PBS. The solutions 
containing carriers were prepared in RNase free water and diluted by Opti-MEM medium 
to 10% of the original concentration. After stand for 5 min, 60 µL of the solution was 
added to the cells. 3 h later, 60 µL F12-K medium with 20% FBS was added. After 
incubation for 24 hours at 37 °C in a 5% CO2 atmosphere, the cultures were washed with 
PBS. 100 µL of Opti-MEM medium with CCK-8 reagent was then added to each well. 
Cell viability was assessed by measuring the absorbance at 570 nm with a FLUOstar 
OPTIMA microplate reader and expressed as the ratio of the cells treated with the carriers 
over the nontreated cells (negative control). 
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6.3 Results and Discussion 
6.3.1 Modification of oligoarginine 
It has been reported that oligoarginine uptake increases with increasing charge, peaking 
between octaarginine (R8) and pentadecaarginine (R15) [146,245]. For this reason, in our 
approach, ten peptides were designed and investigated including R8 and R15, along with 
their high purity derivatives obtained by modification with oligohistidine and a stearyl 
moiety synthesized by a solid-phase synthesis method and purified by HPLC (Table 6.1).  
Table 6.1 Sequences of the unmodified and modified oligoarginine complexes along with 
their molecular weight and purity. These compounds were synthesized by a solid-phase 
synthesis method and purified by HPLC 
Name Sequences1 MW2 Purity3 
R8 Acetyl-RRRRRRRR-NH2 1,308.6 98.8 
STR-R8 Stearyl-RRRRRRRR-NH2 1.533.0 96.8 
STR-H8R8 Stearyl-HHHHHHHHRRRRRRRR-NH2 2,630.2 94.0 
R15 Acetyl-RRRRRRRRRRRRRRR-NH2 2,401.9 98.8 
H8R15 Acetyl –HHHHHHHHRRRRRRRRRRRRRRR-NH2 3,499.1 99.4 
STR-H8R15 Stearyl-HHHHHHHHRRRRRRRRRRRRRRR-NH2 3,723.6 92.4 
STR-H12R8 Stearyl-HHHHHHHHHHHHRRRRRRRR-NH2 3,178.7 96.0 
H16R8 Acetyl-HHHHHHHHHHHHHHHHRRRRRRRR-NH2 3,503.0 99.9 
STR-H16R8 Stearyl-HHHHHHHHHHHHHHHHRRRRRRRR-NH2 3,727.4 98.3 
STR-H20R8 Stearyl-HHHHHHHHHHHHHHHHHHHHRRRRRRRR-NH2 4276.0 98.7 
1 N-term acetylation or stearylation and C-term amidation 
2 Molecular weight of dalton by LC/MS 
3 by HPLC, % 
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6.3.2 Particle size and morphology of peptides/siRNA complexes 
We first examined the ability of the ten peptides to form nano-sized complexes with 
siRNA. For all the non-stearylated and stearylated peptides only, no diameters were 
detected, which indicated that these molecules were not self-assembled, but freely 
dissolved in water. This highlights that hydrophilicity as well as the positive charges of 
the peptides impeded the aggregation of hydrophobic stearyl moieties. Ideally, cationic 
carrier/siRNA complexes should be smaller than 200 nm to: (i) ensure optimal diffusion 
through tumor tissues by the enhanced permeation retention effect (EPR) [247]; and (ii) 
reduce the recognition and removal by phagocytic cells in vivo. At various molar ratios of 
arginine residues in peptides to phosphate groups of siRNA (R/P ratio), un-stearylated 
peptides of R8, R15, H8R15 and H16R8 failed to condense the siRNA into nanoparticles 
(<200 nm). This was especially apparent for H8R15 and H16R8, which can only form 
complexes with siRNA having particle sizes > 1 µm and polydispersity index (PDI) > 0.5. 
Conversely, peptides with stearic acid modification—STR-R8, STR-H8R8, STR-H8R15, 
STR-H12R8, STR-H16R8 and STR-H20R8 showed particle sizes of less than 200 nm at 
various R/P ratios (Table 6.2), indicating the stearic acid moiety was able to assist 
peptides to condense siRNA into small complexes suitable for transfection. 
 
Table 6.2 Particle Size of the unmodified and modified oligoarginine/siRNA complexes, 
determined by dynamic light scattering (DLS) measurements. The complexes were 
formed by mixing the solutions of cationic carriers and siRNA with the final siRNA 
concentration of 1µM at various molar ratios of arginine residues in peptides versus 
phosphate groups of siRNA (R/P ratio).  
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 Name 
R/P1 2.5 
(nm) 
PDI2 
R/P 5 
(nm) 
PDI 
R/P 10 
(nm) 
PDI 
R8 415±154 0.48±0.17 288±13 0.18±0.03 364±19 0.39±0.1 
STR-R8 120±35 0.31±0.06 89±15 0.29±0.04 73±14 0.24±0.04 
STR-H8R8 65±16 0.22±0.02 71±9 0.27±0.01 78±7 0.29±0.03 
R15 257±27 0.35±0.09 > 1µm > 0.5 > 1µm > 0.5 
H8R15 > 1µm > 0.5 > 1µm > 0.5 > 1µm > 0.5 
STR-H8R15 64±8 0.31±0.05 78±5 0.29±0.05 77±8 0.28±0.04 
STR-H12R8 88±2 0.31±0.01 95±3 0.28±0.03 89±2 0.27±0.01 
H16R8 > 1µm > 0.5 > 1µm > 0.5 > 1µm > 0.5 
STR-H16R8 79±11 0.22±0.03 88±12 0.3±0.03 75±9 0.31±0.03 
STR-H20R8 89±13 0.29±0.05 95±7 0.32±0.04 92±7 0.29±0.04 
1 R/P: Molar ratio of arginine residues in peptides versus phosphate groups of siRNA 
2 PDI: Polydispersity index  
     AFM and TEM imaging also supported the DLS size measurements, showing no 
regular nanoparticles for H16R8/siRNA and peptide STR-H16R8 only (Figure 6.2a and 
6.2b). 
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Figure 6.2 (a) AFM image of H16R8/siRNA complexes does not reveal the formation of 
regular nanoparticles with 1µM siRNA concentration at R/P 10. (b) TEM image of STR-
H16R8 only shows no nanoparticles. The concentration of STR-H16R8 is in accordance 
with that at R/P 10. Scale bar is 100 nm. 
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        AFM images depict the presence of distinct nanoparticles with an average diameter 
of 70 nm for STR-H16R8/siRNA complexes (Figure 6.3). The larger height (2.6 nm, 
Figure 6.3b) of STR-H16R8/siRNA complexes than that from H16R8/siRNA (1.1 nm) 
also suggested the formation of nanoparticles between peptide STR-H16R8 and siRNA. 
TEM image of STR-H16R8/siRNA (Figure 6.4a) also confirm the formation of uniform 
sized particles. These indicated that the hydrophobic stearyl moiety could significantly 
improve the formation of the nano-scaled complexes between siRNA and the cationic 
carriers, even with the addition of oligohistidine. The reason would be that the negative 
charge on siRNA molecules neutralizes the positive charge of the peptides, leading to a 
reduced intermolecular repulsion from arginine residues, and consequently improving the 
hydrophobic interaction of stearyl groups.  
	  	  	  	  	  	  	  The zeta potentials of R8/siRNA complexes at R/P 2.5 and 5 were 15.2 and 19.2 mV, 
but increased to 22.4 mV at R/P 10. We only measured the zeta potential of R15/siRNA 
complexes at R/P 2.5 to be 19.8 mV, because the particle size can be detected only at this 
R/P ratio (Table 2). The zeta potentials of stearylated peptides/siRNA complexes at R/P 
2.5 to 10 were all in the range of 20~30 mV, which is suitable for gene transfection 
(Figure 6.4b). 
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Figure 6.3 AFM images of STR-H16R8/siRNA complexes at a 5 µm × 5 µm scale and  
2 µm × 2 µm scale. AFM image reveals an average particle size of 70 ± 8 nm (n = 96). 
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Figure 6.4 (a) TEM image of STR-H16R8/siRNA complexes with siRNA concentration 
of 1µM at R/P 10. (b) Zeta potential of the oligoarginine based peptides/siRNA 
complexes at R/P ratios of 2.5, 5 and 10. The concentrations of the complexes were the 
same as that of the particle size measurement. The results indicated that stearylation 
modification on oligoarginine increased the surface charges of the complexes. 
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6.3.3 siRNA binding capacity of peptides 
To gain deeper insight into the interactions occurring between these oligoarginine-based 
molecules and siRNA, siRNA loading capacities were determined by RiboGreen assay. 
This assay was based on the strong fluorescence of RiboGreen upon intercalation with 
free siRNA. In this assay, H16R8 and H8R15 were not included as they were difficult to 
form nanoparticles with siRNA at various R/P ratios. 
	  	  	  	  	  	  Generally, R8, R15, STR-R15 and STR-(H)nR8 (n=0, 8, 12, 16 or 20) showed 
significant fluorescence quenching above an R/P ratio of 2.5, meaning these molecules 
could condense siRNA efficiently above this ratio (Figure 6.5). For an R/P ratio of < 2.5, 
R8 exhibits less siRNA binding capacity than the corresponding stearylated R8. This 
confirmed that the stearyl moiety could help condense siRNA more efficiently to form 
smaller complexes as shown in Table 2. Interestingly, after the conjugation of 
oligohistidine, fluorescence quenching was clearly increased with extended chain length 
of oligohistidine in the order of STR-H20R8 > STR-H16R8 > STR-H12R8 > STR-H8R8 
> STR-R8. We assumed that a portion of histidine (pKa of the side chain is 6.0) residues 
in the stearyl-oligohistidine-oligoarginine were positively charged in aqueous solutions 
and interact with siRNA as well, so that they can show a more pronounced binding effect. 
In the case of STR-H8R15 however, this assumption is not suitable, since at the same R/P 
ratio, the number ratio of histidine/arginine in the sequence was only 0.53, far lower than 
that of STR-H8R8 and STR-H12R8 with the histidine/arginine ratio of 1 and 1.5, 
respectively. However, the binding capacity of STR-H8R15 is higher than those of STR-
H8R8 and STR-H12R8. This phenomenon suggested that the extended chain length of 
oligoarginine improved the condensing of siRNA significantly, which surpassed the 
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contributions made by histidine residues to the siRNA binding. In terms of unmodified 
oligoarginine peptides, R15 also showed a higher siRNA binding capacity than that of 
R8, verifying that longer oligoarginine had greater capability to condense siRNA 
compared with the short one. 
 
 
 
 
 
 
 
 
Figure 6.5 siRNA binding capacity of the unmodified and modified oligoarginine 
peptides was measured by RiboGreen intercalation assay. Initial siRNA concentration is 
100 nM. Different volumes of peptide stock solution were added to the fixed siRNA 
concentration to obtain peptide/siRNA charge ratios from 1 to 3. 
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6.3.4 Gene silencing efficiency and cytotoxicity of peptide/siRNA complexes 
on cultured cells 
The gene silencing efficacy of siRNA delivered by the individual oligoarginine-based 
carriers was examined using a GAPDH gene knockdown assay. The mRNA levels in 
CHO-K1 cells after treatment were measured by quantitative real-time PCR. As shown in 
Figure 6.6a, R8, R15 and STR-R8 did not induce GAPDH mRNA knockdown at various 
R/P ratios. The STR-H8R8/siRNA formulations showed 16 and 26% lower mRNA levels 
than that of nontreated cells at R/P 5 and 10, respectively. However, STR-H8R15/siRNA 
formulations revealed decreased mRNA levels by 17% at R/P 10, lower than that of STR-
H8R8. This implied that increased chain length of oligoarginine could not improve the 
efficacy of siRNA delivery. Furthermore, with an increased chain length of 
oligohistidine, STR-H12R8 induced gene silencing with the knockdown efficiency of 
31% at R/P 5 and 59% at R/P 10. Taking the positive correlation between the ratios of 
histidine/arginine in stearylated oligoarginine derivatives and knockdown efficiency into 
consideration as well, we assumed that histidine residues would play an important role in 
the cellular delivery of siRNA. Following this finding, we extended the chain length of 
oligohistidine further in stearylated and oligohistidylated R8 molecules, and STR-H16R8 
and STR-H20R8 were evaluated in gene silencing assays. STR-H16R8 showed 
significant gene knockdown levels of 50% at R/P 5 and 88% at R/P 10. The latter value 
was similar to that of a benchmark, Lipofactamine 2000 (Lipo), which is the most 
commonly utilized and efficient transfection reagent to introduce siRNA into cells, 
inducing 84% gene silencing in this assay. Moreover, the knockdown efficiency was 
improved further to 92% by STR-H20R8, which verified the established theory very well.  
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When these oligoarginine-based peptides are used as siRNA delivery agents, a low 
cytotoxicity is critical. The followed investigation therefore was evaluation of the 
cytotoxicity of these cationic molecules. The viability of cells treated with R8, R15 and 
modified R8 was almost the same as that in nontreated cells. However, Lipo showed 
slight cytotoxicity with only 87% of the cells surviving (Figure 6.6b). The STR-H8R15 
showed 80% cell viability at R/P 10, though the molar concentration of it was much 
lower than those of the molecules containing R8 at the same R/P ratio, which would be 
due to that both the longer chain length of oligoarginine and stearyl group improved the 
interaction between it and cell membrane. Hela cells were also employed for the mRNA 
knockdown study, which showed a similarly higher silencing efficiency induced by STR-
H16R8 than that of Lipo (Figure 6.7a). STR-H16R8 did not show any cytotoxicity up to 
R/P 10 in Hela cells as well (Figure 6.7b).  
 
Figure 6.7 (a) Gene knockdown efficiency and (b) cytotoxicity of STR-H16R8/siRNA 
complexes on Hela cells. In gene knockdown assay, GAPDH siRNA was used and in 
cytotoxicity assay negative control siRNA was used.  
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Figure 6.6 (a) Gene knockdown efficiency and (b) cytotoxicity of STR-H16R8/siRNA 
complexes on CHO-K1 cells. In gene knockdown assay, GAPDH siRNA was used and in 
cytotoxicity assay negative control siRNA was used. 
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6.3.5 Cellular uptake 
Cellular uptake of Cy-3 labeled siRNA formulated with the carriers at R/P 10 was 
measured by fluorescence activated cell sorting (FACS). As shown in Figure 6.8a, in 
comparison to the other modified peptides R8 and R15 mediated a markedly lower 
internalization of siRNA, which would be one main reason for its ineffectiveness in gene 
silencing. In terms of stearylated peptides, STR-R8 had the highest mean fluorescence 
intensity of 260, with STR-H8R8, STR-H8R15, STR-H12R8, STR-H16R8 and STR-
H20R8 inducing mean fluorescence intensities of 160, 195, 187, 220 and 211, 
respectively. These intensities were all much greater than that of Lipo, inducing a mean 
fluorescence intensity of 59 (Figure 6.8b). Based on these observations, we can conclude 
that stearylated peptides with various chain lengths of oligoarginine and oligohistidine 
resulted in similar cellular uptakes of the complexes. These findings were directly in 
accordance with the excellent ability of them to condense siRNA. Furthermore, 
significant differences in the efficacy of the stearylated peptide/siRNA complexes would 
not be attributed to the internalization of the complexes, which were only slightly 
different, but rather to the varying degrees of released siRNA into the cytosol, where 
siRNAs have to reach and then get loaded onto the RNA-induced silencing complex 
(RISC) for gene silencing.   
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Figure 6.8 Cellular uptake of Cy3-siRNA complexes formed with the modified and 
unmodified oligoarginine at 3 h after the treatment in CHO-K1 cells. The same procedure 
as that involved in gene silencing assay was used to prepare the complexes with the final 
siRNA concentration of 100 nM at R/P 10 for all cationic molecules and at R/P 2.5 for 
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R15, only where nanoparticles can be detected. Flow cytometry and reveals the 
stearylated oligoarginine with or without oligohistidine segments deliver similar amounts 
of Cy3-labeled siRNA into cells, which were much higher than these induced by the 
unmodified oligoarginine.  
 
6.3.6 Subcellular localization of peptides/Cy-3 siRNA complexes 
The sub-cellular localization of the complexes was imaged using confocal laser scanning 
microscopy (CLSM). Particularly, DAPI was used to stain nuclei, and Lysotracker Green 
was used to stain endolysosomal vesicles. Figure 6.9 shows that the cells treated with the 
Lysotracker Green revealed a punctuate pattern of endolysosomes in the cytosol. The 
Cy3-labeled GAPDH siRNA with red fluorescence delivered by the two typical cationic 
molecules, STR-R8 and STR-H16R8, also showed a punctuate distribution pattern in the 
cytosol. The majority of Cy-3 fluorescence-labeled siRNA appeared to be trapped in 
endosomal/lysosomal vesicles as demonstrated by its extensive colocalization with the 
LysoTracker Green marker, visualized as yellow punctuate fluorescence. This suggested 
that the uptake of the complexes followed an endocytosis pathway. Moreover, for the 
STR-H16R8/siRNA complexes inducing high gene silencing, a small amount of the Cy3 
labelled siRNA can be observed distributed in the cytosol at 6h (Figure 6.10). A zoomed 
in image for the co-localization of STR-H15R8/Cy-3 siRNA and lysosomes/endosomes 
was shown in Figure 6.11.   
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Figure 6.9 Intracellular localization of Cy-3 siRNA in CHO-K1 cells at 3 h after the 
treatment with STR-R8 or STR-H16R8/Cy3-labeled siRNA (red) complexes at R/P 10 
with 100 nM of siRNA in Opti-MEM medium determined by confocal laser scanning 
microscopy. Nucleic was stained with DAPI (blue). Endosomes/lysosomes were stained 
with LysoTracker Green (green). Full co-localization of siRNA with 
endosomes/lysosomes was observed in punctuate pattern with yellow fluorescence in 
merged images suggesting the complexes were taken up by endocytosis. Both length and 
width are 160 µm for every picture. Plan-Apochromat 20x/0.8 NA objective lens was 
used to obtain these images.  
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Figure 6.10 Intracellular localization of siRNA in CHO-K1 cells at 6 h after the 
treatment with STR-H16R8/Cy3-labeled siRNA (red) complexes at R/P 10 with 100 nM 
of siRNA in Opti-MEM medium determined by confocal microscopy. Nucleic is stained 
with DAPI (blue). Endosomes/lysosomes are stained with LysoTracker Green (green). 
Most of the siRNA is localized in endosome/lysosome and a small amount of siRNA can 
be found distributing in cytosol (red dots). The punctuate distribution pattern of yellow 
fluorescence increase in size and decrease in amount due to the fusion of 
endosome/lysosome compartments into larger vesicles [248–250]. Both length and width 
are 160 µm for each picture. Plan-Apochromat 20x/0.8 NA objective lens was used to 
obtain these images.  
 
	   147	  
 
Figure 6.11 Intracellular localization of siRNA in CHO-K1 cells at 3 h after the 
treatment with STR-H16R8/Cy3-labeled siRNA (red) complexes at R/P 10 with 100 nM 
of siRNA. Nucleic is stained with DAPI (blue). Endosomes/lysosomes are stained with 
LysoTracker Green (green). Most of the siRNA is localized in endosome/lysosome and a 
small amount of siRNA can be found distributing in cytosol (red dots). Plan-Apochromat 
40x/0.8 NA objective lens was used to obtain this image.  
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6.3.7 pH-dependant siRNA release 
It has been suggested that the release of siRNA from the internalized complexes is crucial 
for effective gene silencing, whereby a low intracellular siRNA dissociation would most 
likely reduce the gene silencing efficiency [251]. On the contrary, a premature 
extracellular release of siRNA is also undesired. Therefore, siRNA dissociation from the 
stearylated peptides was investigated in PBS at pH 5.5 and 7.4, mimicking the acidic 
environment in the endosome/lysosome and the physiological conditions during cell 
culturing, respectively. Negatively charged heparin was used to represent the endogenous 
polyanions [252]. For STR-R8 at pH 5.5, siRNA dissociation from the complexes 
decreased by 15 and 10% in comparison to pH 7.4, at heparin concentrations of 0.02 and 
0.05 mg/mL, respectively, while in terms of other stearylated and oligohistidylated 
oligoarginine, no pronounced change of siRNA release was found when the medium was 
acidified (Figure 6.12). These results indicated that the acidic environment did not 
significantly change the release of siRNA from the complexes. In both of the PBS 
solutions, extended chain lengths of oligohistidine and oligoarginine segments reduced 
the siRNA release against the heparin competition, which showed a similar order as the 
siRNA binding capacity of these oligoarginine based molecules (Figure 6.5). Therefore, 
siRNA dissociation from the internalized complexes would not be an issue in terms of 
hindering the effective gene silencing. This is because STR-R8 and STR-H8R8, 
exhibiting higher release of siRNA did not induce effective gene silencing, while STR-
HnR8 (n=12, 16 or 20), inducing a higher knockdown efficiency showed a lower siRNA 
release. On the other hand, less replacement of siRNA by heparin indicated that siRNA 
could be better protected in the complexes formed with the molecules possessing longer 
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oligohistidine and oligoarginine chains, presumably preventing siRNA from the 
degradation in the endosome/lysosome more effectively. However, STR-H8R15, which 
protected siRNA slightly better than STR-H12R8 (showing a significant knockdown 
efficiency) did not induce efficient gene silencing. Thus, better protection of siRNA in 
the complexes, although important, would not be a determining factor to the more 
efficient gene silencing. However, a certain ratio of histidine/arginine (>1.5) in 
stearylated peptides is undoubtedly a necessity to ensure the highly efficient intracellular 
siRNA delivery.  
             
Figure 6.12 pH-dependant siRNA release performed in a serial dilution of heparin in 
PBS, at pH7.4 or 5.5, respectively. The free siRNA was determined by the RiboGreen 
method. At pH 5.5, siRNA dissociated from the STR-R8/siRNA complexes decreased 
slightly, while in terms of the stearylated and oligohistidylated oligoarginine, no 
significant change of siRNA release was found between pH 7.4 and 5.5. 
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6.3.8 Endosomal escape mechanism 
Chloroquine (CQ) is an endosomolytic agent well known to facilitate the release of 
entrapped biomolecules by causing the swelling and disruption of endocytic vesicles by 
osmotic effects [239]. To date, CQ has been widely used to elucidate the uptake 
mechanism of non-viral nucleic acid delivery systems [253] To confirm that stearylated 
peptides/siRNA complexes are taken up by an endocytic pathway, gene silencing was 
carried out in CHO-K1 cells in the presence of CQ at a final concentration of 50 µM. In 
the case of STR-R8, which induced a high uptake of siRNA but hardly detectable gene 
silencing, a 13% decrease in mRNA levels was observed when it was simultaneously 
treated with chloroquine. The effect of CQ was more pronounced however with STR-
H8R8 and STR-H16R8, showing a significant increase in gene silencing from 8% to 49% 
and 45 to 79%, respectively (Figure 6.13a). Therefore, on the one hand, the assay 
confirmed that the stearylated peptides/siRNA complexes were internalized via 
endocytosis. On the other hand, such different enhancements with CQ treatment 
confirmed that the involvement of oligohistidine in STR-R8 could enhance the 
endosomal escape of siRNA substantially. 
    All the aforementioned data clearly suggested the important effects of histidine 
residues on the intracellular trafficking of siRNA. Similar to CQ, the accumulation of 
histidine residues in endosomes can induce a “proton sponge” effect as well, which will 
disrupt the endosomal membranes and inevitably result in the release of trapped 
biologicals. Focusing on STR-H16R8, we used an inhibitor for vacuolar ATPase proton 
pump, bafilomycin A1 (Baf A1), to reduce the acidification of the endosomes [254,255].  
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Figure 6.13 The effect of endosomal pathway inhibitors on the silencing efficiency of 
peptide/siRNA complexes. (a) Effect of an endosomolytic agent, Chloroquine (CQ), on 
gene silencing of siRNA formulated with STR-R8, STR-H8R8 and STR-H16R8 at R/P 5. 
CQ improved the mRNA knockdown more pronouncedly for STR-H8R8 and STR-
H16R8 than that of STR-R8. (b) Acidification inhibition of endosomes induced by 
bafilomycin A1 (Baf A1) reduced the knockdown efficiency of STR-H16R8/siRNA 
complexes at R/P 10 significantly. Both of experiments were conducted in the same 
manner as gene silencing assay with the siRNA concentration of 100 nM, but with 
addition of 50 µM CQ or 20 nM Baf A1, respectively, to the wells 3 h after the CHO-K1 
cells treated with the complexes.  
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Naturally, the inhibition of the proton pumps on the endolysosomes should weaken both 
the “proton-sponge” effect [256]  and the pH-dependent endosomal membrane disruption 
[240]. Figure 6.13b showed that the addition of Baf A1 decreased the gene silencing 
dramatically. These findings clearly indicated that the endosomal acidification was 
important to help the release of siRNA formulated in the complexes from endosomes. 
      The pH-dependent membrane disruption was further investigated by a membrane 
integrity study using the lactate dehydrogenase (LDH) leakage assay [257]. In terms of 
all the stearylated peptides, there was no significant pH-dependent promotion of LDH 
leakage at various concentrations (Figure 6.14), although pH-sensitive membrane 
disruption was demonstrated with R8 and R15. This suggested that after stearylation or 
stearylation/oligohistidylation modifications, the pH-sensitive membrane disruption 
capabilities of the oligoarginine molecules were restrained completely. Moreover, the 
overall capabilities of membrane disruption were similar among these modified R8 
peptides, which were surpassed slightly by STR-H8R15.   
    The results demonstrated that all these modified stearylated oligoarginines of various 
concentrations possessed similar membrane disruption capabilities at pH 5.5, 6.3 and 7.4. 
However, Figure 6.6 revealed that the knockdown efficiency varied remarkably between 
these oligoarginine derivatives. Thus, we believe that pH sensitive membrane disruption 
was less likely to be the major endosomal escape pathway induced by these cationic 
molecules. Based on the comprehensive investigations on the mechanism of endosomal 
escape, we therefore concluded that the “proton-sponge” effect induced by histidine 
residues played a predominant role in the escape of siRNA from endosomes to cytosol. 
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Figure 6.14 Membrane disruption ability of the unmodified and modified oligoarginine 
in CHO-K1 cells at pH 7.4, 6.3 and 5.5. This was measured by comparing the amount of 
leaked lactate dehydrogenase (LDH) in the wells with samples to the control well 
containing the lysis buffer. R8 and R15 showed pH-sensitive membrane disruption, while 
after stearylation or stearylation/oligohistidylation modifications, the membrane 
disruption capabilities of STR-R8, STR-H8R8, STR-H12R8, STR-H16R8 and STR-
H20R8 are pH-independent and similar. The membrane disruption ability of STR-H8R15 
is also not pH-sensitive but induces a slightly higher LDH leakage.  
 
 
6.4 Conclusions 
By fully taking into account the formation of nanoparticles, cellular uptake and 
intracellular trafficking of siRNA, we have rationally modified oligoarginine with stearic 
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acid and various oligoarginine in order to deliver siRNA with high efficiency. 
Furthermore, the relationship between the structures/properties of the oligoarginine based 
molecules and their biological activities have been investigated in detail. It was found 
that stearyl moieties could facilitate the formation of small complexes (<200 nm). 
Extended oligohistidine or oligoarginine segments can further promote the co-assembly 
of siRNA with these cationic molecules. Increased oligohistidine segments improved the 
gene silencing, but did not cause the toxicity. Moreover, stearylation modification was 
necessary to enhance the cellular internalization of siRNA. Most importantly, it was 
found that improved gene silencing was induced by the stearylated peptides with 
increased number ratio of histidine/arginine in a peptide sequence. On the contrary, 
longer oligoarginine segments will induce the toxicity but not enhance the knockdown 
efficiency. Using these findings, STR-HnR8 (n=16 and 20) were deliberately designed 
and developed, showing outstanding knockdown efficiency capabilities compared to the 
most commonly used benchmark delivery systems. Finally, we found that either siRNA 
release from the complexes or protection of siRNA by the complexes was not a 
determining factor for highly efficient gene silencing. Also, endosomal escape of siRNA 
induced by stearylated peptides was not due to pH-dependent membrane disruption, but 
from “proton-sponge” effect induced by the oligohistidine segments. In summary, we 
developed a promising platform for the improvement and optimization of CPP-based 
vectors that can induce highly efficient siRNA delivery. The knowledge generated 
provides valuable understanding and guidance surrounding the deliberate design and 
preparation of highly practical CCP-based siRNA delivery systems. 
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Chapter 7 
Co-delivery of hybrid drug nanoparticles and siRNA mediated 
by a modified cell penetrating peptide for triple synergy to 
inhibit cancer cell proliferation 
 
7.1 Introduction 
Combinations of two or more chemotherapeutic agents with different anti-cancer 
mechanisms have been proved effective in the treatment of many types of cancer. Since 
cancer is a disease caused by multiple gene mutations [258,259], this combination 
therapy has advantages by affecting multiple disease pathways. Over the past decade, 
combinations of conventional chemotherapeutics and small interfering RNA (siRNA) 
have shown promise with synergistic effects on the treatment of cancer [260,261]. 
However, co-delivery of anticancer drugs and siRNA is particularly challenging, because 
of the large differences in the physicochemical properties of the two types of agents. 
Moreover, uncontrolled agglomerations often lead to the instability of nanoparticles 
(NPs) in aqueous medium [262]. Therefore, this combination therapy is still in its early 
discovery stage. To date, only several types of carriers for single drug-siRNA 
combination have been developed, such as polyplex and lipoplex [263].  
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      Ellipticine (EPT), whose mode of action is based mainly on DNA intercalation and 
inhibition of topoisomerase II, has exhibited significant antitumor activities [264,265]. 
10-Hydroxycamptothecin (HCPT), isolated from Camptotheca acuminata extract, has a 
broad spectrum of anticancer activities by targeting and inhibiting topoisomerase I [266]. 
In terms of drug-siRNA combination therapy for cancer treatment, it has been reported 
that siRNA induced knockdown of the Bcl-2 gene, a key regulator of cell apoptosis [267], 
could sensitize cancer cells to anticancer drugs [268,269]. 
      Here, by taking all this knowledge into account, we hypothesized that co-delivery of 
anti-cancer drugs EPT, HCPT and Bcl-2 siRNA will have multiple synergy effect on the 
treatment of cancer. A novel peptide-based delivery system based on a stearylated and 
oligohistidylated cell penetrating peptide, stearyl-(histidine)16-(arginine)8 (STR-H16R8) 
was used here as carrier. This peptide was recently developed by us for highly efficient 
siRNA delivery [270]. In this chapter, at first, carrier-free EPT/HCPT hybrid 
nanoparticles were prepared by a solvent displacement method [271], as both of the 
molecules have a poor aqueous solubility [272,273]. Secondly, the NPs were stabilized 
by surfactant-like and water soluble STR-H16R8 in the aqueous solution. Thirdly, Bcl-2 
siRNA was introduced into the drug nanosuspension to form complexes with STR-
H16R8. Last, the anti-proliferation effect of this co-delivery system was investigated on 
cancer cells. We demonstrated that the combination of EPT/HCPT exhibited a synergistic 
effect on the inhibition of cancer cell proliferation. Furthermore, we found that the 
cationic stearylated peptide not only improved the stability of nanosuspension, but also 
significantly enhanced the efficacy of the drugs. Moreover, Bcl-2 siRNA further 
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increased efficacy of the chemotherapeutics, leading to the triple synergistic effects on 
suppressing the cancer cell growth. 
7.2 Materials and Methods 
7.2.1 Materials and reagents 
Ellipticine (EPT) (MW, 246.31; >98% purity) was purchased from EMD-Merck 
(Mississauga, Canada). (S)-10-Hydroxycamptothecin (HCPT) (MW, 364.35; >98% 
purity) was provided by AdooQ BioScience (Irvine, US). STR-H16R8 was synthesized 
by Pepscan (Lelystad, The Netherlands). R8 was synthesized by CanPeptide Inc. (Pointe-
Claire, Canada). siRNA targeting Bcl-2 oncogene was purchased from Sigma, (Oakville, 
Canada) with a sense sequence of GUGAAGUCAACAUGCCUGCdTdT and antisense 
sequence of GCAGGCAUGUUGACUUCACdTdT. The scrambled siRNA from Life 
Technologies (Carlsbad, USA) was employed as negative control in the experiments.  
7.2.2 Cell culture 
The non-small lung carcinoma A549 cells (ATCC, Manassas, USA) were cultured in 
Dulbecco’s Modified Eagle Medium-high glucose (DMEM) (Invitrogen, Burlington, 
Canada) with 10% heat-inactivated FBS. All of the cells were incubated at 37°C in a 
humidified atmosphere containing 5% CO2.  
7.2.3 Preparation of the nanosuspension 
	  1 mL of 4 mM of EPT and 0.2 mM of HCPT acetone solution was added into 5 mL 
RNase free water at 40°C under vigorous stirring at 1,000 rpm. 5 min later, 7.5 mL of 
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RNase free water or STR-H16R8 solution was added into the EPT/HCPT suspension, 
which was stirred at 200 rpm for 8 hours to remove acetone, the final volume of which 
was adjusted to 12.5 mL by adding RNase free water. Afterwards, the original 
EPT/HCPT NP suspension was mixed with RNase free water with the volume ratio of 1: 
3, and then mixed with RNase free water or 2 µM siRNA solution, respectively (1:1, v/v). 
The resulting solutions were incubated for 20 min at room temperature before 
characterization, determination of drug contents and in vitro release. The EPT/HCPT 
nanosuspension without STR-H16R8 was subject to lyophilization before observed by 
Leo-1530 scanning electron microscopy (SEM) (Zeiss, Oberkochen). The 
nanosuspension was diluted further to 1/10 of the original concentration with Opti-MEM 
medium (Life Technologies, Carlsbad, USA) before cell treatments with a final 
concentration of siRNA at 100 nM.  
7.2.4 Particle size and zeta potential 
 The hydrodynamic diameter of the complexes were measured on a Zetasizer Nano ZS 
(Malvern Instruments, Malvern, UK) equipped with a 4 mW He-Ne laser operating at 
633 nm. A quartz microcell (45 µL) with a 3 mm light path was used and the scattered 
light intensities were collected at an angle of 173°. Zeta potential measurements were 
also performed on the same machine using clear disposable zeta cells. The zeta potential 
values were obtained with the multimodal algorithm CONTIN, Dispersion Technology 
Software 5.0. Three measurements were performed to generate the intensity-based size 
and zeta potential plot reported herein. 
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7.2.5 Gene silencing effect of peptide/siRNA complexes 
 A549 cells (40,000 cells/well) were plated in a 24-well cell culture plate. 24 h later, the 
medium was removed and washed with PBS. 1.28 µL of Lipofactamine 2000 (Lipo) (Life 
Technologies, Carlsbad, USA), a commercial transfection reagent, was diluted in 30.72 
µL of RNase free water and mixed with 32 µL of Bcl-2 siRNA solution to form 
complexes with the final concentration of siRNA at 1 µM, which was then diluted in 596 
µL of OPTI-MEM medium before transfection. 300 µL of the sample solution containing 
the lipoplexes of Lipo/siRNA or the complexes of STR-H16R8/siRNA was added to the 
cells. 3 h later, 300 µL of DMEM with 20% FBS was added. Afterwards, the cells were 
incubated for 48 hours at 37 °C in a 5% CO2 atmosphere. The cultures were then washed 
with PBS. Total RNA was extracted from the cells with TRIzol reagent (Life 
Technologies, Carlsbad, USA), then treated with chloroform (Sigma, Oakville, Canada) 
and 2-propanol (Sigma-Aldrich, Oakville, Canada) as recommended by the manufacturer. 
RNA concentrations were measured by Nanodrop spectrophotometer ND-1000 (Thermo 
scientific, Ottawa, Canada). All RNAs were reverse transcribed with Bio-Rad iScript 
cDNA synthesis kit (Bio-Rad, Mississauga, Canada). The cDNA synthesis was primed 
with a unique blend of oligo (dT) and random primers. The following pairs of primers 
were used for PCR: 5'-GGTGGGGTCATGTGTGTGG-3' and 5'-
CGGTTCAGGTACTCAGTCATCC-3' (Sigma, Oakville, Canada). Here, the 
housekeeping gene cyclophilin was chosen as an internal control to normalize the Bcl-2 
gene. The normalization was performed by the amplification of human cyclophilin with 
the following primers: 5'-GGTGATCTTTGGTCTCTTCGG-3' and 5’-
TAGATGCTCTTTCCTCCTGTG-3' (Sigma, Oakville, Canada). PCR reaction was 
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performed with Brilliant II Fast SYBR Green QPCR Master Mix (Agilent Technologies, 
Wilmington, USA) on an Mx3005P™ Real-Time PCR System (Agilent Technologies, 
Wilmington, USA).  
7.2.6 Cytotoxicity assay 
A549 cells were plated in to 96-well plates (8,000 cells/well). 24 h later, the medium was 
removed and washed with PBS. 16 µL of 160 µM of EPT or 8 µM of HCPT DMSO 
solution was mixed into 48 µL of RNase free water, which were further diluted with 596 
µL of OPTI-MEM medium. 60 µL of the sample solution was added to the cells. 3 h 
later, 60 µL DMEM medium with 20% FBS was added. After incubation for 24 hours, 
the cultures were washed with PBS. 100 µL of Opti-MEM medium with CCK-8 reagent 
was then added to each well. Cell viability was assessed by measuring the absorbance at 
570 nm with a FLUOstar OPTIMA microplate reader and expressed as the ratio of the 
cells treated over the nontreated cells (negative control). 
7.2.7 Fluorescence-activated cell sorting (FACS) 
 Cellular uptake of EPT and HCPT was studied using BD FACSCalibur Flow Cytometry 
(BD Biosciences, Mississauga, Canada). A549 cells (80,000 cells/well) were plated in a 
24-well cell culture plate. 24 h later, the medium was removed and washed with PBS. 
Afterwards, A549 cells were treated with 300 µL of EPT/HCPT NPs, EPT/HCPT 
NPs/STR-H16R8 or EPT/HCPT NPs/STR-H16R8/BCL-2 siRNA samples in Opti-MEM 
prepared according to the protocol listed above. Nontreated cells served as a negative 
control. After 3 h incubation, the culture medium was discarded and cells were washed 
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with PBS, Trypsin-EDTA was then added to detach the cells from the plate; cells were 
suspended in 4% PFA solution and collected.  
 
7.3 Results and Discussion 
7.3.1 STR-H16R8 could stable EPT/HCPT hybrid nanoparticles in water 
In order to develop a nanoparticulate delivery system for intravenous administration, a 
stable nanoparticle dispersion without agglomeration is prerequisite [262]. In this study, 
EPT/HCPT hybrid nanoparticles (NPs) prepared in 120 µM of STR-H16R8 showed a 
stable nanosuspension (Figure 1a, left), while NPs prepared in water sedimentated on the 
bottom rapidly (Figure 1a, middle). The morphology and structure of the NPs without 
addition of peptide STR-H16R8 were investigated via SEM, which showed the presence 
of distinct spherical NPs with an overall diameter of 170 nm and large agglomerations 
comprising of a number of nanoparticles (Figure 1b). 
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Figure 7.1 a) Photograph of 320 µM of EPT and 16 µM of HCPT hybrid NPs in 120 µM 
of STR-H16R8 (left) and water (middle) 3 h after preparation. Pure water (right) was 
used as reference; b) SEM imaging of freeze-dried unstabilized EPT/HCPT NPs. 
 
 
DLS measurements also showed a > 2 µm diameter of the NPs prepared in water (Figure 
7.2a). All these data suggested that the instability of the drug NPs without stabilizer was 
due to the sedimentation of agglomerations formed by nanoparticles in water. With the 
addition of 0.6 µM of STR-H16R8, particles sizes were reduced significantly to 770 nm, 
see Figure 7.2a. When the concentration of STR-H16R8 increased from 3 to 30 µM, the 
particle sizes decreased further from 331 nm to 195 nm. In 60 µM of the stabilizer, the 
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particle size was 198 nm, which was almost the same as that in 30 µM, suggesting that 
the nanoparticles have been stabilized completely, as showed in Figure 7.1a, left. The 
particle sizes were slightly bigger than that revealed by SEM imaging [274], which could 
be due to the anchor of STR-H16R8 on the surface of the drug NPs.  These results 
indicated that amphiphilic STR-H16R8 could stabilize EPT/HCPT NPs effectively, 
leading to a stable nanosuspension with an average particle size of 200 nm. As showed in 
Figure 7.2b, the zeta potential of drug NPs was -20.4 mV, but increased to 19.2 mV in 
0.6 µM of STR-H16R8. The zeta potentials were further increased from 27.1 to 36.8 mV 
when the concentration of STR-H16R8 altered from 3 to 60 µM. Cationic STR-H16R8 
did not aggregate, but freely dissolved in water showing no zeta potential [270]. 
Therefore, the zeta potential shifting from negative to positive confirmed that cationic 
STR-H16R8 has anchored on the surface of the NPs. Peptide octaarginine (R8) was also 
investigated, which failed to stabilize the EPT/HCPT NPs at various concentrations, 
showing particle sizes of > 2 µm. This proved that it was the hydrophobic interaction 
between hydrophobic segment of STR-H16R8 and the drugs, rather than the coulombic 
interaction between cationic oligoarginine and negatively charged surface of the NPs, 
played a predominant role for improving the stability of the NPs. 
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Figure 7.2 (a) Particle size and (b) zeta potential of 40 µM EPT and 2 µM HCPT hybrid 
NPs in various concentrations of STR-H16R8 solution.  
After the addition of 1 µM siRNA solution, the particle sizes and zeta-potential were 121-
132 nm and 27-33 mV (Figure 7.3), respectively. These values fell in between that of 
STR-H16R8/siRNA complexes (75-88 nm and 22-28 mV) [270] and STR-H16R8 
stabilized drug NPs (195-331 nm and 27.1-36.8 mV). This suggested that a mixture of 
peptide/siRNA complexes and stearylated peptide stabilized drug NPs constituted the 
nanosuspension. More importantly, a particle size of less than 200 nm ensured optimal 
diffusion through tumor tissues by the enhanced permeation retention effect (EPR) [275].     
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Figure 7.3 (a) Particle size and (b) zeta potential of 40 µM EPT and 2 µM HCPT hybrid 
NPs and 1 µM of siRNA in various concentrations of STR-H16R8 solution. 
 
7.3.2 Synergistic antitumor effect of EPT/HCPT NPs combined with Bcl-2 
siRNA delivered by peptide STR-H16R8 
As mentioned above, therapeutic silencing of Bcl-2 gene by specific Bcl-2 siRNA could 
inhibit tumor growth. Thus, we involved Bcl-2 siRNA in the combination therapy. As in 
Figure 7.4, at molar ratio (MR) 15 and 30, the STR-H16R8/Bcl-2 siRNA formulations 
show 33% and 58% lower mRNA levels than that of untreated cells, respectively. At MR 
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60, STR-H16R8/siRNA induced 86% gene knockdown efficiency. This value was 
comparable to that of a benchmark, Lipofactamine 2000 (Lipo), which is the most 
commonly utilized and efficient transfection reagent to introduce siRNA into cells, 
inducing 83% gene silencing in this assay.  
                     
Figure 7.4 Knockdown efficiency of STR-H16R8/Bcl-2 siRNA complexes in A549 cells 
at molar ratio (MR) of 15, 30 and 60. The corresponding STR-H16R8 concentrations 
were 1.5, 3 and 6 µM, respectively. siRNA concentration was 100 nM. Lipofactamine 
2000 (Lipo) was used as positive control.  
Their antitumor cell proliferation ability was evaluated by cytotoxicity assay. The 
viabilities of A549 cells treated with 1.5, 3 and 6 µM peptide STR-H16R8 only were 
almost the same as untreated cells, indicating the safety of peptide itself (Figure 7.5a). 
1.5, 3 and 6 µM STR-H16R8 formulated with 100 nM of siRNA did not induce any 
toxicity as well. Cells treated with anti-cancer drug EPT or HCPT only exhibited low 
cell-killing abilities with > 90% cell viability (Figure 7.5b), while the EPT/HCPT hybrid 
NPs showed enhanced cytotoxicity resulting in a decreased cell viability of 73%. This 
suggested a synergistic anticancer effect of DNA intercalator and topoisomerase II 
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inhibitor, EPT combined with topoisomerase II inhibitor, HCPT. Furthermore, the 
addition of 1.5, 3 and 6 µM peptide STR-H16R8 solution increased the toxicity of 
EPT/HCPT NPs significantly, showing cell viabilities of 39%, 28% and 14%, 
respectively (Figure 7.5c). After 100 nM of Bcl-2 siRNA was involved, the viabilities of 
A549 cells were further reduced to 29%, 14% and 4%, respectively (Figure7.5c). Taken 
together, the combination of EPT and HCPT induced a synergistic effect on inhibiting 
cancer cells growth. With the addition of nontoxic STR-H16R8 and siRNA, a triple 
synergy was revealed, which improved the efficacy of chemotherapeutics dramatically.     
      Cellular uptake of EPT and HCPT after the cells were treated with NPs and stabilized 
NPs was measured by fluorescence activated cell sorting (FACS) in FL-1 channel and 
FL-2 channel separately. As cell viability was low after treated with the hybrid NPs at 
STR-H16R8 concentration of more than 1.5 µM, a lower STR-H16R8 concentration of 
0.06 and 0.6 µM were used in this assay. As shown in Figure 7.6, the EPT/HCPT NPs 
only samples showed mean fluorescence intensities of 9.4 and 39.8 for EPT and HCPT, 
respectively. The addition of 0.06 µM STR-H16R8 significantly increased the mean 
fluorescence intensity to 15.8 and 72.2 for EPT and HCPT. The intensities were enhanced 
further with 0.6 µM of STR-H16R8 to 19.7 (EPT) and 78.3 (HCPT), respectively. This 
increased uptake could be attribute to the change of negatively charged surfaces of drugs 
to positively charged EPT/HCPT NPs after the addition of STR-H16R8, as positively 
charged particles have high affinity for the negatively charged outer-membrane leaflet of 
cancer cells [276].  
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Figure 7.5 Cytotoxicity of (a) STR-H16R8 only and STR-H16R8/Bcl-2 siRNA, (b) EPT 
only, HCPT only and EPT/HCPT NPs and (c) combination of EPT/HCPT NPs/STR-
H16R8 and combination of EPT/HCPT NPs/STR-H16R8/Bcl-2 siRNA on A549 cells. 
The concentrations of EPT and HCPT were 4 µM and 0.2 µM, respectively. The 
concentrations of STR-H16R8 were 1.5, 3 and 6 µM for MR 15, 30 and 60, respectively 
with 100 nM siRNA. 
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Figure 7.6 Cellular uptake of (a) EPT and (b) HCPT in A549 cells after treatment with 
bare EPT/HCPT NPs and stabilized NPs with STR-H16R8.  The concentrations of EPT 
and HCPT were 4 µM and 0.2 µM. 
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7.4 Conclusions 
In summary, negatively charged EPT/HCPT hybrid NPs with the particle sizes of 170 nm 
were prepared, and then further stabilized by surfactant-like and water soluble peptide 
STR-H16R8 in water. The positively charged surfaces of the stabilized NPs confirmed 
that cationic STR-H16R8 anchored on the surface of the NPs. We revealed the 
combination usage of EPT/HCPT exhibited a synergistic effect on the inhibition of 
cancer cell proliferation, compared to EPT or HCPT alone. Furthermore, the cationic 
stearylated peptide not only improved the stability of nanosuspension, but also 
significantly enhanced the efficacy of the drugs due to the increased cellular uptake. 
Moreover, the addition of Bcl-2 siRNA to the system further increased efficacy of the 
chemotherapeutics, leading to a triple synergy to suppress the cancer cell growth. In 
conclusion, a promising co-delivery system for multidrugs and siRNA was developed. 
We demonstrated its capability for combination therapy by co-delivering EPT, HCPT and 
siRNA targeting Bcl-2 gene to A549 cancer cells. The fundamental knowledge generated 
provides valuable understanding and guidance surrounding the combination therapy and 
design of highly practical co-delivery systems. 
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Chapter 8 
Original Contributions and Recommendations 
 
8.1 Original contributions to research  
This thesis presented the potential of peptides as carriers for siRNA delivery both in vitro 
and in vivo. We designed several peptide libraries and explored the possibility of these 
co-assembling, biocompatible peptides for safe and efficient delivery of therapeutic 
siRNA.  The thesis includes the following parts: (i) the discovery and characterization of 
a co-assembling, amphiphilic peptide C6, which demonstrate high siRNA delivery ability 
but low gene knockdown efficiency (Chapter 3); (ii) modification of C6 sequences by 
adding tryptophan residues (Chapter 4) and histidine residues (Chapter 5), both of which 
improved the gene silencing efficiency significantly; (iii) study of the structure-activity 
relationship by rationally modifying oligoarginine peptides with oligohistidine and 
stearyl moieties, providing information for future design of peptide-based delivery 
vehicles for siRNA (Chapter 6); (iv)  exploration of simultaneously delivering anticancer 
drugs and siRNA into cancer cells to achieve a synergistic therapeutic effect. The original 
contributions to research are summarized in the following sections. 
Peptide C6 family as siRNA delivery carriers in vitro and in vivo: A model co-
assembling, amphiphilic peptide, C6, was found to be able to transport large amounts of 
siRNA across the cell membrane. Peptide C6 adopted a helical structure upon 
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coassembling with siRNA. The C6/siRNA coassembly showed a size distribution 
between 50 and 250 nm, confirmed by dynamic light scattering and atomic force 
microscopy. Fluorescence microscopy images confirmed the localization of C6/siRNA 
complexes in the cytoplasm using Cy3-labeled siRNAs. Peptide C6 showed lower 
toxicity and higher efficiency in cellular uptake of siRNA compared with Lipofectamine 
2000. However, the gene silencing efficiency of siRNA delivered by C6 is very low (only 
15%), probably due to endosomal entrapment after endocytosis. To avoid lysosomal 
degradation, siRNAs complexed with the carrier must escape from the endosome into the 
cytosol, where they can associate with the RISC. Hence, developing peptides that 
promote endosomal escape is a prerequisite for successful siRNA implementation. 
Therefore, a peptide library was designed by modifying prototype peptide C6 with 
endosome-disruptive moiety. C6M1 was obtained by replacing some leucine residues in 
the sequence with aromatic tryptophan, which is found abundantly in the pore-forming 
toxins of bacteria. Formed C6M1/siRNA nanoscale complexes are able to deliver siRNA 
into cells and induce improved gene knockdown (58%) with low toxicity. The increased 
membrane disruption ability at acidic condition of the peptide with tryptophan residue 
substitution contributed to the enhanced gene silence efficacy, proved by LDH assay at 
different pH. Intratumoral injection of the complexes results in a marked reduction of 
tumor growth through downregulation of antiapoptotic Bcl-2 protein in mice.  Different 
from C6M1, peptides C6M2 to C6M8 were designed by adding pH responsive histidine 
residues, in order to facilitate the endosomal escape of peptide/siRNA complexes through 
the “proton sponge effect”. All variations improved the transfection efficiency of C6; 
several more promising candidates were used for further in vitro and in vivo evaluation. 
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The two peptides C6M3 and C6M6 could form stable complexes with siRNA, with a size 
of around 100 nm. These complexes could be uptaken by cells and showed a punctuate 
perinuclear distribution after membrane translocation. These peptide/siRNA complexes 
achieved high transfection efficiency in vitro without inducing substantial cytotoxicity. In 
order to evaluate possible immune side effects of these peptide carriers, biocompatibility 
studies were conducted in terms of complement activation and cytokine activation. None 
of the promising peptides induced such activation effects. These data was never reported 
before for peptide-based siRNA carriers. We further examined the therapeutic potential 
of this peptide mediated siRNA delivery for cancer treatment by targeting Bcl-2 gene in a 
mouse tumor model, and demonstrated that tumor growth was inhibited by at least 50%, 
as a result of the downregulation of Bcl-2 protein.   
Primary structure-activity relationship and intracellular trafficking mechanism of 
peptide/siRNA: oligoarginine peptides, prominent members in CPPs, are rationally 
modified with oligohistidine and stearyl moieties (STR-) to study the structure-activity 
relationship of this kind of cell-penetrating peptides. It demonstrated that stearyl groups 
are necessary to facilitate the formation of nanoscale siRNA complexes. siRNA binding 
can be promoted further by increasing the chain length of oliogohistidine or oligoarginine 
segments. Extended oligohistidine segments improve the gene silencing, but do not 
increase the toxicity. When the ratio of histidine/arginine in a peptide sequence is >1.5, 
pronounced gene silencing is induced. Following this rule, STR-HnR8 (n=16 and 20) are 
developed, which showed a high knockdown efficiency (over 90%) rarely reported 
before. It is found that endosomal escape of siRNA mediated by stearylated and 
oligohistidylated oligoarginine is only from “proton-sponge” effect, based on data 
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following the use of chemical inhibitors of endocytic pathways. In addition, the pH 
dependent membrane disruptive ability does not vary significantly among these peptides. 
Co-delivery of anticancer drug nanoparticles and siRNA mediated by STR-H16R8 
for triple synergy to inhibit cancer cell proliferation: The effectiveness of 
combination of two or more chemotherapeutic agents with different mechanisms has 
been proved in the treatment of cancer. The ability of STR-H16R8 to co-delivery DNA 
intercalator and topoisomerase II inhibitor, Ellipticine (EPT), topoisomerase I inhibitor, 
10-Hydroxycamptothecin (HCPT) and Bcl-2 siRNA into cancer cells were investigated. 
A solvent displacement method was used to produce the negatively charged EPT/HCPT 
hybrid nanoparticles (NPs) with a particle size of ca. 170 nm, which exhibited a 
synergistic effect on the inhibition of cancer cells. The stability of the nanosuspension 
was improved immensely by the cationic amphiphilic stearylated peptide STR-H16R8, 
due to the anchor of the peptide on the surface of the NPs through the hydrophobic 
interaction between hydrophobic segment of STR-H16R8 and the drugs. Moreover, the 
stabilized NPs showed significantly enhanced efficacy, by reducing the cell viability from 
73% to 14%, compared with the bare NPs. The efficacy of the chemotherapeutics was 
further increased with the addition of Bcl-2 siRNA, leading to the triple synergy to 
suppress cancer cell growth. This novel multidrugs-siRNA co-delivery platform suggests 
a new strategy of combination therapy for the treatment of cancer. 
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8.2 Recommendations 
Recommended future work to develop peptide-based nanocarriers for efficient and safe 
siRNA delivery can be divided into following major parts: 
     Optimize the peptide/siRNA formulation to further increase transfection 
efficiency  
     1. Complete stability studies of peptide/siRNA complexes should be carried out. It is 
necessary to ascertain that this delivery system can tolerate various physiological 
conditions during transport to target site in serum. We can consider incorporate 
polyethylene glycol (PEG) moiety into peptide sequences. PEG is one of the most 
frequently used polymers for drug delivery with high water solubility, biocompatibility 
and chain flexibility; it has been introduced to help protect the siRNA by minimizing the 
interaction with serum proteins in biological fluids. Covalent attachment of PEG to 
siRNA or its delivery system was found to enhance the circulation time of the complex. 
Thus, PEG of varying chain lengths can be incorporated in the peptide-siRNA 
formulation.  
      2. If any of the tested peptides turns out to be effective at encapsulating, transporting 
and releasing siRNAs, we can further modify its sequence for cell targeting. Such 
modifications can be done by one of the following methods: 1) the targeting moiety is 
attached to one end of the original peptide chain if it is relatively short; 2) the targeting 
moiety is incorporated into the peptide assemblies by being attached onto the complex 
surface after the complexation.  
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       3. Since it has been confirmed that our peptide-mediated siRNA delivery is through 
endocytosis, rather than direct penetration across cell membranes, the specific 
translocation pathways can be further examined. Chemical inhibitors of endocytosis 
(sucrose, chlorpromazine, fillipin, nystatin and EIPA) will be used to identify the 
internalization mechanisms among the three main endocytosis pathways, namely clathrin-
dependent, lipid raft/caveolae-mediated and macropinocytosis pathways. Temperature 
dependence of the uptake will also be studied as an indicator for endocytosis in general. So 
far, the uptake for all tested peptide-mediated siRNA delivery systems was found to be 
using endocytosis. 
     
    Evaluate therapeutic effect and biocompatibility of peptide/siRNA complexes using 
intravenous injection in vivo: 
 Preliminary in vivo results have shown that intratumoral injection of Bcl-2 siRNA 
delivered by C6 family peptides can significantly inhibit the proliferation of tumor cells 
in a xenograft NSCLC model with nude mice. To explore the possibility of systemic 
delivery, the complexes of Bcl-2 siRNA with promising peptides with high transfection 
efficiency and low toxicity in vitro will be administered intravenously. The circulating 
complexes in the bloodstream will accumulate in the tumor through the enhanced 
permeability and retention (EPR) effect. The animal model can be established as 
mentioned in the methods part, by subcutaneous inoculation of 5×106 NSCLC A549 cells 
at the right armpit of six-week-old BALB/c nude mice, or other cell lines can be used. 
Tumor growth should be monitored on alternating days during treatment and the results 
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will be compared with those of control groups. After treatments, the animals will be 
sacrificed; tumor tissue and surrounding skin are excised and put on a microscopy glass 
slide. Tissue examination for vascularization and angiogenesis will be performed on a 
microscope. Western blotting can be used to detect knockdown efficiency at the protein 
level to ascertain whether the Bcl-2 protein level is reduced in the tumor. Note that 
besides Bcl-2, anti-RRM2, anti-VEGF, anti-HER2, and survivin targeted siRNAs are 
other extensively used targets. The efficiency of these siRNAs can be assessed on 
cultured cells first and then choose the best therapeutic siRNA for this and following in 
vivo studies. 
Preliminary in vitro experiment results have showed the biocompatibility of these 
peptide/siRNA complexes. To validate safety and biocompatibility of the peptide/siRNA 
complexes in vivo, immune responses and biocompatibility can be examined in mice. 
After treatments, blood will be collected, liver and kidney will be dissected, collected and 
frozen stored in -80°C. Blood samples are used to detect liver metabolic biomarkers, 
bilirubin and alanine aminotransferase (ALT). Plasma cytokines of interleukin (IL) IL1, 
IL2, IL 6 IL8, and IL18, Tumor necrosis factor alpha (TNFα) can be measured (Multiplex 
assay). Erythrocyte sedimentation rate (ESR), total and differential white blood cell 
counts can be performed with flow cytometry. Liver samples are homogenized and 
hepatic proteins are extracted for alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and cytochrome P450 activity analyses. Kidney samples can be 
processed to assay clusterin and cystatin C for determining renal function.  
If the therapeutic efficacy is confirmed by intravenous administration, further 
biodistribution and pharmacokinetics study can then be carried out.   
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                                             Appendix  
Peptide library for siRNA delivery * 
No Name Sequence AA Design principle 
1 C6 RLLRLLLRLWRRLLRLLR 18 
2 C6M RLWRLWLRLWRRLWRLLR 18 
3 C6M1 RLWRLLWRLWRRLWRLLR 18 
4 C6M2 RLWRLLWHLWRHLWRLLR 18 
5 C6M3 RLWHLLWRLWRRLHRLLR 18 
6 C6M4 HLLRLLLRLWHRLWRLLR 18 
7 C6M5 HLWHLLLRLWRRLLRLLR 18 
8 C6M6 GLWHLLLHLWRRLLRLLR 18 
9 C6M7 GLWHLLLHLWRRHHRHHR 18 
10 C6M8 GLWHLHLHLWRRHHRLLR 18 
These sequences are different derivatives of C6 
peptide.  W and H amino acids are added at 
different positions to the sequence to increase 
the affinity of peptide with membrane and 
increase endosome escape, respectively. 
The peptides are synthesized with a cysteamide 
group at its C-terminus so as to stabilize the 
carrier/cargo complex and to improve its 
potency to cross cell membranes. Also the n-
term domain was replaced with GLW, which 
seems to be important in CADY and MPG 
peptides. The peptides are designed with a 
stearic acid conjugated to the N-terminal as to 
increase membrane affinity. 
11 CADY GLWRALWRLLRSLWRLLW
RA-cysteamide 
20 
12 MPG-
NLS 
GALFLGFLGAAGSTMGAW
SQPKSKRKV-cysteamide 
27 
13 EB1 LIRLWSHLIHIWFQNRRLK
WKKK 
23 
Peptide controls: all there sequences have 
shown significant gene silencing efficiency  
14 C6-
CYSt 
RLLRLLLRLWRRLLRLLR-
cysteamide 
18 
15 C6M1-
CYSt 
RLWRLLWRLWRRLWRLLR
-Cysteamide 
18 
16 C6M3-
CYSt 
RLWHLLWRLWRRLHRLLR
-Cysteamide 
18 
C-terminal are modified by Cysteamide group -
NH-CH2-CH2-SH which was reported to 
increase transfection efficiency 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  *	   Peptide Sequence Design and Use Thereof for Peptide-Mediated siRNA Delivery. 
Patent number: WO2013075244 A1.           Inventors: Pu Chen, Mousa Jafari, Wen Xu, 
Baoling Chen, Ran Pan, Nedra Karunaratne.	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17 C6M6-
CYSt 
GLWHLLLHLWRRLLRLLR-
Cysteamide 
18  
18 C6-Dr rLLrLLLrLWrrLLrLLr 18 
19 C6-D rllrlllrlwrrllrllr 18 
20 C6M1-
Dr 
rLWrLLWrLWrrLWrLLr 18 
21 C6M1-
D 
rlwrllwrlwrrlwrllr 18 
22 C6M3-
Dr 
rLWHLLWrLWrrLHrLLr 18 
23 C6M3-
D 
rlwhllwrlwrrlhrllr 18 
24 C6M6-
Dr 
GLWHLLLHLWrrLLrLLr 18 
25 C6M6-
D 
glwhlllhlwrrllrllr 18 
D form of arginine residue and all amino acids 
are used in these sequences to evaluate the 
effect of using two different isomers of 
arginine and whole sequence on transfection 
efficiency, stability, and cytotoxicity. 
26 C1 FQFNFQFNGGGHRRRRRRR 19 
27 C1M FQFNFQFNGGGPKKKRKV 18 
28 C1M1 FQFNFQFNGGGPKPKRKV 18 
29 C1M2 FQFNFQFNFQFNGGGPKKK
RKV 
22 
30 C1M3 FQFNFQFNFQFNWSQPKPK
RKV 
22 
31 C1M4 FQFNFQFNFQFNGGGPKPK
RKV 
22 
32 C1M5 FQFNFQFNFQFNGGGCHHR
RRRRRHC 
26 
33 C1M6 FQFNFQFNFQFNGGGCPKP
KRKVC 
24 
C1-family peptides: arginine-Rich domain was 
replaced with Lysine- rich segment 
PKKKRKV and PKPKRKV which have shown 
high nuclear and cytoplasmic localization 
properties, respectively. The length of self- 
assembling domain was also changed. H an C 
amino acids were added to enhance the 
endosomal scape and siRNA release. In C1M3 
the linker GGG was replaced with WSQ. 
34 STR-C1 CH3(CH2)16-GGGPKPKRKV 10+ 
35 STR-
HK 
CH3(CH2)16-HHHPKPKRKV 10+ 
36 STR-
HKC 
CH3(CH2)16-
HHHCPKKKRKVC 
12+ 
Stearic acid is used as the hydrophobic domain 
in a primary amphiphilic structure. The 
hydrophilic domains are chosen from C1 
family peptides. 
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37 E3 RFTFHFRFEFTFHFE 15 
38 E3M RLTLHLRLELTLHLE 15 
39 E3M1 RWTWHWRWEWTWHWE 15 
E3-family peptides: the hydrophobic amino 
acids of E3 were replaced with L and W which 
were reported to have higher affinity with cell 
membrane. 
40 A7 HRLRHALAHLLHKLKHLLH
ALAHRLRH 
27 
41 A7M RHALAHLLHKLKHLLHAL
AHR 
21 
42 A7M1 RHALAHLLHRLRHLLHALA
HR 
21 
A7-family peptides: the length of A7 sequence 
was shorten in A7M and the amino acid K was 
replaced with R in A7M1 
43 MW1 MWKSKIGSWILVRWAMWS
KKRPKP 
24 
44 MW2 MWKSHIGSWILVRWAMWS
HKRPKP 
24 
45 MW3 MWKSKISWILVSKPGLCKK
RPKP 
23 
46 MW4 MHKSKISWHLVSKPGLCHK
RPKP 
23 
These sequences are derived from CPP Bovine 
PrP MVKSKIGSWILVLFVAMWSDVG 
LCKKRPKP.  The transfection efficiency of 
Bovine PrP is 48%.  Some W and H are added 
to the sequence to increase the affinity of 
peptide with membrane and increase 
endosomal escape. 
47 HA2 GLFGAIAGFIENGWEGMID
GWYG 
23 
48 GL1 GLWRAWLWKAFLASNWR
RLLRLLR 
24 
49 GL2 GLWRASWLKAWLASNWH
KKHRLLR 
24 
50 GL3 GLWGAWFIEGWEGMIDGR
RLLRLLR  
23 
51 GL4 GLWRASWLKAFLASNWHK
KLHKK 
25 
52 HA2-C6 GLFGAIAGFIENGWEGMID
GRLLRLLLRLWRRLLRLLR 
38 
53 HA2-
PK 
GLFGAIAGFIENGWEGMID
GWYGPKKKRKV 
28 
55 CLK CLKHALAHLAKLRHLLRLL
RR 
21 
HA2 has been added to facilitate the endosomal 
escape for some CPPs, e.g., Penetratin HA2-
Penetratin was proved to increase the 
transfection efficiency of Penetratin.  
r=D-arginine, h=D-histidine, w=D-tryptophan, g=D-glycine, i=D-leucine  
C-terminal cysteamide= NH-CH2-CH2-SH   Stearic acid modified N-term=CH3(CH2)16-      
Peptides are N-term acetylated, C-term amidated, otherwise mentioned 
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